11-May-12	18-May-12	25-May-12	1-Jun-12	8-Jun-12	15-Jun-12	22-Jun-12
118,056	118,182	122,070	112,484	121,604	117,421	118,726
24,694	24,597	25,260	22,598	25,358	24,612	24,878
3,424	3,510	3,553	3,295	3,662	3,523	3,529
30,482	30,679	31,327	28,725	31,199	30,356	30,061
10,904	11,136	11,668	10,623	11,382	11,231	11,293
23,186	23,106	23,735	22,444	24,047	22,908	23,175
8,827	8,939	9,356	8,707	9,117	8,888	9,219
16,539	16,215	17,171	16,092	16,839	15,903	16,571
142	150	141	143	173	149	152
63	59	64	65	79	78	73
43	56	32	44	40	37	48
22	25	28	24	27	21	19
14	10	17	10	27	13	12
118,198	118,332	122,211	112,627	121,777	117,570	118,878
24,757	24,656	25,324	22,663	25,437	24,690	24,951
3,424	3,510	3,553	3,295	3,662	3,523	3,529
30,525	30,735	31,359	28,769	31,239	30,393	30,109
10,904	11,136	11,668	10,623	11,382	11,231	11,293
23,208	23,131	23,763	22,468	24,074	22,929	23,194
8,827	8,939	9,356	8,707	9,117	8,888	9,219
16,553	16,225	17,188	16,102	16,866	15,916	16,583

29-Jun-12	6-Jul-12	13-Jul-12	20-Jul-12	27-Jul-12	3-Aug-12	10-Aug-12
119,243	116,154	119,139	118,784	116,567	117,416	115,928
24,839	22,927	24,571	24,474	24,189	24,085	23,942
3,479	3,470	3,697	3,597	3,561	3,628	3,559
30,739	29,235	30,567	30,270	29,599	30,017	29,413
11,432	11,211	11,389	11,410	11,245	11,395	11,227
23,246	23,564	23,332	23,257	22,701	23,069	22,792
9,059	9,152	9,112	9,288	9,121	9,116	8,982
16,449	16,595	16,471	16,488	16,151	16,106	16,013
113	118	101	129	109	100	105
48	47	48	63	53	55	49
47	42	35	45	36	28	42
8	15	9	13	10	10	3
10	14	9	8	10	7	11
119,356	116,272	119,240	118,913	116,676	117,516	116,033
24,887	22,974	24,619	24,537	24,242	24,140	23,991
3,479	3,470	3,697	3,597	3,561	3,628	3,559
30,786	29,277	30,602	30,315	29,635	30,045	29,455
11,432	11,211	11,389	11,410	11,245	11,395	11,227
23,254	23,579	23,341	23,270	22,711	23,079	22,795
9,059	9,152	9,112	9,288	9,121	9,116	8,982
16,459	16,609	16,480	16,496	16,161	16,113	16,024

17-Aug-12	24-Aug-12	31-Aug-12	7-Sep-12	14-Sep-12	21-Sep-12	28-Sep-12
118,476	117,202	119,054	113,825	119,368	118,261	119,766
24,305	24,548	24,950	23,222	24,886	24,754	25,350
3,736	3,484	3,695	3,489	3,852	3,740	3,984
30,096	29,863	30,281	28,823	30,288	30,197	30,675
11,692	11,402	11,620	11,057	11,678	11,500	11,732
23,006	22,555	23,184	22,363	23,113	22,709	23,197
9,268	9,253	9,188	8,884	9,268	9,297	9,042
16,373	16,097	16,136	15,987	16,283	16,064	15,786
94	94	70	85	66	38	59
41	50	29	45	34	22	29
34	22	20	28	18	10	19
10	11	8	5	6	1	5
9	11	13	7	8	5	6
118,570	117,296	119,124	113,910	119,434	118,299	119,825
24,346	24,598	24,979	23,267	24,920	24,776	25,379
3,736	3,484	3,695	3,489	3,852	3,740	3,984
30,130	29,885	30,301	28,851	30,306	30,207	30,694
11,692	11,402	11,620	11,057	11,678	11,500	11,732
23,016	22,566	23,192	22,368	23,119	22,710	23,202
9,268	9,253	9,188	8,884	9,268	9,297	9,042
16,382	16,108	16,149	15,994	16,291	16,069	15,792

5-Oct-12	12-Oct-12	19-Oct-12	26-Oct-12	2-Nov-12	9-Nov-12	16-Nov-12	23-Nov-12
121,919	117,232	118,675	118,211	116,115	121,778	120,116	108,593
25,838	24,616	25,288	25,395	24,696	26,154	26,215	23,221
3,855	3,786	3,765	3,828	3,765	3,932	3,921	3,491
30,727	29,825	30,326	30,000	29,535	30,912	30,176	27,610
11,835	11,606	11,565	11,566	11,440	11,920	11,644	10,833
23,543	22,555	22,590	22,546	22,344	23,004	22,628	20,580
9,437	9,086	9,190	9,068	8,909	9,562	9,410	8,376
16,684	15,758	15,951	15,808	15,426	16,294	16,122	14,482
59	43	29	43	32	21	30	19
32	21	14	27	18	13	17	9
18	6	12	12	11	5	12	7
4	10	1		3	3		2
5	6	2	4			1	1
121,978	117,275	118,704	118,254	116,147	121,799	120,146	108,612
25,870	24,637	25,302	25,422	24,714	26,167	26,232	23,230
3,855	3,786	3,765	3,828	3,765	3,932	3,921	3,491
30,745	29,831	30,338	30,012	29,546	30,917	30,188	27,617
11,835	11,606	11,565	11,566	11,440	11,920	11,644	10,833
23,547	22,565	22,591	22,546	22,347	23,007	22,628	20,582
9,437	9,086	9,190	9,068	8,909	9,562	9,410	8,376
16,689	15,764	15,953	15,812	15,426	16,294	16,123	14,483

30-Nov-12	7-Dec-12	14-Dec-12	21-Dec-12	28-Dec-12	4-Jan-13	11-Jan-13
123,659	125,259	120,714	125,619	101,167	112,524	120,276
26,489	26,517	26,051	27,077	21,021	23,087	25,231
4,109	4,032	4,026	4,170	3,207	3,595	4,111
31,374	31,846	30,640	31,888	25,515	28,300	30,360
12,244	12,447	12,006	12,563	10,004	11,327	11,931
23,701	23,716	22,772	23,677	19,428	21,885	23,056
9,642	9,734	9,380	9,610	8,046	8,923	9,488
16,100	16,967	15,839	16,634	13,946	15,407	16,099
19	16	15	19	17	11	18
11	8	8	6	6	3	10
4	6	6	8	7	2	3
2			4	4	3	1
2	2	1	1		3	4
123,678	125,275	120,729	125,638	101,184	112,535	120,294
26,500	26,525	26,059	27,083	21,027	23,090	25,241
4,109	4,032	4,026	4,170	3,207	3,595	4,111
31,378	31,852	30,646	31,896	25,522	28,302	30,363
12,244	12,447	12,006	12,563	10,004	11,327	11,931
23,703	23,716	22,772	23,681	19,432	21,888	23,057
9,642	9,734	9,380	9,610	8,046	8,923	9,488
16,102	16,969	15,840	16,635	13,946	15,410	16,103

18-Jan-13	25-Jan-13	1-Feb-13	8-Feb-13	15-Feb-13	22-Feb-13	1-Mar-13	8-Mar-13
118,988	108,221	115,072	121,640	117,664	109,872	120,657	123,202
25,634	23,858	24,986	26,132	25,813	24,646	25,914	26,268
3,971	3,681	3,765	4,144	3,910	3,804	4,030	4,198
29,828	27,539	28,981	30,406	29,720	27,875	30,374	31,167
12,055	10,790	11,542	12,411	11,513	11,117	12,375	12,450
22,211	20,069	21,557	22,693	22,037	20,090	22,469	23,244
9,336	8,328	9,012	9,660	9,086	8,397	9,655	9,514
15,953	13,956	15,229	16,194	15,585	13,943	15,840	16,361
25	8	18	11	14	20	17	13
17	5	9	7	13	14	6	5
8		3	2		1	5	3
		3	1		1	4	
	3	3	1	1	4	2	5
119,013	108,229	115,090	121,651	117,678	109,892	120,674	123,215
25,651	23,863	24,995	26,139	25,826	24,660	25,920	26,273
3,971	3,681	3,765	4,144	3,910	3,805	4,035	4,201
29,836	27,539	28,984	30,408	29,720	27,876	30,378	31,167
12,055	10,790	11,542	12,411	11,513	11,121	12,377	12,455
22,211	20,069	21,560	22,694	22,037	20,090	22,469	23,244
9,336	8,328	9,012	9,660	9,086	8,397	9,655	9,514
15,953	13,959	15,232	16,195	15,586	13,947	15,842	16,366

15-Mar-13	22-Mar-13	29-Mar-13	5-Apr-13	12-Apr-13	19-Apr-13	26-Apr-13	3-May-13
116,106	111,519	110,562	116,985	113,283	109,820	111,523	119,075
25,511	24,829	24,147	24,786	24,574	24,247	24,428	25,505
3,983	3,849	3,806	4,016	4,071	3,886	3,884	4,204
29,367	28,215	27,841	29,443	28,561	27,759	28,034	29,677
11,612	11,419	11,413	11,917	11,576	11,535	11,556	12,166
21,400	20,358	20,331	22,027	20,935	20,003	20,692	22,404
9,026	8,713	8,840	9,295	8,954	8,650	8,791	9,372
15,207	14,136	14,184	15,501	14,612	13,740	14,138	15,747
15	15	8	14	17	13	12	9
12	9	7	11	10	6	11	5
3	6		2	2	5		2
		1	1	5	2	1	
							2
116,121	111,534	110,570	116,999	113,300	109,833	111,535	119,084
25,523	24,838	24,154	24,797	24,584	24,253	24,439	25,510
3,986	3,855	3,806	4,018	4,073	3,891	3,884	4,206
29,367	28,215	27,842	29,444	28,566	27,761	28,035	29,677
11,612	11,419	11,413	11,917	11,576	11,535	11,556	12,168
21,400	20,358	20,331	22,027	20,935	20,003	20,692	22,404
9,026	8,713	8,840	9,295	8,954	8,650	8,791	9,372
15,207	14,136	14,184	15,501	14,612	13,740	14,138	15,749

10-May-13	17-May-13	24-May-13	31-May-13	7-Jun-13	14-Jun-13	21-Jun-13	28-Jun-13
114,849	110,628	115,142	105,510	119,269	111,927	112,247	
24,914	24,582	25,086	22,589	25,704	25,022	24,707	
4,142	4,010	4,155	3,865	4,318	4,120	4,050	
29,288	28,309	29,165	26,604	30,155	28,142	28,339	
11,779	11,585	11,976	10,936	12,213	11,836	11,765	
20,933	19,867	21,012	19,640	22,124	19,962	20,610	
9,166	8,664	9,204	8,305	9,380	8,759	8,918	
14,627	13,611	14,544	13,571	15,375	14,086	13,858	
1	13	10	6	21	8	8	
	5	4		10	4	5	
	7	3	4	9	3	3	
1		1	2	2			
	1	2			1		
114,850	110,641	115,152	105,516	119,290	111,935	112,255	
24,914	24,587	25,090	22,589	25,714	25,026	24,712	
4,142	4,017	4,158	3,869	4,327	4,123	4,053	
29,289	28,309	29,166	26,606	30,157	28,142	28,339	
11,779	11,586	11,978	10,936	12,213	11,837	11,765	
20,933	19,867	21,012	19,640	22,124	19,962	20,610	
9,166	8,664	9,204	8,305	9,380	8,759	8,918	
14,627	13,612	14,546	13,571	15,375	14,087	13,858	

1/1 Week Growth	3/3 Week Growth	6/6 Week Growth
0.3%	3.7%	-1.6%
-1.3%	4.4%	-0.5%
-1.7%	3.8%	1.3%
0.7%	3.0%	-1.2%
-0.6%	3.8%	-0.3%
3.2%	3.6%	-3.0%
1.8%	3.4%	-1.8%
-1.6%	3.8%	-3.8%
0.0%	27.6%	0.0%
25.0%	111.1%	-34.9%
0.0%	7.1%	163.6%
#DIV/0!	-33.3%	-50.0%
-100.0%	-66.7%	100.0%
0.3%	3.7%	-1.6%
-1.3%	4.4%	-0.5%
-1.7%	3.8%	1.4%
0.7%	3.0%	-1.2%
-0.6%	3.8%	-0.3%
3.2%	3.6%	-3.0%
1.8%	3.4%	-1.8%
-1.6%	3.8%	-3.8%

Total Branded OxyContin

"= needs to be

Gross Up	0.55%	1.0055

notes: in Feb 2013, we changed to reporting from retail pharmacy only
the weekly budget is based on the agreed upon full year total, tl

	4-Jan-13	11-Jan-13	18-Jan-13	25-Jan-13
Actual Weekly TRx	112,524	120,276	118,988	108,221
Grossed Up Weekly TRx	113,143	120,938	119,642	108,816
YTD Grossed Up Weekly TRx	113,143	234,080	353,723	462,539
Budget TRx	115,687	121,404	117,758	112,236
YTD Budget Total	115,687	237,091	354,849	467,085
Weekly Difference	(2,544)	(467)	1,885	(3,420)
YTD Total Difference	(2,544)	(3,011)	(1,126)	(4,546)
Weekly % Difference	-2.2%	-0.4%	1.6%	-3.0%

New Numbers	
2013 TRx Goal	6,017,543
YTD Rolling Grossed Up Weekly TRx	2,882,327
Difference	3,135,216
Remaining Weeks	27
Revised 2012 Weekly TRx Goal	116,119

Goal to date	2,898,679
Actual to date (grossed up)	2,882,327
YTD Difference	-0.6%

: updated

to reporting retail pharmacies, mail order and LTC. The gross up simply reflects the recent difference
hen phased

1-Feb-13	8-Feb-13	15-Feb-13	22-Feb-13	1-Mar-13	8-Mar-13	15-Mar-13
115,072	121,640	117,664	109,872	120,657	123,202	116,106
115,705	122,309	118,311	110,476	121,321	123,880	116,745
578,244	700,553	818,864	929,340	1,050,661	1,174,541	1,291,285
115,207	114,753	112,314	108,273	123,591	119,804	114,547
582,292	697,045	809,359	917,632	1,041,223	1,161,027	1,275,574
498	7,556	5,997	2,203	(2,270)	4,076	2,197
(4,048)	3,508	9,505	11,708	9,438	13,514	15,711
0.4%	6.6%	5.3%	2.0%	-1.8%	3.4%	1.9%

between weekly and monthly Rx's over a 12 month period

22-Mar-13	29-Mar-13	5-Apr-13	12-Apr-13	19-Apr-13	26-Apr-13	3-May-13
111,519	110,562	116,985	113,283	109,820	111,523	119,075
112,132	111,170	117,628	113,906	110,424	112,136	119,730
1,403,418	1,514,588	1,632,216	1,746,122	1,856,546	1,968,683	2,088,412
111,238	113,687	125,840	119,544	119,811	121,039	125,092
1,386,812	1,500,499	1,626,339	1,745,883	1,865,694	1,986,733	2,111,825
895	(2,517)	(8,212)	(5,638)	(9,387)	(8,903)	(5,362)
16,606	14,089	5,877	240	(9,148)	(18,050)	(23,412)
0.8%	-2.2%	-6.5%	-4.7%	-7.8%	-7.4%	-4.3%

10-May-13	17-May-13	24-May-13	31-May-13	7-Jun-13	14-Jun-13	21-Jun-13
114,849	110,628	115,142	105,510	119,269	111,927	112,247
115,481	111,236	115,775	106,090	119,925	112,543	112,864
2,203,893	2,315,130	2,430,905	2,536,995	2,656,920	2,769,463	2,882,327
116,368	116,112	120,508	108,465	108,466	108,467	108,468
2,228,192	2,344,304	2,464,812	2,573,277	2,681,743	2,790,211	2,898,679
(887)	(4,876)	(4,733)	(2,375)	11,459	4,076	4,396
(24,299)	(29,175)	(33,907)	(36,282)	(24,823)	(20,748)	(16,352)
-0.8%	-4.2%	-3.9%	-2.2%	10.6%	3.8%	4.1%

28-Jun-13	5-Jul-13	12-Jul-13	19-Jul-13	26-Jul-13	2-Aug-13	9-Aug-13
115,360	117,630	120,357	119,919	117,559	119,679	118,551

16-Aug-13	23-Aug-13	30-Aug-13	6-Sep-13	13-Sep-13	20-Sep-13	27-Sep-13
120,708	119,089	115,023	110,440	115,685	114,074	115,729

4-Oct-13	11-Oct-13	18-Oct-13	25-Oct-13	1-Nov-13	8-Nov-13	15-Nov-13
118,520	117,059	117,551	117,540	113,593	116,583	114,587

22-Nov-13	29-Nov-13	6-Dec-13	13-Dec-13	20-Dec-13	27-Dec-13
103,144	115,825	117,538	112,710	117,934	96,477

OxyContin Weekly TRx - Original Formulation and Reformulation

Source: IMS Health NPA

Retail Pharmacies Only

Numbers Are Absolute

Strength	NDC	Week Ending	4-Jun-10	11-Jun-10	18-Jun-10	25-Jun-10
Total OER (brand + generics)						
10MG				22,367	22,497	22,666
15MG				2,215	2,154	2,190
20MG				36,046	35,706	36,021
30MG				8,692	9,079	8,951
40MG				33,524	33,569	34,255
60MG				8,767	8,954	8,756
80MG				29,397	29,228	29,572
Total				141,008	141,187	142,411
Oxycodone ER (generics)						
10MG				6,950	6,845	6,809
20MG				11,002	11,080	11,114
40MG				6,216	6,126	6,119
80MG				3,905	3,838	3,814
Total				28,073	27,889	27,856
Original OxyContin						
10MG	59011010010	TAB SA 12HR 10MG	14,577	15,417	15,652	15,857
15MG	59011081510	TAB SA 12HR 15MG	2,092	2,215	2,154	2,190
20MG	59011010310	TAB SA 12HR 20MG	24,314	25,044	24,626	24,907
30MG	59011083010	TAB SA 12HR 30MG	8,367	8,692	9,079	8,951
40MG	59011010510	TAB SA 12HR 40MG	27,682	27,308	27,443	28,136
60MG	59011086010	TAB SA 12HR 60MG	8,599	8,767	8,954	8,756
80MG	59011010710	TAB SA 12HR 80MG	24,914	25,492	25,390	25,758
Total			110,545	112,935	113,298	114,555
Reformulated OxyContin						
10MG	59011041010	TAB SA 12HR 10MG 100 0410-10 NF				
15MG	59011041510	TAB SA 12HR 15MG 100 0415-10 NF				
20MG	59011042010	TAB SA 12HR 20MG 100 0420-10 NF				
30MG	59011043010	TAB SA 12HR 30MG 100 0430-10 NF				
40MG	59011044010	TAB SA 12HR 40MG 100 0440-10 NF				
60MG	59011046010	TAB SA 12HR 60MG 100 0460-10 NF				
80MG	59011048010	TAB SA 12HR 80MG 100 0480-10 NF				
Total			-	-	-	-
Total Branded OxyContin						
10MG			14,577	15,417	15,652	15,857
15MG			2,092	2,215	2,154	2,190
20MG			24,314	25,044	24,626	24,907

30MG	8,367	8,692	9,079	8,951
40MG	27,682	27,308	27,443	28,136
60MG	8,599	8,767	8,954	8,756
80MG	24,914	25,492	25,390	25,758
Total	110,545	112,935	113,298	114,555

1 Weekly Growth of Total Branded OxyContin TRx

10MG	1.5%	1.3%
15MG	-2.8%	1.7%
20MG	-1.7%	1.1%
30MG	4.5%	-1.4%
40MG	0.5%	2.5%
60MG	2.1%	-2.2%
80MG	-0.4%	1.4%
Total	0.3%	1.1%

TRx Distribution by Strength for Total Branded OxyContin

10MG	13.7%	13.8%	13.8%
15MG	2.0%	1.9%	1.9%
20MG	22.2%	21.7%	21.7%
30MG	7.7%	8.0%	7.8%
40MG	24.2%	24.2%	24.6%
60MG	7.8%	7.9%	7.6%
80MG	22.6%	22.4%	22.5%
Total	100.0%	100.0%	100.0%

Weekly Total Prescriptions

2-Jul-10	9-Jul-10	16-Jul-10	23-Jul-10	30-Jul-10	6-Aug-10	13-Aug-10	20-Aug-10	27-Aug-10
24,158	20,973	22,969	22,960	22,532	22,515	22,651	22,613	22,473
2,364	2,193	2,284	2,308	2,280	2,326	2,276	2,213	2,322
38,932	33,905	36,256	36,508	35,824	36,261	35,634	36,541	35,785
9,701	8,686	9,341	9,201	9,066	9,244	9,478	9,519	9,145
37,408	32,071	33,737	34,402	33,455	34,392	32,965	34,230	33,535
9,571	8,699	9,169	9,091	8,870	9,341	9,228	9,354	9,189
31,615	28,074	29,924	30,061	29,034	30,577	30,319	30,398	29,070
153,749	134,601	143,680	144,531	141,061	144,656	142,551	144,868	141,519
7,290	6,169	6,804	6,779	6,519	6,476	6,421	6,354	6,279
11,562	10,129	10,579	10,865	10,449	10,614	10,580	10,150	9,216
6,624	5,701	6,072	6,241	5,973	6,307	6,044	6,291	6,012
4,210	3,754	4,030	3,934	3,949	4,044	4,058	4,087	4,035
29,686	25,753	27,485	27,819	26,890	27,441	27,103	26,882	25,542
16,868	14,804	16,165	16,181	16,013	16,037	16,204	15,751	14,610
2,364	2,193	2,284	2,308	2,280	2,325	2,269	2,092	2,051
27,370	23,776	25,677	25,643	25,374	25,646	25,006	25,527	23,270
9,701	8,686	9,341	9,201	9,066	9,243	9,463	9,254	8,381
30,784	26,370	27,665	28,161	27,482	28,082	26,829	26,466	23,102
9,571	8,699	9,169	9,091	8,870	9,340	9,201	8,982	7,908
27,405	24,320	25,894	26,127	25,083	26,528	26,166	23,600	18,678
124,063	108,848	116,195	116,712	114,168	117,201	115,138	111,672	98,000
					2	26	508	1,584
					1	7	121	271
				1	1	48	864	3,299
					1	15	265	764
					3	92	1,473	4,421
					1	27	372	1,281
				2	5	95	2,711	6,357
-	-	-	-	3	14	310	6,314	17,977
16,868	14,804	16,165	16,181	16,013	16,039	16,230	16,259	16,194
2,364	2,193	2,284	2,308	2,280	2,326	2,276	2,213	2,322
27,370	23,776	25,677	25,643	25,375	25,647	25,054	26,391	26,569

9,701	8,686	9,341	9,201	9,066	9,244	9,478	9,519	9,145
30,784	26,370	27,665	28,161	27,482	28,085	26,921	27,939	27,523
9,571	8,699	9,169	9,091	8,870	9,341	9,228	9,354	9,189
27,405	24,320	25,894	26,127	25,085	26,533	26,261	26,311	25,035
124,063	108,848	116,195	116,712	114,171	117,215	115,448	117,986	115,977

6.4%	-12.2%	9.2%	0.1%	-1.0%	0.2%	1.2%	0.2%	-0.4%
7.9%	-7.2%	4.1%	1.1%	-1.2%	2.0%	-2.1%	-2.8%	4.9%
9.9%	-13.1%	8.0%	-0.1%	-1.0%	1.1%	-2.3%	5.3%	0.7%
8.4%	-10.5%	7.5%	-1.5%	-1.5%	2.0%	2.5%	0.4%	-3.9%
9.4%	-14.3%	4.9%	1.8%	-2.4%	2.2%	-4.1%	3.8%	-1.5%
9.3%	-9.1%	5.4%	-0.9%	-2.4%	5.3%	-1.2%	1.4%	-1.8%
6.4%	-11.3%	6.5%	0.9%	-4.0%	5.8%	-1.0%	0.2%	-4.8%
8.3%	-12.3%	6.7%	0.4%	-2.2%	2.7%	-1.5%	2.2%	-1.7%

13.6%	13.6%	13.9%	13.9%	14.0%	13.7%	14.1%	13.8%	14.0%
1.9%	2.0%	2.0%	2.0%	2.0%	2.0%	2.0%	1.9%	2.0%
22.1%	21.8%	22.1%	22.0%	22.2%	21.9%	21.7%	22.4%	22.9%
7.8%	8.0%	8.0%	7.9%	7.9%	7.9%	8.2%	8.1%	7.9%
24.8%	24.2%	23.8%	24.1%	24.1%	24.0%	23.3%	23.7%	23.7%
7.7%	8.0%	7.9%	7.8%	7.8%	8.0%	8.0%	7.9%	7.9%
22.1%	22.3%	22.3%	22.4%	22.0%	22.6%	22.7%	22.3%	21.6%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

3-Sep-10	10-Sep-10	17-Sep-10	24-Sep-10	1-Oct-10	8-Oct-10	15-Oct-10	22-Oct-10	29-Oct-10
23,538	20,825	23,321	22,943	23,218	22,993	22,827	22,771	22,415
2,581	2,252	2,456	2,311	2,553	2,467	2,418	2,429	2,382
37,815	32,953	36,857	35,692	37,173	35,128	35,294	34,678	34,505
9,984	8,856	9,898	9,364	9,693	9,453	9,628	9,483	9,200
35,737	30,934	33,762	32,509	33,460	31,714	31,957	31,661	30,784
9,923	9,089	9,510	9,237	9,659	9,209	9,207	8,951	8,753
30,082	26,029	28,055	26,103	26,565	25,345	25,492	24,913	24,417
149,660	130,938	143,859	138,159	142,321	136,309	136,823	134,886	132,456
6,509	5,622	6,225	6,361	6,290	6,133	5,595	4,918	4,110
8,647	6,848	8,153	8,295	7,920	6,893	6,118	5,641	4,857
6,545	5,769	6,467	6,603	6,986	6,944	7,302	7,000	6,284
4,531	4,291	4,752	5,063	5,565	5,681	6,232	6,461	6,506
26,232	22,530	25,597	26,322	26,761	25,651	25,247	24,020	21,757
13,547	10,675	10,233	8,374	7,346	6,171	5,454	4,971	4,250
2,191	1,721	1,740	1,527	1,538	1,389	1,238	1,171	1,023
21,599	16,247	14,434	10,835	9,416	7,477	6,170	5,319	4,355
8,322	6,730	6,329	4,929	4,514	3,839	3,287	2,751	2,412
20,664	14,908	12,789	9,812	8,328	6,550	5,332	4,401	3,692
7,705	6,061	5,461	4,395	3,952	3,182	2,762	2,331	1,931
15,716	11,132	9,872	7,096	6,011	4,608	3,859	3,215	2,570
89,744	67,474	60,858	46,968	41,105	33,216	28,102	24,159	20,233
3,482	4,528	6,863	8,208	9,582	10,689	11,778	12,882	14,055
390	531	716	784	1,015	1,078	1,180	1,258	1,359
7,569	9,858	14,270	16,562	19,837	20,758	23,006	23,718	25,293
1,662	2,126	3,569	4,435	5,179	5,614	6,341	6,732	6,788
8,528	10,257	14,506	16,094	18,146	18,220	19,323	20,260	20,808
2,218	3,028	4,049	4,842	5,707	6,027	6,445	6,620	6,822
9,835	10,606	13,431	13,944	14,989	15,056	15,401	15,237	15,341
33,684	40,934	57,404	64,869	74,455	77,442	83,474	86,707	90,466
17,029	15,203	17,096	16,582	16,928	16,860	17,232	17,853	18,305
2,581	2,252	2,456	2,311	2,553	2,467	2,418	2,429	2,382
29,168	26,105	28,704	27,397	29,253	28,235	29,176	29,037	29,648

9,984	8,856	9,898	9,364	9,693	9,453	9,628	9,483	9,200
29,192	25,165	27,295	25,906	26,474	24,770	24,655	24,661	24,500
9,923	9,089	9,510	9,237	9,659	9,209	9,207	8,951	8,753
25,551	21,738	23,303	21,040	21,000	19,664	19,260	18,452	17,911
123,428	108,408	118,262	111,837	115,560	110,658	111,576	110,866	110,699

5.2%	-10.7%	12.5%	-3.0%	2.1%	-0.4%	2.2%	3.6%	2.5%
11.2%	-12.7%	9.1%	-5.9%	10.5%	-3.4%	-2.0%	0.5%	-1.9%
9.8%	-10.5%	10.0%	-4.6%	6.8%	-3.5%	3.3%	-0.5%	2.1%
9.2%	-11.3%	11.8%	-5.4%	3.5%	-2.5%	1.9%	-1.5%	-3.0%
6.1%	-13.8%	8.5%	-5.1%	2.2%	-6.4%	-0.5%	0.0%	-0.7%
8.0%	-8.4%	4.6%	-2.9%	4.6%	-4.7%	0.0%	-2.8%	-2.2%
2.1%	-14.9%	7.2%	-9.7%	-0.2%	-6.4%	-2.1%	-4.2%	-2.9%
6.4%	-12.2%	9.1%	-5.4%	3.3%	-4.2%	0.8%	-0.6%	-0.2%

13.8%	14.0%	14.5%	14.8%	14.6%	15.2%	15.4%	16.1%	16.5%
2.1%	2.1%	2.1%	2.1%	2.2%	2.2%	2.2%	2.2%	2.2%
23.6%	24.1%	24.3%	24.5%	25.3%	25.5%	26.1%	26.2%	26.8%
8.1%	8.2%	8.4%	8.4%	8.4%	8.5%	8.6%	8.6%	8.3%
23.7%	23.2%	23.1%	23.2%	22.9%	22.4%	22.1%	22.2%	22.1%
8.0%	8.4%	8.0%	8.3%	8.4%	8.3%	8.3%	8.1%	7.9%
20.7%	20.1%	19.7%	18.8%	18.2%	17.8%	17.3%	16.6%	16.2%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

5-Nov-10	12-Nov-10	19-Nov-10	26-Nov-10	3-Dec-10	10-Dec-10	17-Dec-10	24-Dec-10	31-Dec-10
22,850	22,537	23,456	19,438	23,538	22,620	23,239	22,281	18,352
2,538	2,505	2,442	2,180	2,711	2,481	2,466	2,315	2,113
35,192	33,996	35,000	30,049	37,108	33,914	34,504	33,339	27,995
9,309	9,345	9,616	8,188	10,352	9,478	9,677	9,077	8,127
30,872	29,854	30,760	26,900	32,627	29,183	29,911	28,487	25,317
8,910	8,747	9,083	7,864	9,531	8,739	8,654	8,473	7,413
24,207	23,942	24,768	21,371	25,838	23,879	23,877	22,109	20,085
133,878	130,926	135,125	115,990	141,705	130,294	132,328	126,081	109,402
3,480	2,988	2,880	2,263	2,483	2,085	1,567	1,353	1,045
4,685	4,241	4,201	3,346	4,138	3,466	3,567	3,236	2,797
5,231	3,938	3,373	2,588	2,697	2,109	1,916	2,817	3,490
6,633	6,763	7,133	6,367	7,561	6,739	6,010	5,089	4,005
20,029	17,930	17,587	14,564	16,879	14,399	13,060	12,495	11,337
4,041	3,464	3,150	2,411	2,752	2,332	1,717	1,930	1,517
912	904	810	683	736	670	488	517	458
3,886	3,118	2,900	2,407	2,578	2,234	1,728	1,784	1,333
2,214	1,964	1,771	1,335	1,408	1,201	1,122	1,190	1,004
3,323	2,914	2,704	2,070	2,391	1,947	1,591	1,449	1,205
1,770	1,554	1,566	1,109	1,301	1,054	870	890	720
2,079	1,848	1,742	1,317	1,515	1,417	1,101	1,014	975
18,225	15,766	14,643	11,332	12,681	10,855	8,617	8,774	7,212
15,329	16,085	17,426	14,764	18,303	18,203	19,955	18,998	15,790
1,626	1,601	1,632	1,497	1,975	1,811	1,978	1,798	1,655
26,621	26,637	27,899	24,296	30,392	28,214	29,209	28,319	23,865
7,095	7,381	7,845	6,853	8,944	8,277	8,555	7,887	7,123
22,318	23,002	24,683	22,242	27,539	25,127	26,404	24,221	20,622
7,140	7,193	7,517	6,755	8,230	7,685	7,784	7,583	6,693
15,495	15,331	15,893	13,687	16,762	15,723	16,766	16,006	15,105
95,624	97,230	102,895	90,094	112,145	105,040	110,651	104,812	90,853
19,370	19,549	20,576	17,175	21,055	20,535	21,672	20,928	17,307
2,538	2,505	2,442	2,180	2,711	2,481	2,466	2,315	2,113
30,507	29,755	30,799	26,703	32,970	30,448	30,937	30,103	25,198

9,309	9,345	9,616	8,188	10,352	9,478	9,677	9,077	8,127
25,641	25,916	27,387	24,312	29,930	27,074	27,995	25,670	21,827
8,910	8,747	9,083	7,864	9,531	8,739	8,654	8,473	7,413
17,574	17,179	17,635	15,004	18,277	17,140	17,867	17,020	16,080
113,849	112,996	117,538	101,426	124,826	115,895	119,268	113,586	98,065

5.8%	0.9%	5.3%	-16.5%	22.6%	-2.5%	5.5%	-3.4%	-17.3%
6.5%	-1.3%	-2.5%	-10.7%	24.4%	-8.5%	-0.6%	-6.1%	-8.7%
2.9%	-2.5%	3.5%	-13.3%	23.5%	-7.6%	1.6%	-2.7%	-16.3%
1.2%	0.4%	2.9%	-14.9%	26.4%	-8.4%	2.1%	-6.2%	-10.5%
4.7%	1.1%	5.7%	-11.2%	23.1%	-9.5%	3.4%	-8.3%	-15.0%
1.8%	-1.8%	3.8%	-13.4%	21.2%	-8.3%	-1.0%	-2.1%	-12.5%
-1.9%	-2.2%	2.7%	-14.9%	21.8%	-6.2%	4.2%	-4.7%	-5.5%
2.8%	-0.7%	4.0%	-13.7%	23.1%	-7.2%	2.9%	-4.8%	-13.7%

17.0%	17.3%	17.5%	16.9%	16.9%	17.7%	18.2%	18.4%	17.6%
2.2%	2.2%	2.1%	2.1%	2.2%	2.1%	2.1%	2.0%	2.2%
26.8%	26.3%	26.2%	26.3%	26.4%	26.3%	25.9%	26.5%	25.7%
8.2%	8.3%	8.2%	8.1%	8.3%	8.2%	8.1%	8.0%	8.3%
22.5%	22.9%	23.3%	24.0%	24.0%	23.4%	23.5%	22.6%	22.3%
7.8%	7.7%	7.7%	7.8%	7.6%	7.5%	7.3%	7.5%	7.6%
15.4%	15.2%	15.0%	14.8%	14.6%	14.8%	15.0%	15.0%	16.4%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

7-Jan-11	14-Jan-11	21-Jan-11	28-Jan-11	4-Feb-11	11-Feb-11	18-Feb-11	25-Feb-11	4-Mar-11
22,404	21,599	21,655	20,631	21,487	21,641	21,137	20,378	23,229
2,590	2,391	2,348	2,361	2,397	2,462	2,471	2,309	2,702
34,434	32,962	32,331	30,654	32,355	33,036	31,922	30,055	35,637
9,871	9,526	9,164	8,689	9,428	9,369	9,184	8,654	10,448
29,970	28,701	27,923	26,325	28,379	28,346	27,402	26,111	31,060
8,931	8,536	8,390	7,715	8,531	8,467	8,473	7,744	9,440
23,157	22,060	20,698	19,593	21,340	20,931	19,578	18,754	22,514
131,357	125,775	122,509	115,968	123,917	124,252	120,167	114,005	135,030
1,076	902	911	851	808	696	648	590	612
3,487	3,178	3,092	2,854	2,934	2,724	2,311	1,851	1,660
3,887	4,174	4,254	3,818	3,766	3,541	2,994	2,639	2,628
3,897	3,035	2,283	1,518	1,178	991	683	487	456
12,347	11,289	10,540	9,041	8,686	7,952	6,636	5,567	5,356
1,841	1,678	1,630	1,475	1,582	1,579	1,467	1,304	1,444
606	522	543	512	504	560	479	493	530
1,680	1,616	1,454	1,391	1,395	1,452	1,305	1,233	1,407
1,170	1,048	1,037	994	1,020	977	925	865	1,008
1,417	1,335	1,157	1,058	1,200	1,143	1,029	920	1,086
823	811	809	673	674	687	711	601	720
1,219	1,078	1,083	993	1,125	948	889	810	899
8,756	8,088	7,713	7,096	7,500	7,346	6,805	6,226	7,094
19,487	19,019	19,114	18,305	19,097	19,366	19,022	18,484	21,173
1,984	1,869	1,805	1,849	1,893	1,902	1,992	1,816	2,172
29,267	28,168	27,785	26,409	28,026	28,860	28,306	26,971	32,570
8,701	8,478	8,127	7,695	8,408	8,392	8,259	7,789	9,440
24,666	23,192	22,512	21,449	23,413	23,662	23,379	22,552	27,346
8,108	7,725	7,581	7,042	7,857	7,780	7,762	7,143	8,720
18,041	17,947	17,332	17,082	19,037	18,992	18,006	17,457	21,159
110,254	106,398	104,256	99,831	107,731	108,954	106,726	102,212	122,580
21,328	20,697	20,744	19,780	20,679	20,945	20,489	19,788	22,617
2,590	2,391	2,348	2,361	2,397	2,462	2,471	2,309	2,702
30,947	29,784	29,239	27,800	29,421	30,312	29,611	28,204	33,977

9,871	9,526	9,164	8,689	9,428	9,369	9,184	8,654	10,448
26,083	24,527	23,669	22,507	24,613	24,805	24,408	23,472	28,432
8,931	8,536	8,390	7,715	8,531	8,467	8,473	7,744	9,440
19,260	19,025	18,415	18,075	20,162	19,940	18,895	18,267	22,058
119,010	114,486	111,969	106,927	115,231	116,300	113,531	108,438	129,674

23.2%	-3.0%	0.2%	-4.6%	4.5%	1.3%	-2.2%	-3.4%	14.3%
22.6%	-7.7%	-1.8%	0.6%	1.5%	2.7%	0.4%	-6.6%	17.0%
22.8%	-3.8%	-1.8%	-4.9%	5.8%	3.0%	-2.3%	-4.8%	20.5%
21.5%	-3.5%	-3.8%	-5.2%	8.5%	-0.6%	-2.0%	-5.8%	20.7%
19.5%	-6.0%	-3.5%	-4.9%	9.4%	0.8%	-1.6%	-3.8%	21.1%
20.5%	-4.4%	-1.7%	-8.0%	10.6%	-0.8%	0.1%	-8.6%	21.9%
19.8%	-1.2%	-3.2%	-1.8%	11.5%	-1.1%	-5.2%	-3.3%	20.8%
21.4%	-3.8%	-2.2%	-4.5%	7.8%	0.9%	-2.4%	-4.5%	19.6%

17.9%	18.1%	18.5%	18.5%	17.9%	18.0%	18.0%	18.2%	17.4%
2.2%	2.1%	2.1%	2.2%	2.1%	2.1%	2.2%	2.1%	2.1%
26.0%	26.0%	26.1%	26.0%	25.5%	26.1%	26.1%	26.0%	26.2%
8.3%	8.3%	8.2%	8.1%	8.2%	8.1%	8.1%	8.0%	8.1%
21.9%	21.4%	21.1%	21.0%	21.4%	21.3%	21.5%	21.6%	21.9%
7.5%	7.5%	7.5%	7.2%	7.4%	7.3%	7.5%	7.1%	7.3%
16.2%	16.6%	16.4%	16.9%	17.5%	17.1%	16.6%	16.8%	17.0%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

11-Mar-11	18-Mar-11	25-Mar-11	1-Apr-11	8-Apr-11	15-Apr-11	22-Apr-11	29-Apr-11	6-May-11
21,235	20,322	20,259	20,077	20,994	20,462	19,783	19,873	21,283
2,519	2,322	2,442	2,416	2,555	2,492	2,440	2,480	2,587
31,337	29,748	29,199	30,213	30,942	29,481	29,004	29,421	31,742
9,146	8,875	8,523	9,024	9,256	9,085	8,599	8,830	9,662
26,567	25,810	25,280	26,156	26,639	25,334	24,847	25,361	27,355
8,313	7,993	7,734	8,028	8,467	8,203	7,729	8,023	8,874
19,723	18,413	17,850	18,975	19,274	17,659	17,130	18,106	19,600
118,840	113,483	111,287	114,889	118,127	112,716	109,532	112,094	121,103
546	440	430	383	379	396	362	332	323
1,294	1,013	810	702	637	545	482	420	402
2,046	1,903	1,831	1,735	1,773	1,730	1,652	1,672	1,749
350	285	235	197	177	184	159	88	83
4,236	3,641	3,306	3,017	2,966	2,855	2,655	2,512	2,557
991	1,010	941	852	862	806	720	658	686
414	368	388	378	352	388	354	316	330
949	897	814	763	731	638	586	555	605
669	624	565	611	647	595	488	454	465
749	718	742	686	607	542	504	461	482
495	465	433	430	377	378	387	308	383
681	546	528	537	490	379	411	344	365
4,948	4,628	4,411	4,257	4,066	3,726	3,450	3,096	3,316
19,698	18,872	18,888	18,842	19,753	19,260	18,701	18,883	20,274
2,105	1,954	2,054	2,038	2,203	2,104	2,086	2,164	2,257
29,094	27,838	27,575	28,748	29,574	28,298	27,936	28,446	30,735
8,477	8,251	7,958	8,413	8,609	8,490	8,111	8,376	9,197
23,772	23,189	22,707	23,735	24,259	23,062	22,691	23,228	25,124
7,818	7,528	7,301	7,598	8,090	7,825	7,342	7,715	8,491
18,692	17,582	17,087	18,241	18,607	17,096	16,560	17,674	19,152
109,656	105,214	103,570	107,615	111,095	106,135	103,427	106,486	115,230
20,689	19,882	19,829	19,694	20,615	20,066	19,421	19,541	20,960
2,519	2,322	2,442	2,416	2,555	2,492	2,440	2,480	2,587
30,043	28,735	28,389	29,511	30,305	28,936	28,522	29,001	31,340

9,146	8,875	8,523	9,024	9,256	9,085	8,599	8,830	9,662
24,521	23,907	23,449	24,421	24,866	23,604	23,195	23,689	25,606
8,313	7,993	7,734	8,028	8,467	8,203	7,729	8,023	8,874
19,373	18,128	17,615	18,778	19,097	17,475	16,971	18,018	19,517
114,604	109,842	107,981	111,872	115,161	109,861	106,877	109,582	118,546

-8.5%	-3.9%	-0.3%	-0.7%	4.7%	-2.7%	-3.2%	0.6%	7.3%
-6.8%	-7.8%	5.2%	-1.1%	5.8%	-2.5%	-2.1%	1.6%	4.3%
-11.6%	-4.4%	-1.2%	4.0%	2.7%	-4.5%	-1.4%	1.7%	8.1%
-12.5%	-3.0%	-4.0%	5.9%	2.6%	-1.8%	-5.3%	2.7%	9.4%
-13.8%	-2.5%	-1.9%	4.1%	1.8%	-5.1%	-1.7%	2.1%	8.1%
-11.9%	-3.8%	-3.2%	3.8%	5.5%	-3.1%	-5.8%	3.8%	10.6%
-12.2%	-6.4%	-2.8%	6.6%	1.7%	-8.5%	-2.9%	6.2%	8.3%
-11.6%	-4.2%	-1.7%	3.6%	2.9%	-4.6%	-2.7%	2.5%	8.2%

18.1%	18.1%	18.4%	17.6%	17.9%	18.3%	18.2%	17.8%	17.7%
2.2%	2.1%	2.3%	2.2%	2.2%	2.3%	2.3%	2.3%	2.2%
26.2%	26.2%	26.3%	26.4%	26.3%	26.3%	26.7%	26.5%	26.4%
8.0%	8.1%	7.9%	8.1%	8.0%	8.3%	8.0%	8.1%	8.2%
21.4%	21.8%	21.7%	21.8%	21.6%	21.5%	21.7%	21.6%	21.6%
7.3%	7.3%	7.2%	7.2%	7.4%	7.5%	7.2%	7.3%	7.5%
16.9%	16.5%	16.3%	16.8%	16.6%	15.9%	15.9%	16.4%	16.5%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

13-May-11	20-May-11	27-May-11	3-Jun-11	10-Jun-11	17-Jun-11	24-Jun-11	1-Jul-11	8-Jul-11
19,945	20,035	20,679	18,713	20,161	19,944	19,897	21,040	18,187
2,536	2,446	2,564	2,333	2,585	2,485	2,473	2,680	2,419
29,273	28,675	29,834	28,258	29,188	28,918	28,805	31,285	27,058
8,984	8,836	9,188	8,779	8,993	9,002	9,037	9,671	8,573
24,931	24,596	25,742	24,609	24,794	24,359	24,832	26,202	23,329
7,878	7,858	8,324	7,943	8,134	7,781	8,079	8,710	7,614
17,455	17,117	18,250	17,563	17,575	17,126	17,619	18,978	16,346
111,002	109,563	114,581	108,198	111,430	109,615	110,742	118,566	103,526
331	288	300	244	223	245	219	221	214
371	344	339	308	293	277	256	275	238
1,653	1,549	1,674	1,571	1,640	1,576	1,641	1,753	1,454
82	64	64	44	69	45	55	52	58
2,437	2,245	2,377	2,167	2,225	2,143	2,171	2,301	1,964
575	526	449	435	394	375	360	389	294
264	261	237	200	235	212	204	225	176
429	417	365	351	312	342	281	280	268
404	296	301	275	261	277	251	239	243
330	311	289	239	240	227	216	180	201
241	238	223	224	183	164	162	170	148
260	227	202	212	179	152	143	162	111
2,503	2,276	2,066	1,936	1,804	1,749	1,617	1,645	1,441
19,039	19,221	19,930	18,034	19,544	19,324	19,318	20,430	17,679
2,272	2,185	2,327	2,133	2,350	2,273	2,269	2,455	2,243
28,473	27,914	29,130	27,599	28,583	28,299	28,268	30,730	26,552
8,580	8,540	8,887	8,504	8,732	8,725	8,786	9,432	8,330
22,948	22,736	23,779	22,799	22,914	22,556	22,975	24,269	21,674
7,637	7,620	8,101	7,719	7,951	7,617	7,917	8,540	7,466
17,113	16,826	17,984	17,307	17,327	16,929	17,421	18,764	16,177
106,062	105,042	110,138	104,095	107,401	105,723	106,954	114,620	100,121
19,614	19,747	20,379	18,469	19,938	19,699	19,678	20,819	17,973
2,536	2,446	2,564	2,333	2,585	2,485	2,473	2,680	2,419
28,902	28,331	29,495	27,950	28,895	28,641	28,549	31,010	26,820

8,984	8,836	9,188	8,779	8,993	9,002	9,037	9,671	8,573
23,278	23,047	24,068	23,038	23,154	22,783	23,191	24,449	21,875
7,878	7,858	8,324	7,943	8,134	7,781	8,079	8,710	7,614
17,373	17,053	18,186	17,519	17,506	17,081	17,564	18,926	16,288
108,565	107,318	112,204	106,031	109,205	107,472	108,571	116,265	101,562

-6.4%	0.7%	3.2%	-9.4%	8.0%	-1.2%	-0.1%	5.8%	-13.7%
-2.0%	-3.5%	4.8%	-9.0%	10.8%	-3.9%	-0.5%	8.4%	-9.7%
-7.8%	-2.0%	4.1%	-5.2%	3.4%	-0.9%	-0.3%	8.6%	-13.5%
-7.0%	-1.6%	4.0%	-4.5%	2.4%	0.1%	0.4%	7.0%	-11.4%
-9.1%	-1.0%	4.4%	-4.3%	0.5%	-1.6%	1.8%	5.4%	-10.5%
-11.2%	-0.3%	5.9%	-4.6%	2.4%	-4.3%	3.8%	7.8%	-12.6%
-11.0%	-1.8%	6.6%	-3.7%	-0.1%	-2.4%	2.8%	7.8%	-13.9%
-8.4%	-1.1%	4.6%	-5.5%	3.0%	-1.6%	1.0%	7.1%	-12.6%

18.1%	18.4%	18.2%	17.4%	18.3%	18.3%	18.1%	17.9%	17.7%
2.3%	2.3%	2.3%	2.2%	2.4%	2.3%	2.3%	2.3%	2.4%
26.6%	26.4%	26.3%	26.4%	26.5%	26.6%	26.3%	26.7%	26.4%
8.3%	8.2%	8.2%	8.3%	8.2%	8.4%	8.3%	8.3%	8.4%
21.4%	21.5%	21.5%	21.7%	21.2%	21.2%	21.4%	21.0%	21.5%
7.3%	7.3%	7.4%	7.5%	7.4%	7.2%	7.4%	7.5%	7.5%
16.0%	15.9%	16.2%	16.5%	16.0%	15.9%	16.2%	16.3%	16.0%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

15-Jul-11	22-Jul-11	29-Jul-11	5-Aug-11	12-Aug-11	19-Aug-11	26-Aug-11	2-Sep-11	9-Sep-11
19,818	19,418	19,934	19,463	19,225	19,392	19,624	19,991	17,575
2,590	2,560	2,443	2,551	2,582	2,603	2,630	2,514	2,461
28,881	28,705	28,190	28,326	27,997	28,212	28,194	28,872	26,186
9,155	8,915	8,933	9,129	8,812	9,094	9,138	9,043	8,509
24,153	24,096	24,035	23,858	23,308	23,616	23,815	23,983	21,866
8,084	7,931	8,030	7,983	7,901	8,007	8,093	8,183	7,423
17,117	17,330	17,376	16,796	16,700	17,028	17,075	17,143	15,891
109,798	108,955	108,941	108,106	106,525	107,952	108,569	109,729	99,911
231	168	174	178	156	138	136	142	118
267	209	235	172	178	187	184	188	187
1,402	1,022	708	468	366	282	248	212	119
39	49	44	33	26	35	30	40	23
1,939	1,448	1,161	851	726	642	598	582	447
335	359	362	309	282	290	258	274	223
179	159	171	157	153	182	161	142	136
271	242	232	214	190	205	163	164	168
211	166	170	195	179	156	140	141	163
158	174	154	154	149	110	149	120	114
131	148	139	153	135	129	127	116	114
105	121	126	116	105	107	116	96	89
1,390	1,369	1,354	1,298	1,193	1,179	1,114	1,053	1,007
19,252	18,891	19,398	18,976	18,787	18,964	19,230	19,575	17,234
2,411	2,401	2,272	2,394	2,429	2,421	2,469	2,372	2,325
28,343	28,254	27,723	27,940	27,629	27,820	27,847	28,520	25,831
8,944	8,749	8,763	8,934	8,633	8,938	8,998	8,902	8,346
22,593	22,900	23,173	23,236	22,793	23,224	23,418	23,651	21,633
7,953	7,783	7,891	7,830	7,766	7,878	7,966	8,067	7,309
16,973	17,160	17,206	16,647	16,569	16,886	16,929	17,007	15,779
106,469	106,138	106,426	105,957	104,606	106,131	106,857	108,094	98,457
19,587	19,250	19,760	19,285	19,069	19,254	19,488	19,849	17,457
2,590	2,560	2,443	2,551	2,582	2,603	2,630	2,514	2,461
28,614	28,496	27,955	28,154	27,819	28,025	28,010	28,684	25,999

9,155	8,915	8,933	9,129	8,812	9,094	9,138	9,043	8,509
22,751	23,074	23,327	23,390	22,942	23,334	23,567	23,771	21,747
8,084	7,931	8,030	7,983	7,901	8,007	8,093	8,183	7,423
17,078	17,281	17,332	16,763	16,674	16,993	17,045	17,103	15,868
107,859	107,507	107,780	107,255	105,799	107,310	107,971	109,147	99,464

9.0%	-1.7%	2.6%	-2.4%	-1.1%	1.0%	1.2%	1.9%	-12.1%
7.1%	-1.2%	-4.6%	4.4%	1.2%	0.8%	1.0%	-4.4%	-2.1%
6.7%	-0.4%	-1.9%	0.7%	-1.2%	0.7%	-0.1%	2.4%	-9.4%
6.8%	-2.6%	0.2%	2.2%	-3.5%	3.2%	0.5%	-1.0%	-5.9%
4.0%	1.4%	1.1%	0.3%	-1.9%	1.7%	1.0%	0.9%	-8.5%
6.2%	-1.9%	1.2%	-0.6%	-1.0%	1.3%	1.1%	1.1%	-9.3%
4.9%	1.2%	0.3%	-3.3%	-0.5%	1.9%	0.3%	0.3%	-7.2%
6.2%	-0.3%	0.3%	-0.5%	-1.4%	1.4%	0.6%	1.1%	-8.9%

18.2%	17.9%	18.3%	18.0%	18.0%	17.9%	18.0%	18.2%	17.6%
2.4%	2.4%	2.3%	2.4%	2.4%	2.4%	2.4%	2.3%	2.5%
26.5%	26.5%	25.9%	26.2%	26.3%	26.1%	25.9%	26.3%	26.1%
8.5%	8.3%	8.3%	8.5%	8.3%	8.5%	8.5%	8.3%	8.6%
21.1%	21.5%	21.6%	21.8%	21.7%	21.7%	21.8%	21.8%	21.9%
7.5%	7.4%	7.5%	7.4%	7.5%	7.5%	7.5%	7.5%	7.5%
15.8%	16.1%	16.1%	15.6%	15.8%	15.8%	15.8%	15.7%	16.0%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

16-Sep-11	23-Sep-11	30-Sep-11	7-Oct-11	14-Oct-11	21-Oct-11	28-Oct-11	4-Nov-11	11-Nov-11
19,953	19,736	19,899	19,572	19,564	19,929	19,836	19,853	19,928
2,692	2,578	2,649	2,629	2,661	2,651	2,632	2,547	2,666
28,531	27,847	28,367	28,276	27,951	27,734	27,727	27,581	27,767
9,204	9,115	9,290	9,234	9,230	9,092	9,174	9,281	9,099
23,603	23,275	23,511	23,498	23,114	22,836	22,756	22,577	22,520
8,112	7,965	8,117	8,190	7,933	7,888	8,080	7,905	7,959
17,170	16,886	16,829	16,901	16,814	16,650	16,102	16,359	16,500
109,265	107,402	108,662	108,300	107,267	106,780	106,307	106,103	106,439
140	144	126	128	142	119	145	128	114
133	98	88	70	92	105	80	105	81
98	70	63	61	57	70	60	57	38
26	34	30	39	24	35	28	25	22
397	346	307	298	315	329	313	315	255
213	208	196	135	149	164	184	135	148
123	108	102	117	82	92	89	97	101
132	152	149	129	125	124	115	111	129
160	114	129	140	106	111	102	120	91
127	110	118	81	80	102	89	103	96
99	89	97	80	74	104	77	71	74
89	86	75	87	80	69	60	67	66
943	867	866	769	696	766	716	704	705
19,600	19,384	19,577	19,309	19,273	19,646	19,507	19,590	19,666
2,569	2,470	2,547	2,512	2,579	2,559	2,543	2,450	2,565
28,266	27,597	28,130	28,077	27,734	27,505	27,532	27,365	27,557
9,044	9,001	9,161	9,094	9,124	8,981	9,072	9,161	9,008
23,378	23,095	23,330	23,356	22,977	22,664	22,607	22,417	22,386
8,013	7,876	8,020	8,110	7,859	7,784	8,003	7,834	7,885
17,055	16,766	16,724	16,775	16,710	16,546	16,014	16,267	16,412
107,925	106,189	107,489	107,233	106,256	105,685	105,278	105,084	105,479
19,813	19,592	19,773	19,444	19,422	19,810	19,691	19,725	19,814
2,692	2,578	2,649	2,629	2,661	2,651	2,632	2,547	2,666
28,398	27,749	28,279	28,206	27,859	27,629	27,647	27,476	27,686

9,204	9,115	9,290	9,234	9,230	9,092	9,174	9,281	9,099
23,505	23,205	23,448	23,437	23,057	22,766	22,696	22,520	22,482
8,112	7,965	8,117	8,190	7,933	7,888	8,080	7,905	7,959
17,144	16,852	16,799	16,862	16,790	16,615	16,074	16,334	16,478
108,868	107,056	108,355	108,002	106,952	106,451	105,994	105,788	106,184

13.5%	-1.1%	0.9%	-1.7%	-0.1%	2.0%	-0.6%	0.2%	0.5%
9.4%	-4.2%	2.8%	-0.8%	1.2%	-0.4%	-0.7%	-3.2%	4.7%
9.2%	-2.3%	1.9%	-0.3%	-1.2%	-0.8%	0.1%	-0.6%	0.8%
8.2%	-1.0%	1.9%	-0.6%	0.0%	-1.5%	0.9%	1.2%	-2.0%
8.1%	-1.3%	1.0%	0.0%	-1.6%	-1.3%	-0.3%	-0.8%	-0.2%
9.3%	-1.8%	1.9%	0.9%	-3.1%	-0.6%	2.4%	-2.2%	0.7%
8.0%	-1.7%	-0.3%	0.4%	-0.4%	-1.0%	-3.3%	1.6%	0.9%
9.5%	-1.7%	1.2%	-0.3%	-1.0%	-0.5%	-0.4%	-0.2%	0.4%

18.2%	18.3%	18.2%	18.0%	18.2%	18.6%	18.6%	18.6%	18.7%
2.5%	2.4%	2.4%	2.4%	2.5%	2.5%	2.5%	2.4%	2.5%
26.1%	25.9%	26.1%	26.1%	26.0%	26.0%	26.1%	26.0%	26.1%
8.5%	8.5%	8.6%	8.5%	8.6%	8.5%	8.7%	8.8%	8.6%
21.6%	21.7%	21.6%	21.7%	21.6%	21.4%	21.4%	21.3%	21.2%
7.5%	7.4%	7.5%	7.6%	7.4%	7.4%	7.6%	7.5%	7.5%
15.7%	15.7%	15.5%	15.6%	15.7%	15.6%	15.2%	15.4%	15.5%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

18-Nov-11	25-Nov-11	2-Dec-11	9-Dec-11	16-Dec-11	23-Dec-11	30-Dec-11	6-Jan-12	13-Jan-12
20,334	17,564	21,054	20,327	20,929	21,348	16,798	18,468	20,051
2,724	2,382	2,699	2,779	2,775	2,752	2,221	2,628	2,777
28,127	24,712	29,861	27,956	28,197	28,920	24,052	26,716	27,622
9,443	8,248	10,102	9,503	9,718	9,556	8,201	9,211	9,576
22,981	20,401	24,756	22,664	23,290	23,514	20,015	21,896	23,015
8,311	7,270	8,793	8,027	8,415	8,353	7,249	7,929	8,198
16,565	14,661	17,770	16,431	16,619	16,714	14,504	15,951	16,524
108,485	95,238	115,035	107,687	109,943	111,157	93,040	102,799	107,763
124	91	113	111	130	99	93	87	109
92	93	82	80	75	74	59	86	49
38	40	50	38	28	38	44	36	30
26	16	17	17	13	26	22	21	15
280	240	262	246	246	237	218	230	203
169	133	145	152	154	170	99	98	139
91	78	80	61	92	61	60	69	69
118	132	127	137	105	127	94	115	108
106	101	119	104	108	104	83	101	98
78	79	89	80	84	91	67	71	65
83	59	73	67	65	68	67	72	80
67	53	74	59	65	74	33	70	66
712	635	707	660	673	695	503	596	625
20,041	17,340	20,796	20,064	20,645	21,079	16,606	18,283	19,803
2,633	2,304	2,619	2,718	2,683	2,691	2,161	2,559	2,708
27,917	24,487	29,652	27,739	28,017	28,719	23,899	26,515	27,465
9,337	8,147	9,983	9,399	9,610	9,452	8,118	9,110	9,478
22,865	20,282	24,617	22,546	23,178	23,385	19,904	21,789	22,920
8,228	7,211	8,720	7,960	8,350	8,285	7,182	7,857	8,118
16,472	14,592	17,679	16,355	16,541	16,614	14,449	15,860	16,443
107,493	94,363	114,066	106,781	109,024	110,225	92,319	101,973	106,935
20,210	17,473	20,941	20,216	20,799	21,249	16,705	18,381	19,942
2,724	2,382	2,699	2,779	2,775	2,752	2,221	2,628	2,777
28,035	24,619	29,779	27,876	28,122	28,846	23,993	26,630	27,573

9,443	8,248	10,102	9,503	9,718	9,556	8,201	9,211	9,576
22,943	20,361	24,706	22,626	23,262	23,476	19,971	21,860	22,985
8,311	7,270	8,793	8,027	8,415	8,353	7,249	7,929	8,198
16,539	14,645	17,753	16,414	16,606	16,688	14,482	15,930	16,509
108,205	94,998	114,773	107,441	109,697	110,920	92,822	102,569	107,560

2.0%	-13.5%	19.8%	-3.5%	2.9%	2.2%	-21.4%	10.0%	8.5%
2.2%	-12.6%	13.3%	3.0%	-0.1%	-0.8%	-19.3%	18.3%	5.7%
1.3%	-12.2%	21.0%	-6.4%	0.9%	2.6%	-16.8%	11.0%	3.5%
3.8%	-12.7%	22.5%	-5.9%	2.3%	-1.7%	-14.2%	12.3%	4.0%
2.1%	-11.3%	21.3%	-8.4%	2.8%	0.9%	-14.9%	9.5%	5.1%
4.4%	-12.5%	20.9%	-8.7%	4.8%	-0.7%	-13.2%	9.4%	3.4%
0.4%	-11.5%	21.2%	-7.5%	1.2%	0.5%	-13.2%	10.0%	3.6%
1.9%	-12.2%	20.8%	-6.4%	2.1%	1.1%	-16.3%	10.5%	4.9%

18.7%	18.4%	18.2%	18.8%	19.0%	19.2%	18.0%	17.9%	18.5%
2.5%	2.5%	2.4%	2.6%	2.5%	2.5%	2.4%	2.6%	2.6%
25.9%	25.9%	25.9%	25.9%	25.6%	26.0%	25.8%	26.0%	25.6%
8.7%	8.7%	8.8%	8.8%	8.9%	8.6%	8.8%	9.0%	8.9%
21.2%	21.4%	21.5%	21.1%	21.2%	21.2%	21.5%	21.3%	21.4%
7.7%	7.7%	7.7%	7.5%	7.7%	7.5%	7.8%	7.7%	7.6%
15.3%	15.4%	15.5%	15.3%	15.1%	15.0%	15.6%	15.5%	15.3%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

20-Jan-12	27-Jan-12	3-Feb-12	10-Feb-12	17-Feb-12	24-Feb-12	2-Mar-12	9-Mar-12	16-Mar-12
19,465	18,955	19,957	19,767	19,314	18,689	20,666	20,292	19,560
2,708	2,576	2,724	2,833	2,781	2,631	2,928	2,863	2,891
27,073	25,890	27,627	27,322	26,885	25,923	29,070	28,105	26,742
9,359	8,856	9,496	9,569	9,236	9,143	10,133	9,855	9,558
22,021	20,793	22,386	22,412	21,844	20,991	23,932	23,126	22,117
7,984	7,583	8,274	8,125	8,157	7,722	9,066	8,601	8,234
15,865	14,868	16,349	16,354	15,857	15,200	17,512	16,963	15,777
104,475	99,521	106,813	106,382	104,074	100,299	113,307	109,805	104,879
109	112	86	104	94	81	84	75	76
51	62	75	63	46	47	47	60	47
36	38	38	33	15	36	29	17	28
13	7	15	12	19	14	7	17	16
209	219	214	212	174	178	167	169	167
144	116	140	120	84	88	99	87	66
65	71	81	69	73	77	58	74	59
99	109	127	88	77	65	71	48	69
114	98	94	90	71	74	63	84	78
74	78	59	69	68	54	57	68	55
69	69	68	83	47	56	36	48	47
50	42	54	58	52	35	38	46	45
615	583	623	577	472	449	422	455	419
19,212	18,727	19,731	19,543	19,136	18,520	20,483	20,130	19,418
2,643	2,505	2,643	2,764	2,708	2,554	2,870	2,789	2,832
26,923	25,719	27,425	27,171	26,762	25,811	28,952	27,997	26,626
9,245	8,758	9,402	9,479	9,165	9,069	10,070	9,771	9,480
21,911	20,677	22,289	22,310	21,761	20,901	23,846	23,041	22,034
7,915	7,514	8,206	8,042	8,110	7,666	9,030	8,553	8,187
15,802	14,819	16,280	16,284	15,786	15,151	17,467	16,900	15,716
103,651	98,719	105,976	105,593	103,428	99,672	112,718	109,181	104,293
19,356	18,843	19,871	19,663	19,220	18,608	20,582	20,217	19,484
2,708	2,576	2,724	2,833	2,781	2,631	2,928	2,863	2,891
27,022	25,828	27,552	27,259	26,839	25,876	29,023	28,045	26,695

9,359	8,856	9,496	9,569	9,236	9,143	10,133	9,855	9,558
21,985	20,755	22,348	22,379	21,829	20,955	23,903	23,109	22,089
7,984	7,583	8,274	8,125	8,157	7,722	9,066	8,601	8,234
15,852	14,861	16,334	16,342	15,838	15,186	17,505	16,946	15,761
104,266	99,302	106,599	106,170	103,900	100,121	113,140	109,636	104,712

-2.9%	-2.7%	5.5%	-1.0%	-2.3%	-3.2%	10.6%	-1.8%	-3.6%
-2.5%	-4.9%	5.7%	4.0%	-1.8%	-5.4%	11.3%	-2.2%	1.0%
-2.0%	-4.4%	6.7%	-1.1%	-1.5%	-3.6%	12.2%	-3.4%	-4.8%
-2.3%	-5.4%	7.2%	0.8%	-3.5%	-1.0%	10.8%	-2.7%	-3.0%
-4.4%	-5.6%	7.7%	0.1%	-2.5%	-4.0%	14.1%	-3.3%	-4.4%
-2.6%	-5.0%	9.1%	-1.8%	0.4%	-5.3%	17.4%	-5.1%	-4.3%
-4.0%	-6.3%	9.9%	0.0%	-3.1%	-4.1%	15.3%	-3.2%	-7.0%
-3.1%	-4.8%	7.3%	-0.4%	-2.1%	-3.6%	13.0%	-3.1%	-4.5%

18.6%	19.0%	18.6%	18.5%	18.5%	18.6%	18.2%	18.4%	18.6%
2.6%	2.6%	2.6%	2.7%	2.7%	2.6%	2.6%	2.6%	2.8%
25.9%	26.0%	25.8%	25.7%	25.8%	25.8%	25.7%	25.6%	25.5%
9.0%	8.9%	8.9%	9.0%	8.9%	9.1%	9.0%	9.0%	9.1%
21.1%	20.9%	21.0%	21.1%	21.0%	20.9%	21.1%	21.1%	21.1%
7.7%	7.6%	7.8%	7.7%	7.9%	7.7%	8.0%	7.8%	7.9%
15.2%	15.0%	15.3%	15.4%	15.2%	15.2%	15.5%	15.5%	15.1%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

23-Mar-12	30-Mar-12	6-Apr-12	13-Apr-12	20-Apr-12	27-Apr-12	4-May-12	11-May-12	18-May-12
19,129	19,270	19,746	19,405	19,331	19,432	20,237	19,368	19,235
2,700	2,729	2,919	2,868	2,887	2,739	3,073	2,857	2,878
26,211	26,828	27,948	26,594	26,735	26,928	28,523	26,911	27,090
9,324	9,595	10,074	9,557	9,809	9,995	10,650	9,866	9,923
21,307	21,721	23,140	21,688	21,481	21,724	23,792	21,628	21,442
8,007	8,327	8,667	8,138	8,183	8,466	9,055	8,224	8,331
15,137	15,621	16,700	15,325	15,327	15,540	17,024	15,543	15,245
101,815	104,091	109,194	103,575	103,753	104,824	112,354	104,397	104,144
68	65	61	71	63	62	65	56	57
45	68	54	34	43	19	34	43	56
28	17	26	18	23	22	29	17	18
13	15	15	26	11	14	9	13	7
154	165	156	149	140	117	137	129	138
86	65	62	67	83	73	69	65	66
51	45	57	41	49	39	50	44	59
57	48	56	77	53	48	41	50	46
59	65	69	57	45	48	59	52	52
43	49	41	46	31	38	43	42	33
47	44	45	44	47	32	50	36	35
26	36	42	24	34	23	40	36	31
369	352	372	356	342	301	352	325	322
18,975	19,140	19,623	19,267	19,185	19,297	20,103	19,247	19,112
2,649	2,684	2,862	2,827	2,838	2,700	3,023	2,813	2,819
26,109	26,712	27,838	26,483	26,639	26,861	28,448	26,818	26,988
9,265	9,530	10,005	9,500	9,764	9,947	10,591	9,814	9,871
21,236	21,655	23,073	21,624	21,427	21,664	23,720	21,569	21,391
7,960	8,283	8,622	8,094	8,136	8,434	9,005	8,188	8,296
15,098	15,570	16,643	15,275	15,282	15,503	16,975	15,494	15,207
101,292	103,574	108,666	103,070	103,271	104,406	111,865	103,943	103,684
19,061	19,205	19,685	19,334	19,268	19,370	20,172	19,312	19,178
2,700	2,729	2,919	2,868	2,887	2,739	3,073	2,857	2,878
26,166	26,760	27,894	26,560	26,692	26,909	28,489	26,868	27,034

9,324	9,595	10,074	9,557	9,809	9,995	10,650	9,866	9,923
21,279	21,704	23,114	21,670	21,458	21,702	23,763	21,611	21,424
8,007	8,327	8,667	8,138	8,183	8,466	9,055	8,224	8,331
15,124	15,606	16,685	15,299	15,316	15,526	17,015	15,530	15,238
101,661	103,926	109,038	103,426	103,613	104,707	112,217	104,268	104,006

-2.2%	0.8%	2.5%	-1.8%	-0.3%	0.5%	4.1%	-4.3%	-0.7%
-6.6%	1.1%	7.0%	-1.7%	0.7%	-5.1%	12.2%	-7.0%	0.7%
-2.0%	2.3%	4.2%	-4.8%	0.5%	0.8%	5.9%	-5.7%	0.6%
-2.4%	2.9%	5.0%	-5.1%	2.6%	1.9%	6.6%	-7.4%	0.6%
-3.7%	2.0%	6.5%	-6.2%	-1.0%	1.1%	9.5%	-9.1%	-0.9%
-2.8%	4.0%	4.1%	-6.1%	0.6%	3.5%	7.0%	-9.2%	1.3%
-4.0%	3.2%	6.9%	-8.3%	0.1%	1.4%	9.6%	-8.7%	-1.9%
-2.9%	2.2%	4.9%	-5.1%	0.2%	1.1%	7.2%	-7.1%	-0.3%

18.7%	18.5%	18.1%	18.7%	18.6%	18.5%	18.0%	18.5%	18.4%
2.7%	2.6%	2.7%	2.8%	2.8%	2.6%	2.7%	2.7%	2.8%
25.7%	25.7%	25.6%	25.7%	25.8%	25.7%	25.4%	25.8%	26.0%
9.2%	9.2%	9.2%	9.2%	9.5%	9.5%	9.5%	9.5%	9.5%
20.9%	20.9%	21.2%	21.0%	20.7%	20.7%	21.2%	20.7%	20.6%
7.9%	8.0%	7.9%	7.9%	7.9%	8.1%	8.1%	7.9%	8.0%
14.9%	15.0%	15.3%	14.8%	14.8%	14.8%	15.2%	14.9%	14.7%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

25-May-12	1-Jun-12	8-Jun-12	15-Jun-12	22-Jun-12	29-Jun-12	6-Jul-12	13-Jul-12	20-Jul-12
19,950	17,751	20,090	19,240	19,435	19,625	18,121	19,401	19,361
2,994	2,763	3,077	2,974	2,961	2,970	2,993	3,162	3,096
27,611	25,256	27,667	26,871	26,516	27,245	26,077	27,246	26,885
10,478	9,523	10,178	10,091	10,138	10,271	10,151	10,246	10,267
22,187	21,004	22,503	21,340	21,546	21,624	22,079	21,694	21,663
8,732	8,124	8,464	8,287	8,493	8,496	8,532	8,535	8,620
16,101	15,161	15,903	15,008	15,583	15,472	15,707	15,535	15,554
108,053	99,582	107,882	103,811	104,672	105,703	103,660	105,819	105,446
60	45	63	70	58	44	39	46	48
31	39	40	37	40	47	38	33	37
23	18	23	17	13	8	15	9	11
13	10	22	9	8	8	10	6	8
127	112	148	133	119	107	102	94	104
49	58	52	64	57	46	30	58	54
39	53	60	51	40	29	36	40	46
50	46	60	39	32	43	33	38	38
83	53	39	39	62	44	37	30	39
42	36	35	33	37	35	30	44	26
33	37	35	37	40	30	37	25	44
27	24	29	21	14	22	9	12	14
323	307	310	284	282	249	212	247	261
19,841	17,648	19,975	19,106	19,320	19,535	18,052	19,297	19,259
2,955	2,710	3,017	2,923	2,921	2,941	2,957	3,122	3,050
27,530	25,171	27,567	26,795	26,444	27,155	26,006	27,175	26,810
10,395	9,470	10,139	10,052	10,076	10,227	10,114	10,216	10,228
22,122	20,950	22,445	21,290	21,496	21,581	22,034	21,641	21,626
8,699	8,087	8,429	8,250	8,453	8,466	8,495	8,510	8,576
16,061	15,127	15,852	14,978	15,561	15,442	15,688	15,517	15,532
107,603	99,163	107,424	103,394	104,271	105,347	103,346	105,478	105,081
19,890	17,706	20,027	19,170	19,377	19,581	18,082	19,355	19,313
2,994	2,763	3,077	2,974	2,961	2,970	2,993	3,162	3,096
27,580	25,217	27,627	26,834	26,476	27,198	26,039	27,213	26,848

10,478	9,523	10,178	10,091	10,138	10,271	10,151	10,246	10,267
22,164	20,986	22,480	21,323	21,533	21,616	22,064	21,685	21,652
8,732	8,124	8,464	8,287	8,493	8,496	8,532	8,535	8,620
16,088	15,151	15,881	14,999	15,575	15,464	15,697	15,529	15,546
107,926	99,470	107,734	103,678	104,553	105,596	103,558	105,725	105,342

3.7%	-11.0%	13.1%	-4.3%	1.1%	1.1%	-7.7%	7.0%	-0.2%
4.0%	-7.7%	11.4%	-3.3%	-0.4%	0.3%	0.8%	5.6%	-2.1%
2.0%	-8.6%	9.6%	-2.9%	-1.3%	2.7%	-4.3%	4.5%	-1.3%
5.6%	-9.1%	6.9%	-0.9%	0.5%	1.3%	-1.2%	0.9%	0.2%
3.5%	-5.3%	7.1%	-5.1%	1.0%	0.4%	2.1%	-1.7%	-0.2%
4.8%	-7.0%	4.2%	-2.1%	2.5%	0.0%	0.4%	0.0%	1.0%
5.6%	-5.8%	4.8%	-5.6%	3.8%	-0.7%	1.5%	-1.1%	0.1%
3.8%	-7.8%	8.3%	-3.8%	0.8%	1.0%	-1.9%	2.1%	-0.4%

18.4%	17.8%	18.6%	18.5%	18.5%	18.5%	17.5%	18.3%	18.3%
2.8%	2.8%	2.9%	2.9%	2.8%	2.8%	2.9%	3.0%	2.9%
25.6%	25.4%	25.6%	25.9%	25.3%	25.8%	25.1%	25.7%	25.5%
9.7%	9.6%	9.4%	9.7%	9.7%	9.7%	9.8%	9.7%	9.7%
20.5%	21.1%	20.9%	20.6%	20.6%	20.5%	21.3%	20.5%	20.6%
8.1%	8.2%	7.9%	8.0%	8.1%	8.0%	8.2%	8.1%	8.2%
14.9%	15.2%	14.7%	14.5%	14.9%	14.6%	15.2%	14.7%	14.8%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

27-Jul-12	3-Aug-12	10-Aug-12	17-Aug-12	24-Aug-12	31-Aug-12	7-Sep-12	14-Sep-12	21-Sep-12
19,124	18,880	18,728	19,146	18,966	19,382	18,162	19,493	19,356
3,010	3,096	3,063	3,163	2,936	3,119	2,941	3,272	3,140
26,251	26,490	26,142	26,661	26,414	26,829	25,783	26,819	26,541
10,122	10,252	10,131	10,474	10,376	10,354	9,993	10,591	10,318
21,141	21,700	21,358	21,459	21,046	21,720	20,946	21,565	21,147
8,510	8,484	8,393	8,628	8,662	8,553	8,237	8,635	8,619
15,153	15,102	15,157	15,418	15,181	15,189	15,156	15,301	15,107
103,311	104,004	102,972	104,949	103,581	105,146	101,218	105,676	104,228
33	45	41	33	41	22	35	25	18
36	18	42	26	22	20	18	15	10
10	8	3	10	7	8	5	6	1
4	5	8	4	9	5	1	6	1
83	76	94	73	79	55	59	52	30
46	52	31	33	15	20	19	19	13
26	23	22	24	14	23	20	27	15
31	39	31	34	15	13	23	10	6
48	24	37	37	29	40	31	34	40
24	40	27	16	15	20	19	19	13
29	35	27	22	11	3	8	13	8
14	10	17	12	8	11	18	9	8
218	223	192	178	107	130	138	131	103
19,045	18,783	18,656	19,080	18,910	19,340	18,108	19,449	19,325
2,984	3,073	3,041	3,139	2,922	3,096	2,921	3,245	3,125
26,184	26,433	26,069	26,601	26,377	26,796	25,742	26,794	26,525
10,074	10,228	10,094	10,437	10,347	10,314	9,962	10,557	10,278
21,107	21,652	21,328	21,433	21,024	21,692	20,922	21,540	21,133
8,481	8,449	8,366	8,606	8,651	8,550	8,229	8,622	8,611
15,135	15,087	15,132	15,402	15,164	15,173	15,137	15,286	15,098
103,010	103,705	102,686	104,698	103,395	104,961	101,021	105,493	104,095
19,091	18,835	18,687	19,113	18,925	19,360	18,127	19,468	19,338
3,010	3,096	3,063	3,163	2,936	3,119	2,941	3,272	3,140
26,215	26,472	26,100	26,635	26,392	26,809	25,765	26,804	26,531

10,122	10,252	10,131	10,474	10,376	10,354	9,993	10,591	10,318
21,131	21,692	21,355	21,449	21,039	21,712	20,941	21,559	21,146
8,510	8,484	8,393	8,628	8,662	8,553	8,237	8,635	8,619
15,149	15,097	15,149	15,414	15,172	15,184	15,155	15,295	15,106
103,228	103,928	102,878	104,876	103,502	105,091	101,159	105,624	104,198

-1.1%	-1.3%	-0.8%	2.3%	-1.0%	2.3%	-6.4%	7.4%	-0.7%
-2.8%	2.9%	-1.1%	3.3%	-7.2%	6.2%	-5.7%	11.3%	-4.0%
-2.4%	1.0%	-1.4%	2.0%	-0.9%	1.6%	-3.9%	4.0%	-1.0%
-1.4%	1.3%	-1.2%	3.4%	-0.9%	-0.2%	-3.5%	6.0%	-2.6%
-2.4%	2.7%	-1.6%	0.4%	-1.9%	3.2%	-3.6%	3.0%	-1.9%
-1.3%	-0.3%	-1.1%	2.8%	0.4%	-1.3%	-3.7%	4.8%	-0.2%
-2.6%	-0.3%	0.3%	1.7%	-1.6%	0.1%	-0.2%	0.9%	-1.2%
-2.0%	0.7%	-1.0%	1.9%	-1.3%	1.5%	-3.7%	4.4%	-1.4%

18.5%	18.1%	18.2%	18.2%	18.3%	18.4%	17.9%	18.4%	18.6%
2.9%	3.0%	3.0%	3.0%	2.8%	3.0%	2.9%	3.1%	3.0%
25.4%	25.5%	25.4%	25.4%	25.5%	25.5%	25.5%	25.4%	25.5%
9.8%	9.9%	9.8%	10.0%	10.0%	9.9%	9.9%	10.0%	9.9%
20.5%	20.9%	20.8%	20.5%	20.3%	20.7%	20.7%	20.4%	20.3%
8.2%	8.2%	8.2%	8.2%	8.4%	8.1%	8.1%	8.2%	8.3%
14.7%	14.5%	14.7%	14.7%	14.7%	14.4%	15.0%	14.5%	14.5%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

28-Sep-12	5-Oct-12	12-Oct-12	19-Oct-12	26-Oct-12	2-Nov-12	9-Nov-12	16-Nov-12	23-Nov-12
19,811	19,974	19,126	19,480	19,587	19,002	20,339	20,284	17,811
3,378	3,270	3,222	3,111	3,213	3,162	3,375	3,323	2,979
26,917	27,276	26,377	26,568	26,375	25,995	27,306	26,609	24,144
10,536	10,711	10,425	10,321	10,400	10,262	10,730	10,526	9,633
21,654	22,031	21,051	20,970	20,996	20,758	21,484	20,976	19,085
8,505	8,678	8,470	8,533	8,476	8,271	8,836	8,760	7,827
14,868	15,729	14,915	15,020	14,927	14,561	15,391	15,116	13,618
105,669	107,669	103,586	104,003	103,974	102,011	107,461	105,594	95,097
25	22	21	13	15	15	8	13	9
19	14	6	9	12	9	3	9	7
5	2	3	1	-	3	-	-	1
4	3	2	2	2	-	-	-	-
53	41	32	25	29	27	11	22	17
14	6	9	8	5	7	21	22	5
36	12	21	17	25	15	13	18	20
21	28	8	12	16	7	8	4	6
32	25	41	38	31	24	32	32	33
10	13	5	6	4	6	3	6	8
9	9	14	13	8	9	12	7	3
5	13	10	3	7	5	13	10	4
127	106	108	97	96	73	102	99	79
19,772	19,946	19,096	19,459	19,567	18,980	20,310	20,249	17,797
3,342	3,258	3,201	3,094	3,188	3,147	3,362	3,305	2,959
26,877	27,234	26,363	26,547	26,347	25,979	27,295	26,596	24,131
10,504	10,686	10,384	10,283	10,369	10,238	10,698	10,494	9,600
21,639	22,016	21,043	20,963	20,992	20,749	21,481	20,970	19,076
8,496	8,669	8,456	8,520	8,468	8,262	8,824	8,753	7,824
14,859	15,713	14,903	15,015	14,918	14,556	15,378	15,106	13,614
105,489	107,522	103,446	103,881	103,849	101,911	107,348	105,473	95,001
19,786	19,952	19,105	19,467	19,572	18,987	20,331	20,271	17,802
3,378	3,270	3,222	3,111	3,213	3,162	3,375	3,323	2,979
26,898	27,262	26,371	26,559	26,363	25,986	27,303	26,600	24,137

10,536	10,711	10,425	10,321	10,400	10,262	10,730	10,526	9,633
21,649	22,029	21,048	20,969	20,996	20,755	21,484	20,976	19,084
8,505	8,678	8,470	8,533	8,476	8,271	8,836	8,760	7,827
14,864	15,726	14,913	15,018	14,925	14,561	15,391	15,116	13,618
105,616	107,628	103,554	103,978	103,945	101,984	107,450	105,572	95,080

2.3%	0.8%	-4.2%	1.9%	0.5%	-3.0%	7.1%	-0.3%	-12.2%
7.6%	-3.2%	-1.5%	-3.4%	3.3%	-1.6%	6.7%	-1.5%	-10.4%
1.4%	1.4%	-3.3%	0.7%	-0.7%	-1.4%	5.1%	-2.6%	-9.3%
2.1%	1.7%	-2.7%	-1.0%	0.8%	-1.3%	4.6%	-1.9%	-8.5%
2.4%	1.8%	-4.5%	-0.4%	0.1%	-1.1%	3.5%	-2.4%	-9.0%
-1.3%	2.0%	-2.4%	0.7%	-0.7%	-2.4%	6.8%	-0.9%	-10.7%
-1.6%	5.8%	-5.2%	0.7%	-0.6%	-2.4%	5.7%	-1.8%	-9.9%
1.4%	1.9%	-3.8%	0.4%	0.0%	-1.9%	5.4%	-1.7%	-9.9%

18.7%	18.5%	18.4%	18.7%	18.8%	18.6%	18.9%	19.2%	18.7%
3.2%	3.0%	3.1%	3.0%	3.1%	3.1%	3.1%	3.1%	3.1%
25.5%	25.3%	25.5%	25.5%	25.4%	25.5%	25.4%	25.2%	25.4%
10.0%	10.0%	10.1%	9.9%	10.0%	10.1%	10.0%	10.0%	10.1%
20.5%	20.5%	20.3%	20.2%	20.2%	20.4%	20.0%	19.9%	20.1%
8.1%	8.1%	8.2%	8.2%	8.2%	8.1%	8.2%	8.3%	8.2%
14.1%	14.6%	14.4%	14.4%	14.4%	14.3%	14.3%	14.3%	14.3%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

30-Nov-12	7-Dec-12	14-Dec-12	21-Dec-12	28-Dec-12	4-Jan-13	11-Jan-13	18-Jan-13	25-Jan-13
20,799	20,914	20,496	21,521	16,162	17,966	19,797	19,703	17,903
3,431	3,492	3,449	3,573	2,728	3,096	3,551	3,341	3,022
27,881	28,197	27,005	28,340	22,397	25,104	26,793	26,177	23,542
11,068	11,293	10,838	11,296	9,015	10,247	10,847	10,667	9,567
22,179	22,137	21,172	22,042	18,122	20,382	21,341	20,543	18,348
8,938	9,076	8,775	8,955	7,478	8,333	8,888	8,631	7,662
15,218	15,980	14,847	15,667	13,090	14,542	15,160	14,947	12,930
109,514	111,089	106,582	111,394	88,992	99,670	106,377	104,009	92,974
8	6	5	3	4	1	4	8	2
4	4	4	8	3		3	3	
-	-	-	2	1	3	1		
1	1	1	1	-	1	4		3
13	11	10	14	8	5	12	11	5
11	8	18	10	4	5	7	8	6
12	16	17	12	15	13	21	13	15
8	8	4	5	6	12	7	3	5
31	28	24	31	33	45	32	37	27
3	6	10	5	5	10	3	8	9
6	4	7	3	1	2	4	1	3
6	11	6	7	6	13	3	4	8
77	81	86	73	70	100	77	74	73
20,780	20,900	20,473	21,508	16,154	17,960	19,786	19,687	17,895
3,419	3,476	3,432	3,561	2,713	3,083	3,530	3,328	3,007
27,869	28,185	26,997	28,327	22,388	25,092	26,783	26,171	23,537
11,037	11,265	10,814	11,265	8,982	10,202	10,815	10,630	9,540
22,176	22,131	21,162	22,035	18,116	20,369	21,337	20,535	18,339
8,932	9,072	8,768	8,952	7,477	8,331	8,884	8,630	7,659
15,211	15,968	14,840	15,659	13,084	14,528	15,153	14,943	12,919
109,424	110,997	106,486	111,307	88,914	99,565	106,288	103,924	92,896
20,791	20,908	20,491	21,518	16,158	17,965	19,793	19,695	17,901
3,431	3,492	3,449	3,573	2,728	3,096	3,551	3,341	3,022
27,877	28,193	27,001	28,332	22,394	25,104	26,790	26,174	23,542

11,068	11,293	10,838	11,296	9,015	10,247	10,847	10,667	9,567
22,179	22,137	21,172	22,040	18,121	20,379	21,340	20,543	18,348
8,938	9,076	8,775	8,955	7,478	8,333	8,888	8,631	7,662
15,217	15,979	14,846	15,666	13,090	14,541	15,156	14,947	12,927
109,501	111,078	106,572	111,380	88,984	99,665	106,365	103,998	92,969

16.8%	0.6%	-2.0%	5.0%	-24.9%	11.2%	10.2%	-0.5%	-9.1%
15.2%	1.8%	-1.2%	3.6%	-23.6%	13.5%	14.7%	-5.9%	-9.5%
15.5%	1.1%	-4.2%	4.9%	-21.0%	12.1%	6.7%	-2.3%	-10.1%
14.9%	2.0%	-4.0%	4.2%	-20.2%	13.7%	5.9%	-1.7%	-10.3%
16.2%	-0.2%	-4.4%	4.1%	-17.8%	12.5%	4.7%	-3.7%	-10.7%
14.2%	1.5%	-3.3%	2.1%	-16.5%	11.4%	6.7%	-2.9%	-11.2%
11.7%	5.0%	-7.1%	5.5%	-16.4%	11.1%	4.2%	-1.4%	-13.5%
15.2%	1.4%	-4.1%	4.5%	-20.1%	12.0%	6.7%	-2.2%	-10.6%

19.0%	18.8%	19.2%	19.3%	18.2%	18.0%	18.6%	18.9%	19.3%
3.1%	3.1%	3.2%	3.2%	3.1%	3.1%	3.3%	3.2%	3.3%
25.5%	25.4%	25.3%	25.4%	25.2%	25.2%	25.2%	25.2%	25.3%
10.1%	10.2%	10.2%	10.1%	10.1%	10.3%	10.2%	10.3%	10.3%
20.3%	19.9%	19.9%	19.8%	20.4%	20.4%	20.1%	19.8%	19.7%
8.2%	8.2%	8.2%	8.0%	8.4%	8.4%	8.4%	8.3%	8.2%
13.9%	14.4%	13.9%	14.1%	14.7%	14.6%	14.2%	14.4%	13.9%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

1-Feb-13	8-Feb-13	15-Feb-13	22-Feb-13	1-Mar-13	8-Mar-13	15-Mar-13	22-Mar-13	29-Mar-13
18,952	19,750	19,566	18,389	19,586	19,978	19,201	18,544	18,160
3,125	3,406	3,302	3,102	3,371	3,504	3,292	3,109	3,053
24,944	26,400	25,697	23,737	26,297	26,961	25,448	24,425	23,882
10,192	11,013	10,314	9,807	11,061	11,121	10,347	10,100	10,077
19,855	20,872	20,142	18,459	20,774	21,411	19,755	18,647	18,633
8,317	8,950	8,425	7,640	8,963	8,873	8,336	7,944	8,090
14,223	15,112	14,526	13,022	14,874	15,387	14,133	13,196	13,291
99,608	105,503	101,972	94,156	104,926	107,235	100,512	95,965	95,186
6	7	13	14	6	5	12	9	7
3	2	-	1	5	3	3	6	-
3	1	-	1	4	-	-	-	1
3	1	1	4	2	5	-	-	-
15	11	14	20	17	13	15	15	8
8	9	10	7	6	6	5	9	3
6	15	9	13	5	8	6	5	9
2	8	5	3	2	7	5	4	3
37	29	24	25	28	3	6	4	4
5	3	6	3	5	1	4	2	4
3	5	5	5	2	6	1	5	3
3	3	1	2	8	1		5	7
64	72	60	58	56	32	27	34	33
18,938	19,734	19,543	18,368	19,574	19,967	19,184	18,526	18,150
3,119	3,391	3,293	3,089	3,366	3,496	3,286	3,104	3,044
24,939	26,390	25,692	23,733	26,290	26,951	25,440	24,415	23,879
10,155	10,984	10,290	9,782	11,033	11,118	10,341	10,096	10,073
19,847	20,868	20,136	18,455	20,765	21,410	19,751	18,645	18,628
8,314	8,945	8,420	7,635	8,961	8,867	8,335	7,939	8,087
14,217	15,108	14,524	13,016	14,864	15,381	14,133	13,191	13,284
99,529	105,420	101,898	94,078	104,853	107,190	100,470	95,916	95,145
18,946	19,743	19,553	18,375	19,580	19,973	19,189	18,535	18,153
3,125	3,406	3,302	3,102	3,371	3,504	3,292	3,109	3,053
24,941	26,398	25,697	23,736	26,292	26,958	25,445	24,419	23,882

10,192	11,013	10,314	9,807	11,061	11,121	10,347	10,100	10,077
19,852	20,871	20,142	18,458	20,770	21,411	19,755	18,647	18,632
8,317	8,950	8,425	7,640	8,963	8,873	8,336	7,944	8,090
14,220	15,111	14,525	13,018	14,872	15,382	14,133	13,196	13,291
99,593	105,492	101,958	94,136	104,909	107,222	100,497	95,950	95,178

5.8%	4.2%	-1.0%	-6.0%	6.6%	2.0%	-3.9%	-3.4%	-2.1%
3.4%	9.0%	-3.1%	-6.1%	8.7%	3.9%	-6.1%	-5.6%	-1.8%
5.9%	5.8%	-2.7%	-7.6%	10.8%	2.5%	-5.6%	-4.0%	-2.2%
6.5%	8.1%	-6.3%	-4.9%	12.8%	0.5%	-7.0%	-2.4%	-0.2%
8.2%	5.1%	-3.5%	-8.4%	12.5%	3.1%	-7.7%	-5.6%	-0.1%
8.5%	7.6%	-5.9%	-9.3%	17.3%	-1.0%	-6.1%	-4.7%	1.8%
10.0%	6.3%	-3.9%	-10.4%	14.2%	3.4%	-8.1%	-6.6%	0.7%
7.1%	5.9%	-3.4%	-7.7%	11.4%	2.2%	-6.3%	-4.5%	-0.8%

19.0%	18.7%	19.2%	19.5%	18.7%	18.6%	19.1%	19.3%
3.1%	3.2%	3.2%	3.3%	3.2%	3.3%	3.3%	3.2%
25.0%	25.0%	25.2%	25.2%	25.1%	25.1%	25.3%	25.4%
10.2%	10.4%	10.1%	10.4%	10.5%	10.4%	10.3%	10.5%
19.9%	19.8%	19.8%	19.6%	19.8%	20.0%	19.7%	19.4%
8.4%	8.5%	8.3%	8.1%	8.5%	8.3%	8.3%	8.3%
14.3%	14.3%	14.2%	13.8%	14.2%	14.3%	14.1%	13.8%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

5-Apr-13	12-Apr-13	19-Apr-13	26-Apr-13	3-May-13	4-Jun-10	11-Jun-10
18,826						
3,312						
25,656						
10,612						
20,195						
8,619						
14,573						
101,793						
11	10	6	11	5		
2	2	5	-	2		
1	5	2	1	-		
-	-	-	-	2		
14	17	13	12	9		
6					100.0%	100.0%
7					100.0%	100.0%
4					100.0%	100.0%
2					100.0%	100.0%
5					100.0%	100.0%
7					100.0%	100.0%
1					100.0%	100.0%
32					100.0%	100.0%
18,809					0.0%	0.0%
3,305					0.0%	0.0%
25,650					0.0%	0.0%
10,610					0.0%	0.0%
20,189					0.0%	0.0%
8,612					0.0%	0.0%
14,572					0.0%	0.0%
101,747					0.0%	0.0%
18,815						
3,312						
25,654						

10,612	3.6%
20,194	8.5%
8,619	7.4%
14,573	5.3%
	8.4%
	6.5%
	9.6%
101,779	6.9%

Share of Total OxyContin Prescriptions (Percent Conversion to I

18-Jun-10	25-Jun-10	2-Jul-10	9-Jul-10	16-Jul-10	23-Jul-10	30-Jul-10	6-Aug-10	13-Aug-10	20-Aug-10
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.8%	96.9%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.7%	94.5%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.8%	96.7%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.8%	97.2%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.7%	94.7%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.7%	96.0%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.6%	89.7%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.7%	94.6%
0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.2%	3.1%
0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.3%	5.5%
0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.2%	3.3%
0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.2%	2.8%
0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.3%	5.3%
0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.3%	4.0%
0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.4%	10.3%
0.0%	0.000%	0.000%	0.000%	0.000%	0.000%	0.003%	0.012%	0.269%	5.351%

Reformulated OxyContin)

27-Aug-10	3-Sep-10	10-Sep-10	17-Sep-10	24-Sep-10	1-Oct-10	8-Oct-10	15-Oct-10	22-Oct-10
90.2%	79.6%	70.2%	59.9%	50.5%	43.4%	36.6%	31.7%	27.8%
88.3%	84.9%	76.4%	70.8%	66.1%	60.2%	56.3%	51.2%	48.2%
87.6%	74.1%	62.2%	50.3%	39.5%	32.2%	26.5%	21.1%	18.3%
91.6%	83.4%	76.0%	63.9%	52.6%	46.6%	40.6%	34.1%	29.0%
83.9%	70.8%	59.2%	46.9%	37.9%	31.5%	26.4%	21.6%	17.8%
86.1%	77.6%	66.7%	57.4%	47.6%	40.9%	34.6%	30.0%	26.0%
74.6%	61.5%	51.2%	42.4%	33.7%	28.6%	23.4%	20.0%	17.4%
84.5%	72.7%	62.2%	51.5%	42.0%	35.6%	30.0%	25.2%	21.8%
9.8%	20.4%	29.8%	40.1%	49.5%	56.6%	63.4%	68.3%	72.2%
11.7%	15.1%	23.6%	29.2%	33.9%	39.8%	43.7%	48.8%	51.8%
12.4%	25.9%	37.8%	49.7%	60.5%	67.8%	73.5%	78.9%	81.7%
8.4%	16.6%	24.0%	36.1%	47.4%	53.4%	59.4%	65.9%	71.0%
16.1%	29.2%	40.8%	53.1%	62.1%	68.5%	73.6%	78.4%	82.2%
13.9%	22.4%	33.3%	42.6%	52.4%	59.1%	65.4%	70.0%	74.0%
25.4%	38.5%	48.8%	57.6%	66.3%	71.4%	76.6%	80.0%	82.6%
15.500%	27.290%	37.759%	48.540%	58.003%	64.430%	69.983%	74.814%	78.209%

29-Oct-10	5-Nov-10	12-Nov-10	19-Nov-10	26-Nov-10	3-Dec-10	10-Dec-10	17-Dec-10	24-Dec-10
23.2%	20.9%	17.7%	15.3%	14.0%	13.1%	11.4%	7.9%	9.2%
42.9%	35.9%	36.1%	33.2%	31.3%	27.1%	27.0%	19.8%	22.3%
14.7%	12.7%	10.5%	9.4%	9.0%	7.8%	7.3%	5.6%	5.9%
26.2%	23.8%	21.0%	18.4%	16.3%	13.6%	12.7%	11.6%	13.1%
15.1%	13.0%	11.2%	9.9%	8.5%	8.0%	7.2%	5.7%	5.6%
22.1%	19.9%	17.8%	17.2%	14.1%	13.7%	12.1%	10.1%	10.5%
14.3%	11.8%	10.8%	9.9%	8.8%	8.3%	8.3%	6.2%	6.0%
18.3%	16.0%	14.0%	12.5%	11.2%	10.2%	9.4%	7.2%	7.7%
76.8%	79.1%	82.3%	84.7%	86.0%	86.9%	88.6%	92.1%	90.8%
57.1%	64.1%	63.9%	66.8%	68.7%	72.9%	73.0%	80.2%	77.7%
85.3%	87.3%	89.5%	90.6%	91.0%	92.2%	92.7%	94.4%	94.1%
73.8%	76.2%	79.0%	81.6%	83.7%	86.4%	87.3%	88.4%	86.9%
84.9%	87.0%	88.8%	90.1%	91.5%	92.0%	92.8%	94.3%	94.4%
77.9%	80.1%	82.2%	82.8%	85.9%	86.3%	87.9%	89.9%	89.5%
85.7%	88.2%	89.2%	90.1%	91.2%	91.7%	91.7%	93.8%	94.0%
81.723%	83.992%	86.047%	87.542%	88.827%	89.841%	90.634%	92.775%	92.275%

31-Dec-10	7-Jan-11	14-Jan-11	21-Jan-11	28-Jan-11	4-Feb-11	11-Feb-11	18-Feb-11	25-Feb-11
8.8%	8.6%	8.1%	7.9%	7.5%	7.7%	7.5%	7.2%	6.6%
21.7%	23.4%	21.8%	23.1%	21.7%	21.0%	22.7%	19.4%	21.4%
5.3%	5.4%	5.4%	5.0%	5.0%	4.7%	4.8%	4.4%	4.4%
12.4%	11.9%	11.0%	11.3%	11.4%	10.8%	10.4%	10.1%	10.0%
5.5%	5.4%	5.4%	4.9%	4.7%	4.9%	4.6%	4.2%	3.9%
9.7%	9.2%	9.5%	9.6%	8.7%	7.9%	8.1%	8.4%	7.8%
6.1%	6.3%	5.7%	5.9%	5.5%	5.6%	4.8%	4.7%	4.4%
7.4%	7.4%	7.1%	6.9%	6.6%	6.5%	6.3%	6.0%	5.7%
91.2%	91.4%	91.9%	92.1%	92.5%	92.3%	92.5%	92.8%	93.4%
78.3%	76.6%	78.2%	76.9%	78.3%	79.0%	77.3%	80.6%	78.6%
94.7%	94.6%	94.6%	95.0%	95.0%	95.3%	95.2%	95.6%	95.6%
87.6%	88.1%	89.0%	88.7%	88.6%	89.2%	89.6%	89.9%	90.0%
94.5%	94.6%	94.6%	95.1%	95.3%	95.1%	95.4%	95.8%	96.1%
90.3%	90.8%	90.5%	90.4%	91.3%	92.1%	91.9%	91.6%	92.2%
93.9%	93.7%	94.3%	94.1%	94.5%	94.4%	95.2%	95.3%	95.6%
92.646%	92.643%	92.935%	93.111%	93.364%	93.491%	93.684%	94.006%	94.258%

4-Mar-11	11-Mar-11	18-Mar-11	25-Mar-11	1-Apr-11	8-Apr-11	15-Apr-11	22-Apr-11	29-Apr-11
6.4%	4.8%	5.1%	4.7%	4.3%	4.2%	4.0%	3.7%	3.4%
19.6%	16.4%	15.8%	15.9%	15.6%	13.8%	15.6%	14.5%	12.7%
4.1%	3.2%	3.1%	2.9%	2.6%	2.4%	2.2%	2.1%	1.9%
9.6%	7.3%	7.0%	6.6%	6.8%	7.0%	6.5%	5.7%	5.1%
3.8%	3.1%	3.0%	3.2%	2.8%	2.4%	2.3%	2.2%	1.9%
7.6%	6.0%	5.8%	5.6%	5.4%	4.5%	4.6%	5.0%	3.8%
4.1%	3.5%	3.0%	3.0%	2.9%	2.6%	2.2%	2.4%	1.9%
5.5%	4.3%	4.2%	4.1%	3.8%	3.5%	3.4%	3.2%	2.8%
93.6%	95.2%	94.9%	95.3%	95.7%	95.8%	96.0%	96.3%	96.6%
80.4%	83.6%	84.2%	84.1%	84.4%	86.2%	84.4%	85.5%	87.3%
95.9%	96.8%	96.9%	97.1%	97.4%	97.6%	97.8%	97.9%	98.1%
90.4%	92.7%	93.0%	93.4%	93.2%	93.0%	93.5%	94.3%	94.9%
96.2%	96.9%	97.0%	96.8%	97.2%	97.6%	97.7%	97.8%	98.1%
92.4%	94.0%	94.2%	94.4%	94.6%	95.5%	95.4%	95.0%	96.2%
95.9%	96.5%	97.0%	97.0%	97.1%	97.4%	97.8%	97.6%	98.1%
94.529%	95.683%	95.787%	95.915%	96.195%	96.469%	96.608%	96.772%	97.175%

6-May-11	13-May-11	20-May-11	27-May-11	3-Jun-11	10-Jun-11	17-Jun-11	24-Jun-11	1-Jul-11
3.3%	2.9%	2.7%	2.2%	2.4%	2.0%	1.9%	1.8%	1.9%
12.8%	10.4%	10.7%	9.2%	8.6%	9.1%	8.5%	8.2%	8.4%
1.9%	1.5%	1.5%	1.2%	1.3%	1.1%	1.2%	1.0%	0.9%
4.8%	4.5%	3.3%	3.3%	3.1%	2.9%	3.1%	2.8%	2.5%
1.9%	1.4%	1.3%	1.2%	1.0%	1.0%	1.0%	0.9%	0.7%
4.3%	3.1%	3.0%	2.7%	2.8%	2.2%	2.1%	2.0%	2.0%
1.9%	1.5%	1.3%	1.1%	1.2%	1.0%	0.9%	0.8%	0.9%
2.8%	2.3%	2.1%	1.8%	1.8%	1.7%	1.6%	1.5%	1.4%
96.7%	97.1%	97.3%	97.8%	97.6%	98.0%	98.1%	98.2%	98.1%
87.2%	89.6%	89.3%	90.8%	91.4%	90.9%	91.5%	91.8%	91.6%
98.1%	98.5%	98.5%	98.8%	98.7%	98.9%	98.8%	99.0%	99.1%
95.2%	95.5%	96.7%	96.7%	96.9%	97.1%	96.9%	97.2%	97.5%
98.1%	98.6%	98.7%	98.8%	99.0%	99.0%	99.0%	99.1%	99.3%
95.7%	96.9%	97.0%	97.3%	97.2%	97.8%	97.9%	98.0%	98.0%
98.1%	98.5%	98.7%	98.9%	98.8%	99.0%	99.1%	99.2%	99.1%
97.203%	97.694%	97.879%	98.159%	98.174%	98.348%	98.373%	98.511%	98.585%

8-Jul-11	15-Jul-11	22-Jul-11	29-Jul-11	5-Aug-11	12-Aug-11	19-Aug-11	26-Aug-11	2-Sep-11	9-Sep-11
1.6%	1.7%	1.9%	1.8%	1.6%	1.5%	1.5%	1.3%	1.4%	1.3%
7.3%	6.9%	6.2%	7.0%	6.2%	5.9%	7.0%	6.1%	5.6%	5.5%
1.0%	0.9%	0.8%	0.8%	0.8%	0.7%	0.7%	0.6%	0.6%	0.6%
2.8%	2.3%	1.9%	1.9%	2.1%	2.0%	1.7%	1.5%	1.6%	1.9%
0.9%	0.7%	0.8%	0.7%	0.7%	0.6%	0.5%	0.6%	0.5%	0.5%
1.9%	1.6%	1.9%	1.7%	1.9%	1.7%	1.6%	1.6%	1.4%	1.5%
0.7%	0.6%	0.7%	0.7%	0.7%	0.6%	0.6%	0.7%	0.6%	0.6%
1.4%	1.3%	1.3%	1.3%	1.2%	1.1%	1.1%	1.0%	1.0%	1.0%
98.4%	98.3%	98.1%	98.2%	98.4%	98.5%	98.5%	98.7%	98.6%	98.7%
92.7%	93.1%	93.8%	93.0%	93.8%	94.1%	93.0%	93.9%	94.4%	94.5%
99.0%	99.1%	99.2%	99.2%	99.2%	99.3%	99.3%	99.4%	99.4%	99.4%
97.2%	97.7%	98.1%	98.1%	97.9%	98.0%	98.3%	98.5%	98.4%	98.1%
99.1%	99.3%	99.2%	99.3%	99.3%	99.4%	99.5%	99.4%	99.5%	99.5%
98.1%	98.4%	98.1%	98.3%	98.1%	98.3%	98.4%	98.4%	98.6%	98.5%
99.3%	99.4%	99.3%	99.3%	99.3%	99.4%	99.4%	99.3%	99.4%	99.4%
98.581%	98.711%	98.727%	98.744%	98.790%	98.872%	98.901%	98.968%	99.035%	98.988%

16-Sep-11	23-Sep-11	30-Sep-11	7-Oct-11	14-Oct-11	21-Oct-11	28-Oct-11	4-Nov-11	11-Nov-11
1.1%	1.1%	1.0%	0.7%	0.8%	0.8%	0.9%	0.7%	0.7%
4.6%	4.2%	3.9%	4.5%	3.1%	3.5%	3.4%	3.8%	3.8%
0.5%	0.5%	0.5%	0.5%	0.4%	0.4%	0.4%	0.4%	0.5%
1.7%	1.3%	1.4%	1.5%	1.1%	1.2%	1.1%	1.3%	1.0%
0.5%	0.5%	0.5%	0.3%	0.3%	0.4%	0.4%	0.5%	0.4%
1.2%	1.1%	1.2%	1.0%	0.9%	1.3%	1.0%	0.9%	0.9%
0.5%	0.5%	0.4%	0.5%	0.5%	0.4%	0.4%	0.4%	0.4%
0.9%	0.8%	0.8%	0.7%	0.7%	0.7%	0.7%	0.7%	0.7%
98.9%	98.9%	99.0%	99.3%	99.2%	99.2%	99.1%	99.3%	99.3%
95.4%	95.8%	96.1%	95.5%	96.9%	96.5%	96.6%	96.2%	96.2%
99.5%	99.5%	99.5%	99.5%	99.6%	99.6%	99.6%	99.6%	99.5%
98.3%	98.7%	98.6%	98.5%	98.9%	98.8%	98.9%	98.7%	99.0%
99.5%	99.5%	99.5%	99.7%	99.7%	99.6%	99.6%	99.5%	99.6%
98.8%	98.9%	98.8%	99.0%	99.1%	98.7%	99.0%	99.1%	99.1%
99.5%	99.5%	99.6%	99.5%	99.5%	99.6%	99.6%	99.6%	99.6%
99.134%	99.190%	99.201%	99.288%	99.349%	99.280%	99.324%	99.335%	99.336%

18-Nov-11	25-Nov-11	2-Dec-11	9-Dec-11	16-Dec-11	23-Dec-11	30-Dec-11	6-Jan-12	13-Jan-12
0.8%	0.8%	0.7%	0.8%	0.7%	0.8%	0.6%	0.5%	0.7%
3.3%	3.3%	3.0%	2.2%	3.3%	2.2%	2.7%	2.6%	2.5%
0.4%	0.5%	0.4%	0.5%	0.4%	0.4%	0.4%	0.4%	0.4%
1.1%	1.2%	1.2%	1.1%	1.1%	1.1%	1.0%	1.1%	1.0%
0.3%	0.4%	0.4%	0.4%	0.4%	0.4%	0.3%	0.3%	0.3%
1.0%	0.8%	0.8%	0.8%	0.8%	0.8%	0.9%	0.9%	1.0%
0.4%	0.4%	0.4%	0.4%	0.4%	0.4%	0.2%	0.4%	0.4%
0.7%	0.7%	0.6%	0.6%	0.6%	0.6%	0.5%	0.6%	0.6%
99.2%	99.2%	99.3%	99.2%	99.3%	99.2%	99.4%	99.5%	99.3%
96.7%	96.7%	97.0%	97.8%	96.7%	97.8%	97.3%	97.4%	97.5%
99.6%	99.5%	99.6%	99.5%	99.6%	99.6%	99.6%	99.6%	99.6%
98.9%	98.8%	98.8%	98.9%	98.9%	98.9%	99.0%	98.9%	99.0%
99.7%	99.6%	99.6%	99.6%	99.6%	99.6%	99.7%	99.7%	99.7%
99.0%	99.2%	99.2%	99.2%	99.2%	99.2%	99.1%	99.1%	99.0%
99.6%	99.6%	99.6%	99.6%	99.6%	99.6%	99.8%	99.6%	99.6%
99.342%	99.332%	99.384%	99.386%	99.386%	99.373%	99.458%	99.419%	99.419%

20-Jan-12	27-Jan-12	3-Feb-12	10-Feb-12	17-Feb-12	24-Feb-12	2-Mar-12	9-Mar-12	16-Mar-12
0.7%	0.6%	0.7%	0.6%	0.4%	0.5%	0.5%	0.4%	0.3%
2.4%	2.8%	3.0%	2.4%	2.6%	2.9%	2.0%	2.6%	2.0%
0.4%	0.4%	0.5%	0.3%	0.3%	0.3%	0.2%	0.2%	0.3%
1.2%	1.1%	1.0%	0.9%	0.8%	0.8%	0.6%	0.9%	0.8%
0.3%	0.4%	0.3%	0.3%	0.3%	0.3%	0.2%	0.3%	0.2%
0.9%	0.9%	0.8%	1.0%	0.6%	0.7%	0.4%	0.6%	0.6%
0.3%	0.3%	0.3%	0.4%	0.3%	0.2%	0.2%	0.3%	0.3%
0.6%	0.6%	0.6%	0.5%	0.5%	0.4%	0.4%	0.4%	0.4%
99.3%	99.4%	99.3%	99.4%	99.6%	99.5%	99.5%	99.6%	99.7%
97.6%	97.2%	97.0%	97.6%	97.4%	97.1%	98.0%	97.4%	98.0%
99.6%	99.6%	99.5%	99.7%	99.7%	99.7%	99.8%	99.8%	99.7%
98.8%	98.9%	99.0%	99.1%	99.2%	99.2%	99.4%	99.1%	99.2%
99.7%	99.6%	99.7%	99.7%	99.7%	99.7%	99.8%	99.7%	99.8%
99.1%	99.1%	99.2%	99.0%	99.4%	99.3%	99.6%	99.4%	99.4%
99.7%	99.7%	99.7%	99.6%	99.7%	99.8%	99.8%	99.7%	99.7%
99.410%	99.413%	99.416%	99.457%	99.546%	99.552%	99.627%	99.585%	99.600%

23-Mar-12	30-Mar-12	6-Apr-12	13-Apr-12	20-Apr-12	27-Apr-12	4-May-12	11-May-12	18-May-12
0.5%	0.3%	0.3%	0.3%	0.4%	0.4%	0.3%	0.3%	0.3%
1.9%	1.6%	2.0%	1.4%	1.7%	1.4%	1.6%	1.5%	2.1%
0.2%	0.2%	0.2%	0.3%	0.2%	0.2%	0.1%	0.2%	0.2%
0.6%	0.7%	0.7%	0.6%	0.5%	0.5%	0.6%	0.5%	0.5%
0.2%	0.2%	0.2%	0.2%	0.1%	0.2%	0.2%	0.2%	0.2%
0.6%	0.5%	0.5%	0.5%	0.6%	0.4%	0.6%	0.4%	0.4%
0.2%	0.2%	0.3%	0.2%	0.2%	0.1%	0.2%	0.2%	0.2%
0.4%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%
99.5%	99.7%	99.7%	99.7%	99.6%	99.6%	99.7%	99.7%	99.7%
98.1%	98.4%	98.0%	98.6%	98.3%	98.6%	98.4%	98.5%	97.9%
99.8%	99.8%	99.8%	99.7%	99.8%	99.8%	99.9%	99.8%	99.8%
99.4%	99.3%	99.3%	99.4%	99.5%	99.5%	99.4%	99.5%	99.5%
99.8%	99.8%	99.8%	99.8%	99.9%	99.8%	99.8%	99.8%	99.8%
99.4%	99.5%	99.5%	99.5%	99.4%	99.6%	99.4%	99.6%	99.6%
99.8%	99.8%	99.7%	99.8%	99.8%	99.9%	99.8%	99.8%	99.8%
99.637%	99.661%	99.659%	99.656%	99.670%	99.713%	99.686%	99.688%	99.690%

25-May-12	1-Jun-12	8-Jun-12	15-Jun-12	22-Jun-12	29-Jun-12	6-Jul-12	13-Jul-12	20-Jul-12	27-Jul-12
0.2%	0.3%	0.3%	0.3%	0.3%	0.2%	0.2%	0.3%	0.3%	0.2%
1.3%	1.9%	1.9%	1.7%	1.4%	1.0%	1.2%	1.3%	1.5%	0.9%
0.2%	0.2%	0.2%	0.1%	0.1%	0.2%	0.1%	0.1%	0.1%	0.1%
0.8%	0.6%	0.4%	0.4%	0.6%	0.4%	0.4%	0.3%	0.4%	0.5%
0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.1%	0.2%	0.1%	0.1%
0.4%	0.5%	0.4%	0.4%	0.5%	0.4%	0.4%	0.3%	0.5%	0.3%
0.2%	0.2%	0.2%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
0.3%	0.3%	0.3%	0.3%	0.3%	0.2%	0.2%	0.2%	0.2%	0.2%
99.8%	99.7%	99.7%	99.7%	99.7%	99.8%	99.8%	99.7%	99.7%	99.8%
98.7%	98.1%	98.1%	98.3%	98.6%	99.0%	98.8%	98.7%	98.5%	99.1%
99.8%	99.8%	99.8%	99.9%	99.9%	99.8%	99.9%	99.9%	99.9%	99.9%
99.2%	99.4%	99.6%	99.6%	99.4%	99.6%	99.6%	99.7%	99.6%	99.5%
99.8%	99.8%	99.8%	99.8%	99.8%	99.8%	99.9%	99.8%	99.9%	99.9%
99.6%	99.5%	99.6%	99.6%	99.5%	99.6%	99.6%	99.7%	99.5%	99.7%
99.8%	99.8%	99.8%	99.9%	99.9%	99.9%	99.9%	99.9%	99.9%	99.9%
99.701%	99.691%	99.712%	99.726%	99.730%	99.764%	99.795%	99.766%	99.752%	99.789%

3-Aug-12	10-Aug-12	17-Aug-12	24-Aug-12	31-Aug-12	7-Sep-12	14-Sep-12	21-Sep-12	28-Sep-12
0.3%	0.2%	0.2%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
0.7%	0.7%	0.8%	0.5%	0.7%	0.7%	0.8%	0.5%	1.1%
0.1%	0.1%	0.1%	0.1%	0.0%	0.1%	0.0%	0.0%	0.1%
0.2%	0.4%	0.4%	0.3%	0.4%	0.3%	0.3%	0.4%	0.3%
0.2%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.0%
0.4%	0.3%	0.3%	0.1%	0.0%	0.1%	0.2%	0.1%	0.1%
0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.0%
0.2%	0.2%	0.2%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
99.7%	99.8%	99.8%	99.9%	99.9%	99.9%	99.9%	99.9%	99.9%
99.3%	99.3%	99.2%	99.5%	99.3%	99.3%	99.2%	99.5%	98.9%
99.9%	99.9%	99.9%	99.9%	100.0%	99.9%	100.0%	100.0%	99.9%
99.8%	99.6%	99.6%	99.7%	99.6%	99.7%	99.7%	99.6%	99.7%
99.8%	99.9%	99.9%	99.9%	99.9%	99.9%	99.9%	99.9%	100.0%
99.6%	99.7%	99.7%	99.9%	100.0%	99.9%	99.8%	99.9%	99.9%
99.9%	99.9%	99.9%	99.9%	99.9%	99.9%	99.9%	99.9%	100.0%
99.785%	99.813%	99.830%	99.897%	99.876%	99.864%	99.876%	99.901%	99.880%

5-Oct-12	12-Oct-12	19-Oct-12	26-Oct-12	2-Nov-12	9-Nov-12	16-Nov-12	23-Nov-12	30-Nov-12
0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%	0.0%	0.1%
0.4%	0.7%	0.5%	0.8%	0.5%	0.4%	0.5%	0.7%	0.3%
0.1%	0.0%	0.0%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%
0.2%	0.4%	0.4%	0.3%	0.2%	0.3%	0.3%	0.3%	0.3%
0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
0.1%	0.2%	0.2%	0.1%	0.1%	0.1%	0.1%	0.0%	0.1%
0.1%	0.1%	0.0%	0.0%	0.0%	0.1%	0.1%	0.0%	0.0%
0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
100.0%	100.0%	100.0%	100.0%	100.0%	99.9%	99.9%	100.0%	99.9%
99.6%	99.3%	99.5%	99.2%	99.5%	99.6%	99.5%	99.3%	99.7%
99.9%	100.0%	100.0%	99.9%	100.0%	100.0%	100.0%	100.0%	100.0%
99.8%	99.6%	99.6%	99.7%	99.8%	99.7%	99.7%	99.7%	99.7%
99.9%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
99.9%	99.8%	99.8%	99.9%	99.9%	99.9%	99.9%	100.0%	99.9%
99.9%	99.9%	100.0%	100.0%	100.0%	99.9%	99.9%	100.0%	100.0%
99.902%	99.896%	99.907%	99.908%	99.928%	99.905%	99.906%	99.917%	99.930%

7-Dec-12	14-Dec-12	21-Dec-12	28-Dec-12	4-Jan-13	11-Jan-13	18-Jan-13	25-Jan-13	1-Feb-13	8-Feb-13
0.0%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
0.5%	0.5%	0.3%	0.5%	0.4%	0.6%	0.4%	0.5%	0.2%	0.4%
0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
0.2%	0.2%	0.3%	0.4%	0.4%	0.3%	0.3%	0.3%	0.4%	0.3%
0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
0.0%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%
0.1%	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%	0.1%	0.0%	0.0%
0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
100.0%	99.9%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
99.5%	99.5%	99.7%	99.5%	99.6%	99.4%	99.6%	99.5%	99.8%	99.6%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
99.8%	99.8%	99.7%	99.6%	99.6%	99.7%	99.7%	99.7%	99.6%	99.7%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
100.0%	99.9%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.9%
99.9%	100.0%	100.0%	100.0%	99.9%	100.0%	100.0%	99.9%	100.0%	100.0%
99.927%	99.919%	99.934%	99.921%	99.900%	99.928%	99.929%	99.921%	99.936%	99.932%

15-Feb-13	22-Feb-13	1-Mar-13	8-Mar-13	15-Mar-13	22-Mar-13	29-Mar-13	5-Apr-13	12-Apr-13
0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
0.3%	0.4%	0.1%	0.2%	0.2%	0.2%	0.3%	0.2%	
0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
0.2%	0.3%	0.3%	0.0%	0.1%	0.0%	0.0%	0.0%	
0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
0.1%	0.1%	0.0%	0.1%	0.0%	0.1%	0.0%	0.1%	
0.0%	0.0%	0.1%	0.0%	0.0%	0.0%	0.1%	0.0%	
0.1%	0.1%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	
99.9%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	
99.7%	99.6%	99.9%	99.8%	99.8%	99.8%	99.7%	99.8%	
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	
99.8%	99.7%	99.7%	100.0%	99.9%	100.0%	100.0%	100.0%	
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	
99.9%	99.9%	100.0%	99.9%	100.0%	99.9%	100.0%	99.9%	
100.0%	100.0%	99.9%	100.0%	100.0%	100.0%	99.9%	100.0%	
99.941%	99.938%	99.947%	99.970%	99.973%	99.965%	99.965%	99.969%	


Weekly OxyContin Total Prescriptions
Retail Pharmacies, Mail order, and LTC
All Numbers are Absolute
160,000
140,000
120,000
100,000
80,000
60,000
40,000
20,000
-
3-Dec-10
17-Dec-10
31-Dec-10
14-Jan-11
28-Jan-11
11-Feb-11
25-Feb-11
11-Mar-11
25-Mar-11
8-Apr-11
22-Apr-11
6-May-11
20-May-11
3-Jun-11
17-Jun-11
1-Jul-11
15-Jul-11
29-Jul-11
12-Aug-11
26-Aug-11
9-Sep-11
23-Sep-11
7-Oct-11
21-Oct-11
4-Nov-11
18-Nov-11
2-Dec-11
16-Dec-11
30-Dec-11
13-Jan-12
27-Jan-12
10-Feb-12
24-Feb-12
9-Mar-12
23-Mar-12
6-Apr-12
20-Apr-12
4-May-12
18-May-12
1-Jun-12
15-Jun-12
29-Jun-12
13-Jul-12
27-Jul-12
10-Aug-12
24-Aug-12
7-Sep-12
21-Sep-12
5-Oct-12
19-Oct-12
2-Nov-12
16-Nov-12
30-Nov-12
14-Dec-12
28-Dec-12
11-Jan-13
25-Jan-13
8-Feb-13
22-Feb-13
8-Mar-13
22-Mar-13
5-Apr-13
19-Apr-13
3-May-13
17-May-13
31-May-13
14-Jun-13
28-Jun-13
OxyContin


OxyContin Total Prescriptions By Strength
Retail Pharmacies, Mail Order, and LTC
All Numbers Absolute
40,000
35,000
30,000
25,000
20,000
15,000
10,000
5,000
-
7-Jan-11
21-Jan-11
4-Feb-11
18-Feb-11
4-Mar-11
18-Mar-11
1-Apr-11
15-Apr-11
29-Apr-11
13-May-11
27-May-11
10-Jun-11
24-Jun-11
8-Jul-11
22-Jul-11
5-Aug-11
19-Aug-11
2-Sep-11
16-Sep-11
30-Sep-11
14-Oct-11
28-Oct-11
11-Nov-11
25-Nov-11
9-Dec-11
23-Dec-11
6-Jan-12
20-Jan-12
3-Feb-12
17-Feb-12
2-Mar-12
16-Mar-12
30-Mar-12
13-Apr-12
27-Apr-12
11-May-12
25-May-12
8-Jun-12
22-Jun-12
6-Jul-12
20-Jul-12
3-Aug-12
17-Aug-12
31-Aug-12
14-Sep-12
28-Sep-12
12-Oct-12
26-Oct-12
9-Nov-12
23-Nov-12
7-Dec-12
21-Dec-12
4-Jan-13
18-Jan-13
1-Feb-13
15-Feb-13
1-Mar-13
15-Mar-13
29-Mar-13
12-Apr-13
26-Apr-13
10-May-13
24-May-13
7-Jun-13
21-Jun-13
10MG
15MG
20MG
30MG
40MG
60MG
80MG

Embeda Total Prescriptions
IMS NPA
numbers are absolute. Retail pharmacy only.

		20-Jan-12	27-Jan-12	3-Feb-12	10-Feb-12	17-Feb-12	24-Feb-12
Embeda	Total						
	20-0.8mg						
	30-1.8mg						
	60-2.4mg						

2-Mar-12	9-Mar-12	16-Mar-12	23-Mar-12	30-Mar-12	6-Apr-12	13-Apr-12	20-Apr-12	27-Apr-12
1				1				
1								
				1				

4-May-12	11-May-12	18-May-12	25-May-12	1-Jun-12	8-Jun-12	15-Jun-12	22-Jun-12	29-Jun-12
					1			
					1			

6-Jul-12 13-Jul-12 20-Jul-12 27-Jul-12 3-Aug-12 10-Aug-12 17-Aug-12 24-Aug-12 31-Aug-12

7-Sep-12 14-Sep-12 21-Sep-12 28-Sep-12 5-Oct-12 12-Oct-12 19-Oct-12 26-Oct-12 2-Nov-12

9-Nov-12	16-Nov-12	23-Nov-12	30-Nov-12	7-Dec-12	14-Dec-12	21-Dec-12	28-Dec-12	4-Jan-13
1		1						
		1						
1								

11-Jan-13 18-Jan-13 25-Jan-13 1-Feb-13 8-Feb-13 15-Feb-13


Comparison of Weekly OxyContin TRx's
2009-2013
Retail Pharmacies, Mail Order and LTC
160,000
140,000
120,000
100,000
80,000
60,000
40,000
20,000
-
Week 1
Week 3
Week 5
Week 7
Week 9
Week 11
Week 13
Week 15
Week 17
Week 19
Week 21
Week 23
Week 25
Week 27
Week 29
Week 31
Week 33
Week 35
Week 37
Week 39
Week 41
Week 43
Week 45
Week 47
Week 49
Week 51
2009
2010
2011
2012
2013

OxyContin Weekly TRx - Original Formulation and Reformulation							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 1	**Week 2**	**Week 3**	**Week 4**	**Week 5**	**Week 6**
Strength	**Week Ending**	**2-Jan-09**	**9-Jan-09**	**16-Jan-09**	**23-Jan-09**	**30-Jan-09**	**6-Feb-09**
10MG		14,904	18,498	18,242	16,859	16,605	18,379
15MG		1,087	1,490	1,336	1,171	1,128	1,300
20MG		28,407	34,398	32,742	27,630	25,232	28,854
30MG		4,284	5,468	5,380	4,921	4,603	5,327
40MG		25,393	30,567	30,047	27,015	24,862	28,662
60MG		4,336	5,273	5,095	4,783	4,541	5,349
80MG		21,508	26,618	25,483	21,655	20,320	24,194
Total	**2009**	99,919	122,312	118,325	104,034	97,291	112,065
		8-Jan-10	**15-Jan-10**	**22-Jan-10**	**29-Jan-10**	**5-Feb-10**	**12-Feb-10**
10MG		15,812	19,748	18,906	20,664	19,175	20,070
15MG		1,643	2,072	2,007	2,260	2,293	2,542
20MG		26,804	32,159	29,875	30,068	28,571	31,249
30MG		6,994	8,689	8,190	8,997	8,882	9,772
40MG		27,435	33,418	30,776	30,018	28,291	31,702
60MG		7,248	8,574	8,214	8,326	8,203	9,104
80MG		22,376	28,047	26,191	25,286	24,406	27,199
Total	**2010**	108,312	132,707	124,159	125,619	119,821	131,638
		7-Jan-11	**14-Jan-11**	**21-Jan-11**	**28-Jan-11**	**4-Feb-11**	**11-Feb-11**
10MG		27,567	27,181	27,431	26,218	27,359	28,076
15MG		3,125	2,986	2,963	2,913	3,054	3,117
20MG		35,502	34,019	33,496	32,085	33,707	34,570
30MG		11,149	10,736	10,255	9,720	10,743	10,563
40MG		27,583	25,880	24,853	23,601	26,130	26,037
60MG		9,745	9,326	8,988	8,333	9,199	9,239

OxyContin Weekly TRx - Original Formulation and Reformulation							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 1	**Week 2**	**Week 3**	**Week 4**	**Week 5**	**Week 6**
Strength	**Week Ending**	**2-Jan-09**	**9-Jan-09**	**16-Jan-09**	**23-Jan-09**	**30-Jan-09**	**6-Feb-09**
80MG		20,305	20,250	19,480	19,071	21,226	21,141
Total	**2011**	134,976	130,378	127,466	121,941	131,418	132,743
		6-Jan-12	**13-Jan-12**	**20-Jan-12**	**27-Jan-12**	**3-Feb-12**	**10-Feb-12**
10MG		23,413	25,422	24,657	24,317	25,318	25,339
15MG		3,181	3,323	3,275	3,165	3,227	3,349
20MG		30,028	31,200	30,546	29,447	31,100	30,832
30MG		10,274	10,686	10,528	10,002	10,602	10,646
40MG		23,382	24,667	23,720	22,374	24,012	24,017
60MG		8,527	8,821	8,660	8,192	8,907	8,745
80MG		16,876	17,560	16,865	15,856	17,372	17,425
Total	**2012**	115,681	121,679	118,251	113,353	120,538	120,353
		4-Jan-13	**11-Jan-13**	**18-Jan-13**	**25-Jan-13**	**1-Feb-13**	**8-Feb-13**
10MG		23,087	25,231	25,634	23,858	24,986	26,132
15MG		3,595	4,111	3,971	3,681	3,765	4,144
20MG		28,300	30,360	29,828	27,539	28,981	30,406
30MG		11,327	11,931	12,055	10,790	11,542	12,411
40MG		21,885	23,056	22,211	20,069	21,557	22,693
60MG		8,923	9,488	9,336	8,328	9,012	9,660
80MG		15,407	16,099	15,953	13,956	15,229	16,194
Total	**2013**	112,524	120,276	118,988	108,221	115,072	121,640
	1 week % Change						

OxyContin Weekly TRx - Original Formulation and Reformulation							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 1	**Week 2**	**Week 3**	**Week 4**	**Week 5**	**Week 6**
Strength	**Week Ending**	**2-Jan-09**	**9-Jan-09**	**16-Jan-09**	**23-Jan-09**	**30-Jan-09**	**6-Feb-09**
	2009		22.4%	-3.3%	-12.1%	-6.5%	15.2%
	2010		22.5%	-6.4%	1.2%	-4.6%	9.9%
	2011		-3.4%	-2.2%	-4.3%	7.8%	1.0%
	2012		5.2%	-2.8%	-4.1%	6.3%	-0.2%
	2013		6.9%	-1.1%	-9.0%	6.3%	5.7%

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 7	**Week 8**	**Week 9**	**Week 10**	**Week 11**	**Week 12**
Strength	**Week Ending**	**13-Feb-09**	**20-Feb-09**	**27-Feb-09**	**6-Mar-09**	**13-Mar-09**	**20-Mar-09**
10MG		17,330	16,337	16,651	18,382	17,352	16,603
15MG		1,363	1,309	1,274	1,510	1,458	1,345
20MG		28,074	25,718	25,443	29,400	26,232	24,425
30MG		5,470	5,143	5,251	6,063	5,884	5,381
40MG		27,221	24,850	25,527	30,276	27,307	24,659
60MG		5,271	4,996	5,200	6,169	5,591	5,413
80MG		23,351	20,896	21,620	25,823	22,901	20,977
Total	**2009**	108,080	99,249	100,966	117,623	106,725	98,803
		19-Feb-10	**26-Feb-10**	**5-Mar-10**	**12-Mar-10**	**19-Mar-10**	**26-Mar-10**
10MG		18,919	18,743	18,572	20,656	18,741	19,125
15MG		2,422	2,383	2,519	2,658	2,479	2,598
20MG		29,031	28,644	28,009	31,775	28,088	27,174
30MG		9,348	9,392	9,229	10,367	9,849	9,445
40MG		29,560	28,920	28,177	32,938	29,370	28,114
60MG		8,892	8,696	8,694	9,974	9,288	8,899
80MG		25,860	25,378	25,316	29,168	26,063	25,526
Total	**2010**	124,032	122,156	120,516	137,536	123,878	120,881
		18-Feb-11	**25-Feb-11**	**4-Mar-11**	**11-Mar-11**	**18-Mar-11**	**25-Mar-11**
10MG		27,450	25,995	28,804	27,569	26,286	26,368
15MG		3,108	3,010	3,314	3,116	2,844	2,889
20MG		33,726	32,427	37,890	34,704	33,241	32,998
30MG		10,562	9,898	11,629	10,588	10,115	9,991
40MG		25,722	25,009	30,008	26,733	26,005	25,511
60MG		9,083	8,484	10,061	9,130	8,755	8,496

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 7	**Week 8**	**Week 9**	**Week 10**	**Week 11**	**Week 12**
Strength	**Week Ending**	**13-Feb-09**	**20-Feb-09**	**27-Feb-09**	**6-Mar-09**	**13-Mar-09**	**20-Mar-09**
80MG		19,946	19,207	23,133	20,532	19,175	18,743
Total	**2011**	129,597	124,030	144,839	132,372	126,421	124,996
		17-Feb-12	**24-Feb-12**	**2-Mar-12**	**9-Mar-12**	**16-Mar-12**	**23-Mar-12**
10MG		24,539	24,320	26,245	25,819	25,038	24,587
15MG		3,308	3,182	3,453	3,404	3,416	3,222
20MG		30,339	29,474	32,682	31,516	30,350	29,821
30MG		10,254	10,272	11,277	10,982	10,724	10,438
40MG		23,621	22,660	25,519	24,714	23,867	22,869
60MG		8,771	8,308	9,681	9,222	8,802	8,554
80MG		16,881	16,304	18,557	18,062	16,832	16,203
Total	**2012**	117,713	114,520	127,414	123,719	119,029	115,694
		15-Feb-13	**22-Feb-13**	**1-Mar-13**	**8-Mar-13**	**15-Mar-13**	**22-Mar-13**
10MG		25,813	24,646	25,914	26,268	25,511	24,829
15MG		3,910	3,804	4,030	4,198	3,983	3,849
20MG		29,720	27,875	30,374	31,167	29,367	28,215
30MG		11,513	11,117	12,375	12,450	11,612	11,419
40MG		22,037	20,090	22,469	23,244	21,400	20,358
60MG		9,086	8,397	9,655	9,514	9,026	8,713
80MG		15,585	13,943	15,840	16,361	15,207	14,136
Total	**2013**	117,664	109,872	120,657	123,202	116,106	111,519
	1 week % Change						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 7	**Week 8**	**Week 9**	**Week 10**	**Week 11**	**Week 12**
Strength	**Week Ending**	**13-Feb-09**	**20-Feb-09**	**27-Feb-09**	**6-Mar-09**	**13-Mar-09**	**20-Mar-09**
	2009	-3.6%	-8.2%	1.7%	16.5%	-9.3%	-7.4%
	2010	-5.8%	-1.5%	-1.3%	14.1%	-9.9%	-2.4%
	2011	-2.4%	-4.3%	16.8%	-8.6%	-4.5%	-1.1%
	2012	-2.2%	-2.7%	11.3%	-2.9%	-3.8%	-2.8%
	2013	-3.3%					

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 13	**Week 14**	**Week 15**	**Week 16**	**Week 17**	**Week 18**
Strength	**Week Ending**	**27-Mar-09**	**3-Apr-09**	**10-Apr-09**	**17-Apr-09**	**24-Apr-09**	**1-May-09**
10MG		16,754	17,752	17,975	17,966	18,416	19,519
15MG		1,322	1,411	1,521	1,366	1,358	1,552
20MG		23,351	25,206	24,024	23,246	22,976	24,072
30MG		5,358	5,860	5,860	5,530	5,771	6,125
40MG		24,560	26,463	25,609	24,575	24,212	25,574
60MG		5,401	5,987	5,839	5,641	5,963	6,128
80MG		21,019	22,986	22,665	21,276	21,245	22,540
Total	**2009**	97,765	105,665	103,493	99,600	99,941	105,510
		2-Apr-10	**9-Apr-10**	**16-Apr-10**	**23-Apr-10**	**30-Apr-10**	**7-May-10**
10MG		19,207	19,150	19,508	19,135	18,758	19,222
15MG		2,431	2,580	2,553	2,548	2,525	2,575
20MG		26,432	27,672	27,998	27,269	27,327	27,781
30MG		9,458	9,828	9,880	9,776	9,964	10,001
40MG		27,324	29,084	29,232	28,416	27,871	28,608
60MG		8,918	9,335	9,501	9,191	9,445	9,225
80MG		24,889	26,447	26,590	26,315	26,256	26,575
Total	**2010**	118,659	124,096	125,262	122,650	122,146	123,987
		1-Apr-11	**8-Apr-11**	**15-Apr-11**	**22-Apr-11**	**29-Apr-11**	**6-May-11**
10MG		25,999	26,920	26,486	25,724	26,052	26,976
15MG		2,975	3,076	3,052	2,964	3,042	3,154
20MG		33,707	34,637	33,185	32,785	33,260	35,802
30MG		10,220	10,590	10,316	9,934	10,006	10,915
40MG		26,360	26,853	25,596	25,226	25,665	27,613
60MG		8,772	9,215	8,999	8,445	8,758	9,670

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 13	**Week 14**	**Week 15**	**Week 16**	**Week 17**	**Week 18**
Strength	**Week Ending**	**27-Mar-09**	**3-Apr-09**	**10-Apr-09**	**17-Apr-09**	**24-Apr-09**	**1-May-09**
80MG		19,914	20,125	18,473	18,028	19,072	20,628
Total	**2011**	127,947	131,416	126,107	123,106	125,855	134,758
		30-Mar-12	**6-Apr-12**	**13-Apr-12**	**20-Apr-12**	**27-Apr-12**	**4-May-12**
10MG		24,510	25,298	24,741	24,631	25,096	25,823
15MG		3,293	3,456	3,396	3,479	3,337	3,655
20MG		30,389	31,676	30,161	30,298	30,562	32,072
30MG		10,692	11,134	10,693	10,968	11,218	11,808
40MG		23,292	24,654	23,285	23,106	23,307	25,335
60MG		8,955	9,248	8,737	8,813	9,005	9,673
80MG		16,562	17,712	16,370	16,368	16,598	17,978
Total	**2012**	117,693	123,178	117,383	117,663	119,123	126,344
		29-Mar-13	**5-Apr-13**	**12-Apr-13**	**19-Apr-13**	**26-Apr-13**	**3-May-13**
10MG		24,147	24,786	24,574	24,247	24,428	25,505
15MG		3,806	4,016	4,071	3,886	3,884	4,204
20MG		27,841	29,443	28,561	27,759	28,034	29,677
30MG		11,413	11,917	11,576	11,535	11,556	12,166
40MG		20,331	22,027	20,935	20,003	20,692	22,404
60MG		8,840	9,295	8,954	8,650	8,791	9,372
80MG		14,184	15,501	14,612	13,740	14,138	15,747
Total	**2013**	110,562	116,985	113,283	109,820	111,523	119,075
	1 week % Change						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 13	**Week 14**	**Week 15**	**Week 16**	**Week 17**	**Week 18**
Strength	**Week Ending**	**27-Mar-09**	**3-Apr-09**	**10-Apr-09**	**17-Apr-09**	**24-Apr-09**	**1-May-09**
	2009	-1.1%	8.1%	-2.1%	-3.8%	0.3%	5.6%
	2010	-1.8%	4.6%	0.9%	-2.1%	-0.4%	1.5%
	2011	2.4%	2.7%	-4.0%	-2.4%	2.2%	7.1%
	2012	1.7%	4.7%	-4.7%	0.2%	1.2%	6.1%
	2013						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 19	**Week 20**	**Week 21**	**Week 22**	**Week 23**	**Week 24**
Strength	**Week Ending**	**8-May-09**	**15-May-09**	**22-May-09**	**29-May-09**	**5-Jun-09**	**12-Jun-09**
10MG		19,962	19,726	20,541	18,667	21,782	20,884
15MG		1,548	1,543	1,540	1,415	1,562	1,569
20MG		24,458	23,655	24,008	22,033	25,528	24,151
30MG		6,267	6,058	6,275	5,740	6,450	6,269
40MG		26,151	24,108	25,010	23,739	27,988	26,033
60MG		6,226	6,030	6,087	5,784	6,626	6,009
80MG		22,607	21,376	21,969	20,676	23,608	21,625
Total	**2009**	107,219	102,496	105,430	98,054	113,544	106,540
		14-May-10	**21-May-10**	**28-May-10**	**4-Jun-10**	**11-Jun-10**	**18-Jun-10**
10MG		20,056	19,914	20,002	20,648	19,283	20,900
15MG		2,607	2,562	2,601	2,775	2,535	2,689
20MG		29,096	27,159	27,586	28,796	27,208	28,398
30MG		10,490	9,983	10,218	10,817	9,730	10,274
40MG		32,256	28,866	28,629	30,133	29,493	29,131
60MG		10,159	9,802	9,480	9,785	9,453	9,650
80MG		29,082	26,528	26,718	27,826	26,558	27,488
Total	**2010**	133,746	124,814	125,234	130,780	124,260	128,530
		13-May-11	**20-May-11**	**27-May-11**	**3-Jun-11**	**10-Jun-11**	**17-Jun-11**
10MG		25,903	25,804	26,764	24,175	26,090	25,752
15MG		3,028	3,006	3,061	2,842	3,074	3,050
20MG		33,201	32,613	33,990	31,701	33,117	32,826
30MG		10,182	10,053	10,407	9,958	10,301	10,233
40MG		25,313	25,048	26,070	24,967	25,279	24,760
60MG		8,642	8,564	9,122	8,602	8,880	8,460

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 19	**Week 20**	**Week 21**	**Week 22**	**Week 23**	**Week 24**
Strength	**Week Ending**	**8-May-09**	**15-May-09**	**22-May-09**	**29-May-09**	**5-Jun-09**	**12-Jun-09**
80MG		18,461	18,078	19,286	18,450	18,580	18,059
Total	**2011**	124,730	123,166	128,700	120,695	125,321	123,140
		11-May-12	**18-May-12**	**25-May-12**	**1-Jun-12**	**8-Jun-12**	**15-Jun-12**
10MG		24,694	24,597	25,260	22,598	25,358	24,612
15MG		3,424	3,510	3,553	3,295	3,662	3,523
20MG		30,482	30,679	31,327	28,725	31,199	30,356
30MG		10,904	11,136	11,668	10,623	11,382	11,231
40MG		23,186	23,106	23,735	22,444	24,047	22,908
60MG		8,827	8,939	9,356	8,707	9,117	8,888
80MG		16,539	16,215	17,171	16,092	16,839	15,903
Total	**2012**	118,056	118,182	122,070	112,484	121,604	117,421
		10-May-13	**17-May-13**	**24-May-13**	**31-May-13**	**7-Jun-13**	**14-Jun-13**
10MG		24,914	24,582	25,086	22,589	25,704	25,022
15MG		4,142	4,010	4,155	3,865	4,318	4,120
20MG		29,288	28,309	29,165	26,604	30,155	28,142
30MG		11,779	11,585	11,976	10,936	12,213	11,836
40MG		20,933	19,867	21,012	19,640	22,124	19,962
60MG		9,166	8,664	9,204	8,305	9,380	8,759
80MG		14,627	13,611	14,544	13,571	15,375	14,086
Total	**2013**	114,849	110,628	115,142	105,510	119,269	111,927
	1 week % Change						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 19	**Week 20**	**Week 21**	**Week 22**	**Week 23**	**Week 24**
Strength	**Week Ending**	**8-May-09**	**15-May-09**	**22-May-09**	**29-May-09**	**5-Jun-09**	**12-Jun-09**
	2009	1.6%	-4.4%	2.9%	-7.0%	15.8%	-6.2%
	2010	7.9%	-6.7%	0.3%	4.4%	-5.0%	3.4%
	2011	-7.4%	-1.3%	4.5%	-6.2%	3.8%	-1.7%
	2012	-6.6%	0.1%	3.3%	-7.9%	8.1%	-3.4%
	2013						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 25	**Week 26**	**Week 27**	**Week 28**	**Week 29**	**Week 30**
Strength	**Week Ending**	**19-Jun-09**	**26-Jun-09**	**3-Jul-09**	**10-Jul-09**	**17-Jul-09**	**24-Jul-09**
10MG		20,963	20,962	22,353	20,917	21,614	21,439
15MG		1,602	1,514	1,666	1,505	1,590	1,597
20MG		24,357	24,272	26,827	24,524	25,695	25,836
30MG		6,268	6,105	6,919	6,351	6,578	6,392
40MG		27,124	27,548	31,107	27,653	29,049	28,512
60MG		6,364	6,336	6,743	6,290	6,494	6,416
80MG		21,837	21,973	24,120	21,551	22,428	21,947
Total	**2009**	108,515	108,710	119,735	108,791	113,448	112,139
		25-Jun-10	**2-Jul-10**	**9-Jul-10**	**16-Jul-10**	**23-Jul-10**	**30-Jul-10**
10MG		21,669	22,239	23,049	21,109	22,981	22,783
15MG		2,602	2,715	2,874	2,702	2,790	2,724
20MG		28,011	28,836	31,277	27,786	29,917	29,733
30MG		10,551	10,354	11,062	10,063	10,725	10,540
40MG		29,274	30,068	32,789	28,057	29,519	29,807
60MG		9,844	9,622	10,348	9,601	10,050	9,942
80MG		27,328	27,793	29,250	26,144	27,840	28,098
Total	**2010**	129,279	131,627	140,649	125,462	133,822	133,627
		24-Jun-11	**1-Jul-11**	**8-Jul-11**	**15-Jul-11**	**22-Jul-11**	**29-Jul-11**
10MG		25,756	26,776	23,375	25,477	25,092	25,513
15MG		2,991	3,160	2,924	3,089	3,088	2,944
20MG		32,617	35,184	30,589	32,817	32,473	31,894
30MG		10,293	11,014	9,766	10,441	10,091	10,189
40MG		25,288	26,387	23,718	24,752	24,919	25,179
60MG		8,896	9,423	8,281	8,798	8,525	8,755

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 25	**Week 26**	**Week 27**	**Week 28**	**Week 29**	**Week 30**
Strength	**Week Ending**	**19-Jun-09**	**26-Jun-09**	**3-Jul-09**	**10-Jul-09**	**17-Jul-09**	**24-Jul-09**
80MG		18,589	20,021	17,265	18,059	18,218	18,199
Total	**2011**	124,430	131,965	115,918	123,433	122,406	122,673
		22-Jun-12	**29-Jun-12**	**6-Jul-12**	**13-Jul-12**	**20-Jul-12**	**27-Jul-12**
10MG		24,878	24,839	22,927	24,571	24,474	24,189
15MG		3,529	3,479	3,470	3,697	3,597	3,561
20MG		30,061	30,739	29,235	30,567	30,270	29,599
30MG		11,293	11,432	11,211	11,389	11,410	11,245
40MG		23,175	23,246	23,564	23,332	23,257	22,701
60MG		9,219	9,059	9,152	9,112	9,288	9,121
80MG		16,571	16,449	16,595	16,471	16,488	16,151
Total	**2012**	118,726	119,243	116,154	119,139	118,784	116,567
		21-Jun-13	**28-Jun-13**	**5-Jul-13**	**12-Jul-13**	**19-Jul-13**	**26-Jul-13**
10MG		24,707					
15MG		4,050					
20MG		28,339					
30MG		11,765					
40MG		20,610					
60MG		8,918					
80MG		13,858					
Total	**2013**	112,247					
	1 week % Change						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 25	**Week 26**	**Week 27**	**Week 28**	**Week 29**	**Week 30**
Strength	**Week Ending**	**19-Jun-09**	**26-Jun-09**	**3-Jul-09**	**10-Jul-09**	**17-Jul-09**	**24-Jul-09**
	2009	1.9%	0.2%	10.1%	-9.1%	4.3%	-1.2%
	2010	0.6%	1.8%	6.9%	-10.8%	6.7%	-0.1%
	2011	1.0%	6.1%	-12.2%	6.5%	-0.8%	0.2%
	2012	1.1%	0.4%	-2.6%	2.6%	-0.3%	-1.9%
	2013						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 31	**Week 32**	**Week 33**	**Week 34**	**Week 35**	**Week 36**
Strength	**Week Ending**	**31-Jul-09**	**7-Aug-09**	**14-Aug-09**	**21-Aug-09**	**28-Aug-09**	**4-Sep-09**
10MG		21,576	21,992	21,636	21,817	22,134	22,820
15MG		1,621	1,700	1,642	1,634	1,650	1,701
20MG		27,017	28,660	28,805	29,855	30,664	33,993
30MG		6,666	6,596	6,828	6,774	6,780	7,302
40MG		29,259	30,165	29,716	29,905	30,487	32,789
60MG		6,558	6,835	6,612	6,708	6,846	7,288
80MG		22,027	22,819	22,374	22,692	22,715	24,140
Total	**2009**	114,724	118,767	117,613	119,385	121,276	130,033
		6-Aug-10	**13-Aug-10**	**20-Aug-10**	**27-Aug-10**	**3-Sep-10**	**10-Sep-10**
10MG		22,890	22,558	22,560	22,605	22,678	23,977
15MG		2,808	2,780	2,753	2,695	2,902	3,121
20MG		29,518	29,945	29,409	30,746	30,977	33,480
30MG		10,523	10,722	10,810	10,896	10,466	11,424
40MG		29,486	29,810	28,567	29,602	29,254	31,078
60MG		9,671	10,114	10,138	10,139	10,045	10,814
80MG		26,984	28,428	28,029	28,195	26,769	27,275
Total	**2010**	131,880	134,357	132,266	134,878	133,091	141,169
		5-Aug-11	**12-Aug-11**	**19-Aug-11**	**26-Aug-11**	**2-Sep-11**	**9-Sep-11**
10MG		24,932	24,760	24,963	25,056	25,649	22,679
15MG		3,073	3,010	3,174	3,144	2,989	2,919
20MG		32,066	31,819	31,968	31,881	32,467	29,616
30MG		10,295	10,140	10,385	10,331	10,239	9,634
40MG		25,196	24,802	25,097	25,350	25,499	23,338
60MG		8,719	8,623	8,641	8,772	8,875	8,099

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 31	**Week 32**	**Week 33**	**Week 34**	**Week 35**	**Week 36**
Strength	**Week Ending**	**31-Jul-09**	**7-Aug-09**	**14-Aug-09**	**21-Aug-09**	**28-Aug-09**	**4-Sep-09**
80MG		17,684	17,567	17,906	17,951	18,126	16,843
Total	**2011**	121,965	120,721	122,134	122,485	123,844	113,128
		3-Aug-12	**10-Aug-12**	**17-Aug-12**	**24-Aug-12**	**31-Aug-12**	**7-Sep-12**
10MG		24,085	23,942	24,305	24,548	24,950	23,222
15MG		3,628	3,559	3,736	3,484	3,695	3,489
20MG		30,017	29,413	30,096	29,863	30,281	28,823
30MG		11,395	11,227	11,692	11,402	11,620	11,057
40MG		23,069	22,792	23,006	22,555	23,184	22,363
60MG		9,116	8,982	9,268	9,253	9,188	8,884
80MG		16,106	16,013	16,373	16,097	16,136	15,987
Total	**2012**	117,416	115,928	118,476	117,202	119,054	113,825
		2-Aug-13	**9-Aug-13**	**16-Aug-13**	**23-Aug-13**	**30-Aug-13**	**6-Sep-13**
10MG							
15MG							
20MG							
30MG							
40MG							
60MG							
80MG							
Total	**2013**						
	1 week % Change						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 31	**Week 32**	**Week 33**	**Week 34**	**Week 35**	**Week 36**
Strength	**Week Ending**	**31-Jul-09**	**7-Aug-09**	**14-Aug-09**	**21-Aug-09**	**28-Aug-09**	**4-Sep-09**
	2009	2.3%	3.5%	-1.0%	1.5%	1.6%	7.2%
	2010	-1.3%	1.9%	-1.6%	2.0%	-1.3%	6.1%
	2011	-0.6%	-1.0%	1.2%	0.3%	1.1%	-8.7%
	2012	0.7%	-1.3%	2.2%	-1.1%	1.6%	-4.4%
	2013						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 37	**Week 38**	**Week 39**	**Week 40**	**Week 41**	**Week 42**
Strength	**Week Ending**	**11-Sep-09**	**18-Sep-09**	**25-Sep-09**	**2-Oct-09**	**9-Oct-09**	**16-Oct-09**
10MG		20,094	22,738	22,421	22,854	21,841	22,171
15MG		1,587	1,819	1,676	1,809	1,723	1,739
20MG		29,938	33,349	33,400	36,149	33,743	34,078
30MG		6,443	7,158	6,765	7,433	6,870	7,202
40MG		29,230	32,284	32,096	34,177	32,136	32,649
60MG		6,298	7,111	6,808	7,496	6,809	7,144
80MG		21,491	23,682	23,946	25,310	24,334	24,945
Total	**2009**	115,081	128,141	127,112	135,228	127,456	129,928
		17-Sep-10	**24-Sep-10**	**1-Oct-10**	**8-Oct-10**	**15-Oct-10**	**22-Oct-10**
10MG		21,794	23,930	23,708	24,274	23,939	24,310
15MG		2,769	3,020	2,800	3,134	2,988	2,893
20MG		30,411	33,476	32,159	33,860	33,054	33,810
30MG		10,179	11,308	10,774	11,064	10,879	10,990
40MG		26,620	29,020	27,518	28,143	26,424	26,143
60MG		9,828	10,396	9,954	10,447	10,024	9,918
80MG		23,153	24,743	22,512	22,375	20,904	20,552
Total	**2010**	124,754	135,893	129,425	133,297	128,212	128,616
		16-Sep-11	**23-Sep-11**	**30-Sep-11**	**7-Oct-11**	**14-Oct-11**	**21-Oct-11**
10MG		25,600	25,315	25,531	25,173	25,182	25,253
15MG		3,178	3,121	3,173	3,230	3,150	3,163
20MG		32,268	31,633	32,218	32,005	31,677	31,346
30MG		10,415	10,237	10,480	10,386	10,382	10,222
40MG		25,367	24,928	25,082	25,214	24,779	24,444
60MG		8,733	8,654	8,822	8,825	8,634	8,580

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 37	**Week 38**	**Week 39**	**Week 40**	**Week 41**	**Week 42**
Strength	**Week Ending**	**11-Sep-09**	**18-Sep-09**	**25-Sep-09**	**2-Oct-09**	**9-Oct-09**	**16-Oct-09**
80MG		18,183	17,880	17,806	17,842	17,870	17,628
Total	**2011**	123,744	121,768	123,112	122,675	121,674	120,636
		14-Sep-12	**21-Sep-12**	**28-Sep-12**	**5-Oct-12**	**12-Oct-12**	**19-Oct-12**
10MG		24,886	24,754	25,350	25,838	24,616	25,288
15MG		3,852	3,740	3,984	3,855	3,786	3,765
20MG		30,288	30,197	30,675	30,727	29,825	30,326
30MG		11,678	11,500	11,732	11,835	11,606	11,565
40MG		23,113	22,709	23,197	23,543	22,555	22,590
60MG		9,268	9,297	9,042	9,437	9,086	9,190
80MG		16,283	16,064	15,786	16,684	15,758	15,951
Total	**2012**	119,368	118,261	119,766	121,919	117,232	118,675
		13-Sep-13	**20-Sep-13**	**27-Sep-13**	**4-Oct-13**	**11-Oct-13**	**18-Oct-13**
10MG							
15MG							
20MG							
30MG							
40MG							
60MG							
80MG							
Total	**2013**						
	1 week % Change						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 37	**Week 38**	**Week 39**	**Week 40**	**Week 41**	**Week 42**
Strength	**Week Ending**	**11-Sep-09**	**18-Sep-09**	**25-Sep-09**	**2-Oct-09**	**9-Oct-09**	**16-Oct-09**
	2009	-11.5%	11.3%	-0.8%	6.4%	-5.7%	1.9%
	2010	-11.6%	8.9%	-4.8%	3.0%	-3.8%	0.3%
	2011	9.4%	-1.6%	1.1%	-0.4%	-0.8%	-0.9%
	2012	4.9%	-0.9%	1.3%	1.8%	-3.8%	1.2%
	2013						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							**Weekly Total Presc**
		Week 43	**Week 44**	**Week 45**	**Week 46**	**Week 47**	**Week 48**
Strength	**Week Ending**	**23-Oct-09**	**30-Oct-09**	**6-Nov-09**	**13-Nov-09**	**20-Nov-09**	**27-Nov-09**
10MG		22,567	22,054	21,863	21,463	21,895	18,595
15MG		1,742	1,727	1,885	1,793	1,833	1,706
20MG		34,754	34,649	34,277	32,522	33,862	29,406
30MG		7,103	7,259	7,275	7,391	7,709	6,789
40MG		32,809	32,823	33,577	31,791	32,627	29,053
60MG		6,992	7,228	7,340	7,288	7,468	6,678
80MG		25,436	24,782	25,802	25,325	26,045	23,031
Total	**2009**	131,403	130,522	132,019	127,573	131,439	115,258
		29-Oct-10	**5-Nov-10**	**12-Nov-10**	**19-Nov-10**	**26-Nov-10**	**3-Dec-10**
10MG		24,950	25,222	26,143	26,513	27,687	23,447
15MG		3,042	2,892	3,042	2,983	3,012	2,726
20MG		33,695	34,448	35,145	34,663	35,581	31,196
30MG		10,847	10,495	10,676	10,673	10,876	9,391
40MG		26,126	26,040	27,173	27,400	28,942	25,635
60MG		9,757	9,525	9,716	9,533	9,874	8,537
80MG		19,642	19,000	18,724	18,367	18,836	15,958
Total	**2010**	128,059	127,622	130,619	130,132	134,808	116,890
		28-Oct-11	**4-Nov-11**	**11-Nov-11**	**18-Nov-11**	**25-Nov-11**	**2-Dec-11**
10MG		25,300	25,314	25,302	25,776	22,486	26,481
15MG		3,143	3,109	3,177	3,278	2,899	3,251
20MG		31,483	31,178	31,529	31,779	28,017	33,356
30MG		10,340	10,417	10,255	10,541	9,246	11,315
40MG		24,446	24,252	24,246	24,618	21,864	26,379
60MG		8,761	8,568	8,639	8,952	7,876	9,465

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							**Weekly Total Presc**
		Week 43	**Week 44**	**Week 45**	**Week 46**	**Week 47**	**Week 48**
Strength	**Week Ending**	**23-Oct-09**	**30-Oct-09**	**6-Nov-09**	**13-Nov-09**	**20-Nov-09**	**27-Nov-09**
80MG		17,058	17,364	17,604	17,557	15,654	18,839
Total	**2011**	120,531	120,202	120,752	122,501	108,042	129,086
		26-Oct-12	**2-Nov-12**	**9-Nov-12**	**16-Nov-12**	**23-Nov-12**	**30-Nov-12**
10MG		25,395	24,696	26,154	26,215	23,221	26,489
15MG		3,828	3,765	3,932	3,921	3,491	4,109
20MG		30,000	29,535	30,912	30,176	27,610	31,374
30MG		11,566	11,440	11,920	11,644	10,833	12,244
40MG		22,546	22,344	23,004	22,628	20,580	23,701
60MG		9,068	8,909	9,562	9,410	8,376	9,642
80MG		15,808	15,426	16,294	16,122	14,482	16,100
Total	**2012**	118,211	116,115	121,778	120,116	108,593	123,659
		25-Oct-13	**1-Nov-13**	**8-Nov-13**	**15-Nov-13**	**22-Nov-13**	**29-Nov-13**
10MG							
15MG							
20MG							
30MG							
40MG							
60MG							
80MG							
Total	**2013**						
	1 week % Change						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							**Weekly Total Presc**
		Week 43	**Week 44**	**Week 45**	**Week 46**	**Week 47**	**Week 48**
Strength	**Week Ending**	**23-Oct-09**	**30-Oct-09**	**6-Nov-09**	**13-Nov-09**	**20-Nov-09**	**27-Nov-09**
	2009	1.1%	-0.7%	1.1%	-3.4%	3.0%	-12.3%
	2010	-0.4%	-0.3%	2.3%	-0.4%	3.6%	-13.3%
	2011	-0.1%	-0.3%	0.5%	1.4%	-11.8%	19.5%
	2012	-0.4%	-1.8%	4.9%	-1.4%	-9.6%	13.9%
	2013						

OxyContin Weekly TRx - Original Formul					
Source: IMS Health NPA					
Retail, LTC, and Mail Order					
Numbers Are Absolute		**riptions**			
		Week 49	**Week 50**	**Week 51**	**Week 52**
Strength	**Week Ending**	**4-Dec-09**	**11-Dec-09**	**18-Dec-09**	**25-Dec-09**
10MG		22,639	20,166	20,630	16,597
15MG		2,035	1,951	2,018	1,640
20MG		36,781	31,249	32,379	26,619
30MG		8,421	7,564	8,002	6,672
40MG		36,299	31,623	32,218	26,653
60MG		8,677	7,583	8,094	6,744
80MG		29,078	25,527	26,567	21,644
Total	**2009**	143,930	125,663	129,908	106,569
		10-Dec-10	**17-Dec-10**	**24-Dec-10**	**31-Dec-10**
10MG		27,965	27,477	28,407	27,439
15MG		3,278	3,051	3,044	2,892
20MG		37,879	35,095	35,533	34,714
30MG		11,649	10,767	10,799	10,408
40MG		31,691	28,560	29,516	27,042
60MG		10,399	9,510	9,414	9,262
80MG		19,510	18,227	19,040	18,086
Total	**2010**	142,371	132,687	135,753	129,843
		9-Dec-11	**16-Dec-11**	**23-Dec-11**	**30-Dec-11**
10MG		25,722	26,431	26,774	21,386
15MG		3,338	3,378	3,332	2,757
20MG		31,760	31,757	32,674	27,251
30MG		10,557	10,790	10,741	9,248
40MG		24,313	24,853	25,292	21,455
60MG		8,662	9,102	9,080	7,741

OxyContin Weekly TRx - Original Formul						
Source: IMS Health NPA						
Retail, LTC, and Mail Order						
Numbers Are Absolute		**riptions**				
		Week 49	**Week 50**	**Week 51**	**Week 52**	
Strength	**Week Ending**	**4-Dec-09**	**11-Dec-09**	**18-Dec-09**	**25-Dec-09**	
80MG		17,560	17,690	17,758	15,431	
Total	**2011**	121,912	124,001	125,651	105,269	
		7-Dec-12	**14-Dec-12**	**21-Dec-12**	**28-Dec-12**	
10MG		26,517	26,051	27,077	21,021	
15MG		4,032	4,026	4,170	3,207	
20MG		31,846	30,640	31,888	25,515	
30MG		12,447	12,006	12,563	10,004	
40MG		23,716	22,772	23,677	19,428	
60MG		9,734	9,380	9,610	8,046	
80MG		16,967	15,839	16,634	13,946	
Total	**2012**	125,259	120,714	125,619	101,167	
		6-Dec-13	**13-Dec-13**	**20-Dec-13**	**27-Dec-13**	
10MG						
15MG						
20MG						
30MG						
40MG						
60MG						
80MG						
Total	**2013**					
	1 week % Change					

	OxyContin Weekly TRx - Original Formul						
	Source: IMS Health NPA						
	Retail, LTC, and Mail Order						
	Numbers Are Absolute		**riptions**				
			Week 49	**Week 50**	**Week 51**	**Week 52**	
	Strength	**Week Ending**	**4-Dec-09**	**11-Dec-09**	**18-Dec-09**	**25-Dec-09**	
		2009	24.9%	-12.7%	3.4%	-18.0%	
		2010	21.8%	-6.8%	2.3%	-4.4%	
		2011	-5.6%	1.7%	1.3%	-16.2%	
		2012	1.3%	-3.6%	4.1%	-19.5%	
		2013					

Product	2011/04/08 EUTRx	2011/04/15 EUTRx	2011/04/22 EUTRx	2011/04/29 EUTRx
OXYCONTIN 01/1996 PUF	9,245,201	8,798,770	8,573,636	8,811,087
10MG	1,478,660	1,427,631	1,390,912	1,405,432
15MG	183,269	180,224	173,573	179,380
20MG	2,290,945	2,192,332	2,165,596	2,193,475
30MG	692,907	673,958	647,518	666,744
40MG	2,055,364	1,943,620	1,899,504	1,960,507
60MG	671,650	658,988	610,461	638,010
80MG	1,872,406	1,722,017	1,686,072	1,767,539
Grand Total	**9,245,201**	**8,798,770**	**8,573,636**	**8,811,087**

MG Totals

OXYCONTIN 01/1996 PUF				
10MG	14,786,600	14,276,310	13,909,120	14,054,320
15MG	2,749,035	2,703,360	2,603,595	2,690,700
20MG	45,818,900	43,846,640	43,311,920	43,869,500
30MG	20,787,210	20,218,740	19,425,540	20,002,320
40MG	82,214,560	77,744,800	75,980,160	78,420,280
60MG	40,299,000	39,539,280	36,627,660	38,280,600
80MG	149,792,480	137,761,360	134,885,760	141,403,120
Grand Total	**356,447,785**	**336,090,490**	**326,743,755**	**338,720,840**

Millions of MG	4/8/2011	4/15/2011	4/22/2011	4/29/2011
OXYCONTIN 01/1996 PUF				
10MG	15	14	14	14
15MG	3	3	3	3
20MG	46	44	43	44
30MG	21	20	19	20
40MG	82	78	76	78
60MG	40	40	37	38
80MG	150	138	135	141
Grand Total	**356**	**336**	**327**	**339**

2011/05/06 EUTRx	2011/05/13 EUTRx	2011/05/20 EUTRx	2011/05/27 EUTRx	2011/06/03 EUTRx	2011/06/10 EUTRx
9,501,374	8,741,359	8,573,294	9,026,667	8,430,496	8,792,965
1,487,471	1,400,215	1,390,618	1,450,473	1,311,696	1,431,988
185,164	181,782	178,413	184,192	166,081	181,190
2,391,478	2,199,539	2,152,247	2,232,569	2,096,801	2,197,315
717,131	661,119	661,896	689,695	650,666	677,241
2,110,498	1,935,334	1,891,439	2,010,862	1,887,654	1,930,916
700,016	634,357	629,136	664,006	627,137	649,340
1,909,616	1,729,013	1,669,545	1,794,870	1,690,461	1,724,975
9,501,374	**8,741,359**	**8,573,294**	**9,026,667**	**8,430,496**	**8,792,965**

14,874,710	14,002,150	13,906,180	14,504,730	13,116,960	14,319,880
2,777,460	2,726,730	2,676,195	2,762,880	2,491,215	2,717,850
47,829,560	43,990,780	43,044,940	44,651,380	41,936,020	43,946,300
21,513,930	19,833,570	19,856,880	20,690,850	19,519,980	20,317,230
84,419,920	77,413,360	75,657,560	80,434,480	75,506,160	77,236,640
42,000,960	38,061,420	37,748,160	39,840,360	37,628,220	38,960,400
152,769,280	138,321,040	133,563,600	143,589,600	135,236,880	137,998,000
366,185,820	**334,349,050**	**326,453,515**	**346,474,280**	**325,435,435**	**335,496,300**

5/6/2011	5/13/2011	5/20/2011	5/27/2011	6/3/2011	6/10/2011
15	14	14	15	13	14
3	3	3	3	2	3
48	44	43	45	42	44
22	20	20	21	20	20
84	77	76	80	76	77
42	38	38	40	38	39
153	138	134	144	135	138
366	**334**	**326**	**346**	**325**	**335**

2011/06/17 EUTRx	2011/06/24 EUTRx	2011/07/01 EUTRx	2011/07/08 EUTRx	2011/07/15 EUTRx	2011/07/22 EUTRx
8,581,589	8,758,691	9,331,763	8,126,682	8,625,729	8,619,338
1,389,967	1,391,937	1,474,790	1,283,213	1,387,431	1,367,678
177,671	180,557	189,408	170,738	183,608	182,874
2,157,000	2,161,652	2,351,092	2,026,960	2,159,950	2,143,410
673,071	680,089	726,907	641,157	682,731	672,123
1,882,461	1,953,240	2,021,413	1,795,202	1,887,344	1,921,136
618,362	650,976	683,878	604,158	645,302	634,734
1,683,057	1,740,240	1,884,275	1,605,254	1,679,363	1,697,383
8,581,589	**8,758,691**	**9,331,763**	**8,126,682**	**8,625,729**	**8,619,338**

13,899,670	13,919,370	14,747,900	12,832,130	13,874,310	13,676,780
2,665,065	2,708,355	2,841,120	2,561,070	2,754,120	2,743,110
43,140,000	43,233,040	47,021,840	40,539,200	43,199,000	42,868,200
20,192,130	20,402,670	21,807,210	19,234,710	20,481,930	20,163,690
75,298,440	78,129,600	80,856,520	71,808,080	75,493,760	76,845,440
37,101,720	39,058,560	41,032,680	36,249,480	38,718,120	38,084,040
134,644,560	139,219,200	150,742,000	128,420,320	134,349,040	135,790,640
326,941,585	**336,670,795**	**359,049,270**	**311,644,990**	**328,870,280**	**330,171,900**

6/17/2011	6/24/2011	7/1/2011	7/8/2011	7/15/2011	7/22/2011
14	14	15	13	14	14
3	3	3	3	3	3
43	43	47	41	43	43
20	20	22	19	20	20
75	78	81	72	75	77
37	39	41	36	39	38
135	139	151	128	134	136
327	**337**	**359**	**312**	**329**	**330**

2011/07/29 EUTRx	2011/08/05 EUTRx	2011/08/12 EUTRx	2011/08/19 EUTRx	2011/08/26 EUTRx	2011/09/02 EUTRx
8,639,239	8,539,432	8,432,171	8,561,895	8,586,953	8,700,800
1,389,900	1,351,652	1,352,449	1,347,382	1,361,439	1,415,584
176,085	182,481	181,231	186,212	186,411	178,550
2,123,617	2,112,497	2,094,035	2,110,746	2,107,274	2,147,515
667,672	674,468	661,561	678,745	683,683	676,670
1,936,667	1,936,788	1,887,976	1,937,511	1,935,523	1,953,056
645,107	634,667	627,548	634,527	640,278	646,482
1,700,191	1,646,879	1,627,371	1,666,772	1,672,345	1,682,943
8,639,239	**8,539,432**	**8,432,171**	**8,561,895**	**8,586,953**	**8,700,800**

13,899,000	13,516,520	13,524,490	13,473,820	13,614,390	14,155,840
2,641,275	2,737,215	2,718,465	2,793,180	2,796,165	2,678,250
42,472,340	42,249,940	41,880,700	42,214,920	42,145,480	42,950,300
20,030,160	20,234,040	19,846,830	20,362,350	20,510,490	20,300,100
77,466,680	77,471,520	75,519,040	77,500,440	77,420,920	78,122,240
38,706,420	38,080,020	37,652,880	38,071,620	38,416,680	38,788,920
136,015,280	131,750,320	130,189,680	133,341,760	133,787,600	134,635,440
331,231,155	**326,039,575**	**321,332,085**	**327,758,090**	**328,691,725**	**331,631,090**

7/29/2011	8/5/2011	8/12/2011	8/19/2011	8/26/2011	9/2/2011
14	14	14	13	14	14
3	3	3	3	3	3
42	42	42	42	42	43
20	20	20	20	21	20
77	77	76	78	77	78
39	38	38	38	38	39
136	132	130	133	134	135
331	**326**	**321**	**328**	**329**	**332**

2011/09/09 EUTRx	2011/09/16 EUTRx	2011/09/23 EUTRx	2011/09/30 EUTRx	2011/10/07 EUTRx	2011/10/14 EUTRx
7,939,083	8,695,016	8,573,455	8,609,904	8,575,899	8,500,737
1,229,109	1,381,856	1,381,121	1,373,109	1,368,633	1,352,102
175,024	189,614	186,948	190,182	190,450	185,702
1,967,166	2,144,689	2,112,236	2,135,620	2,105,859	2,086,422
636,604	677,628	673,665	691,553	689,623	676,394
1,785,643	1,965,443	1,913,663	1,915,038	1,921,786	1,904,402
590,123	642,338	635,168	644,614	645,360	634,044
1,555,414	1,693,448	1,670,654	1,659,788	1,654,188	1,661,671
7,939,083	**8,695,016**	**8,573,455**	**8,609,904**	**8,575,899**	**8,500,737**

12,291,090	13,818,560	13,811,210	13,731,090	13,686,330	13,521,020
2,625,360	2,844,210	2,804,220	2,852,730	2,856,750	2,785,530
39,343,320	42,893,780	42,244,720	42,712,400	42,117,180	41,728,440
19,098,120	20,328,840	20,209,950	20,746,590	20,688,690	20,291,820
71,425,720	78,617,720	76,546,520	76,601,520	76,871,440	76,176,080
35,407,380	38,540,280	38,110,080	38,676,840	38,721,600	38,042,640
124,433,120	135,475,840	133,652,320	132,783,040	132,335,040	132,933,680
304,624,110	**332,519,230**	**327,379,020**	**328,104,210**	**327,277,030**	**325,479,210**

9/9/2011	9/16/2011	9/23/2011	9/30/2011	10/7/2011	10/14/2011
12	14	14	14	14	14
3	3	3	3	3	3
39	43	42	43	42	42
19	20	20	21	21	20
71	79	77	77	77	76
35	39	38	39	39	38
124	135	134	133	132	133
305	**333**	**327**	**328**	**327**	**325**

2011/10/21 EUTRx	2011/10/28 EUTRx	2011/11/04 EUTRx	2011/11/11 EUTRx	2011/11/18 EUTRx	2011/11/25 EUTRx
8,433,590	8,378,797	8,364,566	8,419,830	8,534,146	7,488,971
1,374,237	1,356,864	1,366,208	1,351,490	1,383,921	1,208,518
188,811	185,808	181,204	187,251	191,323	170,857
2,056,120	2,058,621	2,052,221	2,068,524	2,087,144	1,824,031
676,712	681,559	688,050	676,655	699,901	607,197
1,867,511	1,875,802	1,843,814	1,868,754	1,888,589	1,654,741
638,311	644,857	630,014	630,742	663,539	578,161
1,631,888	1,575,286	1,603,055	1,636,414	1,619,729	1,445,466
8,433,590	**8,378,797**	**8,364,566**	**8,419,830**	**8,534,146**	**7,488,971**

13,742,370	13,568,640	13,662,080	13,514,900	13,839,210	12,085,180
2,832,165	2,787,120	2,718,060	2,808,765	2,869,845	2,562,855
41,122,400	41,172,420	41,044,420	41,370,480	41,742,880	36,480,620
20,301,360	20,446,770	20,641,500	20,299,650	20,997,030	18,215,910
74,700,440	75,032,080	73,752,560	74,750,160	75,543,560	66,189,640
38,298,660	38,691,420	37,800,840	37,844,520	39,812,340	34,689,660
130,551,040	126,022,880	128,244,400	130,913,120	129,578,320	115,637,280
321,548,435	**317,721,330**	**317,863,860**	**321,501,595**	**324,383,185**	**285,861,145**

10/21/2011	10/28/2011	11/4/2011	11/11/2011	11/18/2011	11/25/2011
14	14	14	14	14	12
3	3	3	3	3	3
41	41	41	41	42	36
20	20	21	20	21	18
75	75	74	75	76	66
38	39	38	38	40	35
131	126	128	131	130	116
322	**318**	**318**	**322**	**324**	**286**

2011/12/02 EUTRx	2011/12/09 EUTRx	2011/12/16 EUTRx	2011/12/23 EUTRx	2011/12/30 EUTRx	2012/01/06 EUTRx
9,056,397	8,496,159	8,633,759	8,783,921	7,373,644	8,063,746
1,439,090	1,374,240	1,423,190	1,451,921	1,158,790	1,282,119
193,397	201,119	197,707	198,672	161,569	192,487
2,213,081	2,074,192	2,094,123	2,151,605	1,806,349	1,971,363
756,778	705,047	714,547	714,302	614,514	680,416
2,012,438	1,871,406	1,903,644	1,932,693	1,627,130	1,771,423
699,049	634,440	666,005	672,301	570,244	618,521
1,742,564	1,635,715	1,634,543	1,662,427	1,434,977	1,547,417
9,056,397	**8,496,159**	**8,633,759**	**8,783,921**	**7,373,644**	**8,063,746**

14,390,900	13,742,400	14,231,900	14,519,210	11,587,900	12,821,190
2,900,955	3,016,785	2,965,605	2,980,080	2,423,535	2,887,305
44,261,620	41,483,840	41,882,460	43,032,100	36,126,980	39,427,260
22,703,340	21,151,410	21,436,410	21,429,060	18,435,420	20,412,480
80,497,520	74,856,240	76,145,760	77,307,720	65,085,200	70,856,920
41,942,940	38,066,400	39,960,300	40,338,060	34,214,640	37,111,260
139,405,120	130,857,200	130,763,440	132,994,160	114,798,160	123,793,360
346,102,395	**323,174,275**	**327,385,875**	**332,600,390**	**282,671,835**	**307,309,775**

12/2/2011	12/9/2011	12/16/2011	12/23/2011	12/30/2011	1/6/2012
14	14	14	15	12	13
3	3	3	3	2	3
44	41	42	43	36	39
23	21	21	21	18	20
80	75	76	77	65	71
42	38	40	40	34	37
139	131	131	133	115	124
346	**323**	**327**	**333**	**283**	**307**

2012/01/13 EUTRx	2012/01/20 EUTRx	2012/01/27 EUTRx	2012/02/03 EUTRx	2012/02/10 EUTRx	2012/02/17 EUTRx
8,469,490	8,227,738	7,838,360	8,386,620	8,396,362	8,231,779
1,365,723	1,332,905	1,291,466	1,357,246	1,377,064	1,329,446
198,357	193,226	188,187	194,964	200,601	198,681
2,048,198	2,015,901	1,934,038	2,031,761	2,033,049	2,000,787
708,312	692,645	670,328	712,690	708,927	684,732
1,886,140	1,796,545	1,695,144	1,830,911	1,832,152	1,809,806
650,576	636,444	603,778	654,117	641,919	649,434
1,612,184	1,560,072	1,455,419	1,604,931	1,602,650	1,558,893
8,469,490	**8,227,738**	**7,838,360**	**8,386,620**	**8,396,362**	**8,231,779**

13,657,230	13,329,050	12,914,660	13,572,460	13,770,640	13,294,460
2,975,355	2,898,390	2,822,805	2,924,460	3,009,015	2,980,215
40,963,960	40,318,020	38,680,760	40,635,220	40,660,980	40,015,740
21,249,360	20,779,350	20,109,840	21,380,700	21,267,810	20,541,960
75,445,600	71,861,800	67,805,760	73,236,440	73,286,080	72,392,240
39,034,560	38,186,640	36,226,680	39,247,020	38,515,140	38,966,040
128,974,720	124,805,760	116,433,520	128,394,480	128,212,000	124,711,440
322,300,785	**312,179,010**	**294,994,025**	**319,390,780**	**318,721,665**	**312,902,095**

1/13/2012	1/20/2012	1/27/2012	2/3/2012	2/10/2012	2/17/2012
14	13	13	14	14	13
3	3	3	3	3	3
41	40	39	41	41	40
21	21	20	21	21	21
75	72	68	73	73	72
39	38	36	39	39	39
129	125	116	128	128	125
322	**312**	**295**	**319**	**319**	**313**

2012/02/24 EUTRx	2012/03/02 EUTRx	2012/03/09 EUTRx	2012/03/16 EUTRx	2012/03/23 EUTRx	2012/03/30 EUTRx
7,919,014	8,894,547	8,618,055	8,238,496	7,986,979	8,159,404
1,281,004	1,412,394	1,385,138	1,339,355	1,311,232	1,322,454
189,318	212,086	207,306	205,175	192,796	191,879
1,926,520	2,146,918	2,067,955	1,977,236	1,948,165	1,990,219
683,706	760,671	737,152	714,539	692,787	707,556
1,720,587	1,948,642	1,875,887	1,805,137	1,719,569	1,775,618
614,941	713,838	680,668	645,508	628,753	658,812
1,502,938	1,699,998	1,663,949	1,551,546	1,493,677	1,512,866
7,919,014	**8,894,547**	**8,618,055**	**8,238,496**	**7,986,979**	**8,159,404**

12,810,040	14,123,940	13,851,380	13,393,550	13,112,320	13,224,540
2,839,770	3,181,290	3,109,590	3,077,625	2,891,940	2,878,185
38,530,400	42,938,360	41,359,100	39,544,720	38,963,300	39,804,380
20,511,180	22,820,130	22,114,560	21,436,170	20,783,610	21,226,680
68,823,480	77,945,680	75,035,480	72,205,480	68,782,760	71,024,720
36,896,460	42,830,280	40,840,080	38,730,480	37,725,180	39,528,720
120,235,040	135,999,840	133,115,920	124,123,680	119,494,160	121,029,280
300,646,370	**339,839,520**	**329,426,110**	**312,511,705**	**301,753,270**	**308,716,505**

2/24/2012	3/2/2012	3/9/2012	3/16/2012	3/23/2012	3/30/2012
13	14	14	13	13	13
3	3	3	3	3	3
39	43	41	40	39	40
21	23	22	21	21	21
69	78	75	72	69	71
37	43	41	39	38	40
120	136	133	124	119	121
301	**340**	**329**	**313**	**302**	**309**

2012/04/06 EUTRx	2012/04/13 EUTRx	2012/04/20 EUTRx	2012/04/27 EUTRx	2012/05/04 EUTRx	2012/05/11 EUTRx
8,537,435	8,120,425	8,115,483	8,255,699	8,770,748	8,152,744
1,351,771	1,330,947	1,313,770	1,351,314	1,392,200	1,321,258
205,525	202,082	208,611	198,534	216,422	204,934
2,072,855	1,979,017	1,975,352	1,991,462	2,102,921	1,983,488
741,174	706,575	728,585	741,427	783,483	718,178
1,857,322	1,758,891	1,741,258	1,776,930	1,913,749	1,758,181
685,446	638,319	649,055	657,771	712,984	648,911
1,623,342	1,504,594	1,498,852	1,538,261	1,648,989	1,517,794
8,537,435	**8,120,425**	**8,115,483**	**8,255,699**	**8,770,748**	**8,152,744**

13,517,710	13,309,470	13,137,700	13,513,140	13,922,000	13,212,580
3,082,875	3,031,230	3,129,165	2,978,010	3,246,330	3,074,010
41,457,100	39,580,340	39,507,040	39,829,240	42,058,420	39,669,760
22,235,220	21,197,250	21,857,550	22,242,810	23,504,490	21,545,340
74,292,880	70,355,640	69,650,320	71,077,200	76,549,960	70,327,240
41,126,760	38,299,140	38,943,300	39,466,260	42,779,040	38,934,660
129,867,360	120,367,520	119,908,160	123,060,880	131,919,120	121,423,520
325,579,905	**306,140,590**	**306,133,235**	**312,167,540**	**333,979,360**	**308,187,110**

4/6/2012	4/13/2012	4/20/2012	4/27/2012	5/4/2012	5/11/2012
14	13	13	14	14	13
3	3	3	3	3	3
41	40	40	40	42	40
22	21	22	22	24	22
74	70	70	71	77	70
41	38	39	39	43	39
130	120	120	123	132	121
326	**306**	**306**	**312**	**334**	**308**

2012/05/18 EUTRx	2012/05/25 EUTRx	2012/06/01 EUTRx	2012/06/08 EUTRx	2012/06/15 EUTRx	2012/06/22 EUTRx
8,160,756	8,436,049	7,779,099	8,429,255	8,091,145	8,214,130
1,319,504	1,359,946	1,212,462	1,367,916	1,321,120	1,325,251
210,277	215,693	195,602	216,327	208,959	211,049
1,989,425	2,027,346	1,882,797	2,043,311	1,978,591	1,964,917
738,781	771,686	698,729	751,715	736,161	743,060
1,759,297	1,788,154	1,683,841	1,828,265	1,726,539	1,764,927
657,251	680,108	641,045	664,304	653,013	675,115
1,486,221	1,593,116	1,464,623	1,557,417	1,466,762	1,529,811
8,160,756	**8,436,049**	**7,779,099**	**8,429,255**	**8,091,145**	**8,214,130**

13,195,040	13,599,460	12,124,620	13,679,160	13,211,200	13,252,510
3,154,155	3,235,395	2,934,030	3,244,905	3,134,385	3,165,735
39,788,500	40,546,920	37,655,940	40,866,220	39,571,820	39,298,340
22,163,430	23,150,580	20,961,870	22,551,450	22,084,830	22,291,800
70,371,880	71,526,160	67,353,640	73,130,600	69,061,560	70,597,080
39,435,060	40,806,480	38,462,700	39,858,240	39,180,780	40,506,900
118,897,680	127,449,280	117,169,840	124,593,360	117,340,960	122,384,880
307,005,745	**320,314,275**	**296,662,640**	**317,923,935**	**303,585,535**	**311,497,245**

5/18/2012	5/25/2012	6/1/2012	6/8/2012	6/15/2012	6/22/2012
13	14	12	14	13	13
3	3	3	3	3	3
40	41	38	41	40	39
22	23	21	23	22	22
70	72	67	73	69	71
39	41	38	40	39	41
119	127	117	125	117	122
307	**320**	**297**	**318**	**304**	**311**

2012/06/29 EUTRx	2012/07/06 EUTRx	2012/07/13 EUTRx	2012/07/20 EUTRx	2012/07/27 EUTRx	2012/08/03 EUTRx
8,246,084	8,065,352	8,208,806	8,219,836	8,049,688	8,109,693
1,331,557	1,247,785	1,333,196	1,320,775	1,293,848	1,294,651
207,192	205,022	220,230	213,404	211,946	225,106
2,009,525	1,917,797	1,993,330	1,981,127	1,931,675	1,958,511
754,691	740,361	746,328	753,942	745,686	752,622
1,762,116	1,774,739	1,743,741	1,752,346	1,710,773	1,726,301
669,984	668,827	674,817	680,461	677,459	674,364
1,511,019	1,510,821	1,497,164	1,517,781	1,478,301	1,478,138
8,246,084	**8,065,352**	**8,208,806**	**8,219,836**	**8,049,688**	**8,109,693**

13,315,570	12,477,850	13,331,960	13,207,750	12,938,480	12,946,510
3,107,880	3,075,330	3,303,450	3,201,060	3,179,190	3,376,590
40,190,500	38,355,940	39,866,600	39,622,540	38,633,500	39,170,220
22,640,730	22,210,830	22,389,840	22,618,260	22,370,580	22,578,660
70,484,640	70,989,560	69,749,640	70,093,840	68,430,920	69,052,040
40,199,040	40,129,620	40,489,020	40,827,660	40,647,540	40,461,840
120,881,520	120,865,680	119,773,120	121,422,480	118,264,080	118,251,040
310,819,880	**308,104,810**	**308,903,630**	**310,993,590**	**304,464,290**	**305,836,900**

6/29/2012	7/6/2012	7/13/2012	7/20/2012	7/27/2012	8/3/2012
13	12	13	13	13	13
3	3	3	3	3	3
40	38	40	40	39	39
23	22	22	23	22	23
70	71	70	70	68	69
40	40	40	41	41	40
121	121	120	121	118	118
311	**308**	**309**	**311**	**304**	**306**

2012/08/10 EUTRx	2012/08/17 EUTRx	2012/08/24 EUTRx	2012/08/31 EUTRx	2012/09/07 EUTRx	2012/09/14 EUTRx
7,974,578	8,149,473	8,080,157	8,197,503	7,825,427	8,192,273
1,273,489	1,301,949	1,311,403	1,335,840	1,244,933	1,325,606
213,871	222,794	209,361	223,269	208,040	225,574
1,911,171	1,962,404	1,947,527	1,977,330	1,874,717	1,967,788
734,455	769,565	759,252	761,468	716,018	767,384
1,723,897	1,724,155	1,701,861	1,744,427	1,670,009	1,738,777
657,871	668,116	680,407	674,342	647,370	682,306
1,459,824	1,500,490	1,470,346	1,480,827	1,464,340	1,484,838
7,974,578	**8,149,473**	**8,080,157**	**8,197,503**	**7,825,427**	**8,192,273**

12,734,890	13,019,490	13,114,030	13,358,400	12,449,330	13,256,060
3,208,065	3,341,910	3,140,415	3,349,035	3,120,600	3,383,610
38,223,420	39,248,080	38,950,540	39,546,600	37,494,340	39,355,760
22,033,650	23,086,950	22,777,560	22,844,040	21,480,540	23,021,520
68,955,880	68,966,200	68,074,440	69,777,080	66,800,360	69,551,080
39,472,260	40,086,960	40,824,420	40,460,520	38,842,200	40,938,360
116,785,920	120,039,200	117,627,680	118,466,160	117,147,200	118,787,040
301,414,085	**307,788,790**	**304,509,085**	**307,801,835**	**297,334,570**	**308,293,430**

8/10/2012	8/17/2012	8/24/2012	8/31/2012	9/7/2012	9/14/2012
13	13	13	13	12	13
3	3	3	3	3	3
38	39	39	40	37	39
22	23	23	23	21	23
69	69	68	70	67	70
39	40	41	40	39	41
117	120	118	118	117	119
301	**308**	**305**	**308**	**297**	**308**

2012/09/21 EUTRx	2012/09/28 EUTRx	2012/10/05 EUTRx	2012/10/12 EUTRx	2012/10/19 EUTRx	2012/10/26 EUTRx
8,136,521	8,213,947	8,361,496	7,998,840	8,124,850	8,050,027
1,325,313	1,344,176	1,374,362	1,303,257	1,338,856	1,331,872
225,149	236,966	226,804	220,912	226,671	225,216
1,961,098	1,998,014	1,997,873	1,923,789	1,961,642	1,935,649
755,777	773,138	775,524	760,819	760,116	757,949
1,707,833	1,745,287	1,764,524	1,682,430	1,686,399	1,684,899
680,595	670,088	688,895	666,696	679,457	661,482
1,480,756	1,446,278	1,533,514	1,440,937	1,471,709	1,452,960
8,136,521	**8,213,947**	**8,361,496**	**7,998,840**	**8,124,850**	**8,050,027**

13,253,130	13,441,760	13,743,620	13,032,570	13,388,560	13,318,720
3,377,235	3,554,490	3,402,060	3,313,680	3,400,065	3,378,240
39,221,960	39,960,280	39,957,460	38,475,780	39,232,840	38,712,980
22,673,310	23,194,140	23,265,720	22,824,570	22,803,480	22,738,470
68,313,320	69,811,480	70,580,960	67,297,200	67,455,960	67,395,960
40,835,700	40,205,280	41,333,700	40,001,760	40,767,420	39,688,920
118,460,480	115,702,240	122,681,120	115,274,960	117,736,720	116,236,800
306,135,135	**305,869,670**	**314,964,640**	**300,220,520**	**304,785,045**	**301,470,090**

9/21/2012	9/28/2012	10/5/2012	10/12/2012	10/19/2012	10/26/2012
13	13	14	13	13	13
3	4	3	3	3	3
39	40	40	38	39	39
23	23	23	23	23	23
68	70	71	67	67	67
41	40	41	40	41	40
118	116	123	115	118	116
306	**306**	**315**	**300**	**305**	**301**

2012/11/02 EUTRx	2012/11/09 EUTRx	2012/11/16 EUTRx	2012/11/23 EUTRx	2012/11/30 EUTRx	2012/12/07 EUTRx
7,884,768	8,339,872	8,169,418	7,392,202	8,446,015	8,599,666
1,297,235	1,379,991	1,366,641	1,217,989	1,419,962	1,401,942
222,271	238,223	233,136	208,902	240,382	240,681
1,904,322	2,009,064	1,937,501	1,784,409	2,032,073	2,073,229
750,263	789,110	769,893	707,008	805,363	822,187
1,659,852	1,725,846	1,696,914	1,541,620	1,760,216	1,790,300
645,429	709,182	685,531	606,318	704,753	719,867
1,405,396	1,488,456	1,479,802	1,325,956	1,483,266	1,551,460
7,884,768	**8,339,872**	**8,169,418**	**7,392,202**	**8,446,015**	**8,599,666**

12,972,350	13,799,910	13,666,410	12,179,890	14,199,620	14,019,420
3,334,065	3,573,345	3,497,040	3,133,530	3,605,730	3,610,215
38,086,440	40,181,280	38,750,020	35,688,180	40,641,460	41,464,580
22,507,890	23,673,300	23,096,790	21,210,240	24,160,890	24,665,610
66,394,080	69,033,840	67,876,560	61,664,800	70,408,640	71,612,000
38,725,740	42,550,920	41,131,860	36,379,080	42,285,180	43,192,020
112,431,680	119,076,480	118,384,160	106,076,480	118,661,280	124,116,800
294,452,245	**311,889,075**	**306,402,840**	**276,332,200**	**313,962,800**	**322,680,645**

11/2/2012	11/9/2012	11/16/2012	11/23/2012	11/30/2012	12/7/2012
13	14	14	12	14	14
3	4	3	3	4	4
38	40	39	36	41	41
23	24	23	21	24	25
66	69	68	62	70	72
39	43	41	36	42	43
112	119	118	106	119	124
294	**312**	**306**	**276**	**314**	**323**

2012/12/14 EUTRx	2012/12/21 EUTRx	2012/12/28 EUTRx	2013/01/04 EUTRx	2013/01/11 EUTRx	2013/01/18 EUTRx
8,234,376	8,591,485	6,903,075	7,648,883	8,143,336	8,052,086
1,356,149	1,424,601	1,108,913	1,228,344	1,319,309	1,327,537
243,353	248,169	193,069	210,753	240,570	230,249
1,979,123	2,070,155	1,643,246	1,823,867	1,946,375	1,919,911
792,021	825,149	650,731	743,527	776,260	779,645
1,700,905	1,774,350	1,446,706	1,598,914	1,712,556	1,647,897
692,300	708,922	594,161	657,326	691,962	686,765
1,470,525	1,540,139	1,266,249	1,386,152	1,456,304	1,460,082
8,234,376	**8,591,485**	**6,903,075**	**7,648,883**	**8,143,336**	**8,052,086**

13,561,490	14,246,010	11,089,130	12,283,440	13,193,090	13,275,370
3,650,295	3,722,535	2,896,035	3,161,295	3,608,550	3,453,735
39,582,460	41,403,100	32,864,920	36,477,340	38,927,500	38,398,220
23,760,630	24,754,470	19,521,930	22,305,810	23,287,800	23,389,350
68,036,200	70,974,000	57,868,240	63,956,560	68,502,240	65,915,880
41,538,000	42,535,320	35,649,660	39,439,560	41,517,720	41,205,900
117,642,000	123,211,120	101,299,920	110,892,160	116,504,320	116,806,560
307,771,075	**320,846,555**	**261,189,835**	**288,516,165**	**305,541,220**	**302,445,015**

12/14/2012	12/21/2012	12/28/2012	1/4/2013	1/11/2013	1/18/2013
14	14	11	12	13	13
4	4	3	3	4	3
40	41	33	36	39	38
24	25	20	22	23	23
68	71	58	64	69	66
42	43	36	39	42	41
118	123	101	111	117	117
308	**321**	**261**	**289**	**306**	**302**

2013/01/25 EUTRx	2013/02/01 EUTRx	2013/02/08 EUTRx	2013/02/15 EUTRx	2013/02/22 EUTRx	2013/03/01 EUTRx
7,200,338	7,683,391	8,162,552	7,879,116	7,253,340	8,096,634
1,204,426	1,250,185	1,323,987	1,311,402	1,234,444	1,313,174
218,947	219,310	238,577	226,095	216,995	241,102
1,728,049	1,846,356	1,923,103	1,877,138	1,744,529	1,938,072
690,742	741,895	806,799	748,911	723,181	801,071
1,479,337	1,592,447	1,685,464	1,640,730	1,479,375	1,662,896
610,193	658,830	706,251	655,037	609,224	701,244
1,268,644	1,374,368	1,478,371	1,419,803	1,245,592	1,439,075
7,200,338	**7,683,391**	**8,162,552**	**7,879,116**	**7,253,340**	**8,096,634**

12,044,260	12,501,850	13,239,870	13,114,020	12,344,440	13,131,740
3,284,205	3,289,650	3,578,655	3,391,425	3,254,925	3,616,530
34,560,980	36,927,120	38,462,060	37,542,760	34,890,580	38,761,440
20,722,260	22,256,850	24,203,970	22,467,330	21,695,430	24,032,130
59,173,480	63,697,880	67,418,560	65,629,200	59,175,000	66,515,840
36,611,580	39,529,800	42,375,060	39,302,220	36,553,440	42,074,640
101,491,520	109,949,440	118,269,680	113,584,240	99,647,360	115,126,000
267,888,285	**288,152,590**	**307,547,855**	**295,031,195**	**267,561,175**	**303,258,320**

1/25/2013	2/1/2013	2/8/2013	2/15/2013	2/22/2013	3/1/2013
12	13	13	13	12	13
3	3	4	3	3	4
35	37	38	38	35	39
21	22	24	22	22	24
59	64	67	66	59	67
37	40	42	39	37	42
101	110	118	114	100	115
268	**288**	**308**	**295**	**268**	**303**

2013/03/08 EUTRx	2013/03/15 EUTRx	2013/03/22 EUTRx	2013/03/29 EUTRx	2013/04/05 EUTRx	2013/04/12 EUTRx
8,277,776	7,711,915	7,398,795	7,332,806	7,831,508	7,526,041
1,334,871	1,279,468	1,257,307	1,210,871	1,270,528	1,255,679
242,567	228,095	227,500	216,006	229,814	232,819
1,979,090	1,850,109	1,782,160	1,764,374	1,858,814	1,809,809
802,211	745,368	735,041	734,465	774,321	742,801
1,728,659	1,568,602	1,501,003	1,497,569	1,619,675	1,529,222
694,780	654,045	621,622	636,926	675,819	640,477
1,495,598	1,386,228	1,274,162	1,272,595	1,402,537	1,315,234
8,277,776	**7,711,915**	**7,398,795**	**7,332,806**	**7,831,508**	**7,526,041**

13,348,710	12,794,680	12,573,070	12,108,710	12,705,280	12,556,790
3,638,505	3,421,425	3,412,500	3,240,090	3,447,210	3,492,285
39,581,800	37,002,180	35,643,200	35,287,480	37,176,280	36,196,180
24,066,330	22,361,040	22,051,230	22,033,950	23,229,630	22,284,030
69,146,360	62,744,080	60,040,120	59,902,760	64,787,000	61,168,880
41,686,800	39,242,700	37,297,320	38,215,560	40,549,140	38,428,620
119,647,840	110,898,240	101,932,960	101,807,600	112,202,960	105,218,720
311,116,345	**288,464,345**	**272,950,400**	**272,596,150**	**294,097,500**	**279,345,505**

3/8/2013	3/15/2013	3/22/2013	3/29/2013	4/5/2013	4/12/2013
13	13	13	12	13	13
4	3	3	3	3	3
40	37	36	35	37	36
24	22	22	22	23	22
69	63	60	60	65	61
42	39	37	38	41	38
120	111	102	102	112	105
311	**288**	**273**	**273**	**294**	**279**

2013/04/19 EUTRx	2013/04/26 EUTRx	2013/05/03 EUTRx	2013/05/10 EUTRx	2013/05/17 EUTRx	2013/05/24 EUTRx
7,248,633	7,378,376	7,960,202	7,591,448	7,283,133	7,581,531
1,219,931	1,230,749	1,297,032	1,245,752	1,237,341	1,264,585
221,863	221,743	243,182	236,717	228,184	232,396
1,751,426	1,759,156	1,877,871	1,838,489	1,783,506	1,820,998
736,584	742,974	790,780	760,706	745,344	776,599
1,457,311	1,514,307	1,645,401	1,547,612	1,454,076	1,526,871
622,198	633,976	681,333	661,094	621,112	660,081
1,239,320	1,275,471	1,424,066	1,301,078	1,213,570	1,300,001
7,249,798	**7,379,028**	**7,960,361**	**7,591,535**	**7,283,970**	**7,581,999**

12,199,310	12,307,490	12,970,320	12,457,520	12,373,410	12,645,850
3,327,945	3,326,145	3,647,730	3,550,755	3,422,760	3,485,940
35,028,520	35,183,120	37,557,420	36,769,780	35,670,120	36,419,960
22,097,520	22,289,220	23,723,400	22,821,180	22,360,320	23,297,970
58,292,440	60,572,280	65,816,040	61,904,480	58,163,040	61,074,840
37,331,880	38,038,560	40,879,980	39,665,640	37,266,720	39,604,860
99,145,600	102,037,680	113,925,280	104,086,240	97,085,600	104,000,080
267,423,215	**273,754,495**	**298,520,170**	**281,255,595**	**266,341,970**	**280,529,500**

4/19/2013	4/26/2013	5/3/2013	5/10/2013	5/17/2013	5/24/2013
12	12	13	12	12	13
3	3	4	4	3	3
35	35	38	37	36	36
22	22	24	23	22	23
58	61	66	62	58	61
37	38	41	40	37	40
99	102	114	104	97	104
267	**274**	**299**	**281**	**266**	**281**

2013/05/31 EUTRx	2013/06/07 EUTRx	2013/06/14 EUTRx	2013/06/21 EUTRx
6,955,687	7,894,454	7,355,086	7,399,395
1,135,887	1,306,249	1,263,289	1,242,713
220,347	240,832	233,898	230,435
1,664,311	1,900,664	1,767,584	1,789,389
696,081	781,148	752,408	756,718
1,430,577	1,621,728	1,460,150	1,496,701
590,116	678,679	625,534	635,692
1,218,368	1,365,154	1,252,223	1,247,747
6,956,349	**7,895,170**	**7,355,525**	**7,399,769**

11,358,870	13,062,490	12,632,890	12,427,130
3,305,205	3,612,480	3,508,470	3,456,525
33,286,220	38,013,280	35,351,680	35,787,780
20,882,430	23,434,440	22,572,240	22,701,540
57,223,080	64,869,120	58,406,000	59,868,040
35,406,960	40,720,740	37,532,040	38,141,520
97,469,440	109,212,320	100,177,840	99,819,760
258,932,205	**292,924,870**	**270,181,160**	**272,202,295**

5/31/2013	6/7/2013	6/14/2013	6/21/2013

11	13	13	12
3	4	4	3
33	38	35	36
21	23	23	23
57	65	58	60
35	41	38	38
97	109	100	100
259	**293**	**270**	**272**


Total Weekly OxyContin - M
Millions of MG
400
350
300
250
200
150
100
50
4/8/2011
5/8/2011
6/8/2011
7/8/2011
8/8/2011
9/8/2011
10/8/2011
11/8/2011
12/8/2011
1/8/2012
2/8/2012
3/8/2012
4/8/2012
5/8/2012
6/8/2012


Total Weekly OxyContin by Str
Millions of MG
180
160
140
120
100
80
60
40
20
4/8/2011
5/8/2011
6/8/2011
7/8/2011
8/8/2011
9/8/2011
10/8/2011
11/8/2011
12/8/2011
1/8/2012
2/8/2012
3/8/2012
4/8/2012
5/8/2012
6/8/2012
7/8/2012


ength - Millions of MG
10MG
15MG
20MG
30MG
40MG
60MG
80MG
012
9/8/2012
10/8/2012
11/8/2012
12/8/2012
1/8/2013
2/8/2013
3/8/2013
4/8/2013
5/8/2013
6/8/2013
7/8/2013

OxyContin Units and Kg Dispensed
IMS Health NPA
numbers are absolute. Retail pharmacies, mail order and LTC

Product	2011/04/08 EUTRx	2011/04/15 EUTRx	2011/04/22 EUTRx	2011/04/29 EUTRx
OXYCONTIN 01/1996 PUF	9,245,201	8,798,770	8,573,636	8,811,087
10MG	1,478,660	1,427,631	1,390,912	1,405,432
15MG	183,269	180,224	173,573	179,380
20MG	2,290,945	2,192,332	2,165,596	2,193,475
30MG	692,907	673,958	647,518	666,744
40MG	2,055,364	1,943,620	1,899,504	1,960,507
60MG	671,650	658,988	610,461	638,010
80MG	1,872,406	1,722,017	1,686,072	1,767,539
Grand Total	**9,245,201**	**8,798,770**	**8,573,636**	**8,811,087**

Kg Dispensed

OXYCONTIN 01/1996 PUF				
10MG	14.8	14.3	13.9	14.1
15MG	2.7	2.7	2.6	2.7
20MG	45.8	43.8	43.3	43.9
30MG	20.8	20.2	19.4	20.0
40MG	82.2	77.7	76.0	78.4
60MG	40.3	39.5	36.6	38.3
80MG	149.8	137.8	134.9	141.4
Grand Total	**356.4**	**336.1**	**326.7**	**338.7**

Weekly Kg Dispensed Budget	**4-Jan-13**	**11-Jan-13**	**18-Jan-13**	**25-Jan-13**
10mg	12	13	13	13
15mg	3	4	3	3
20mg	38	39	39	37
30mg	24	25	24	23
40mg	65	69	66	62
60mg	43	45	44	41
80mg	119	124	119	111
Total	**306**	**318**	**307**	**291**

2011/05/06 EUTRx	2011/05/13 EUTRx	2011/05/20 EUTRx	2011/05/27 EUTRx	2011/06/03 EUTRx	2011/06/10 EUTRx
9,501,374	8,741,359	8,573,294	9,026,667	8,430,496	8,792,965
1,487,471	1,400,215	1,390,618	1,450,473	1,311,696	1,431,988
185,164	181,782	178,413	184,192	166,081	181,190
2,391,478	2,199,539	2,152,247	2,232,569	2,096,801	2,197,315
717,131	661,119	661,896	689,695	650,666	677,241
2,110,498	1,935,334	1,891,439	2,010,862	1,887,654	1,930,916
700,016	634,357	629,136	664,006	627,137	649,340
1,909,616	1,729,013	1,669,545	1,794,870	1,690,461	1,724,975
9,501,374	**8,741,359**	**8,573,294**	**9,026,667**	**8,430,496**	**8,792,965**

14.9	14.0	13.9	14.5	13.1	14.3
2.8	2.7	2.7	2.8	2.5	2.7
47.8	44.0	43.0	44.7	41.9	43.9
21.5	19.8	19.9	20.7	19.5	20.3
84.4	77.4	75.7	80.4	75.5	77.2
42.0	38.1	37.7	39.8	37.6	39.0
152.8	138.3	133.6	143.6	135.2	138.0
366.2	**334.3**	**326.5**	**346.5**	**325.4**	**335.5**

1-Feb-13	8-Feb-13	15-Feb-13	22-Feb-13	1-Mar-13	8-Mar-13
13	13	12	12	13	13
3	3	3	3	4	3
38	37	37	35	40	39
24	24	23	23	25	24
64	65	63	60	70	67
42	42	42	39	47	44
117	117	113	109	128	124
301	**300**	**293**	**282**	**327**	**316**

2011/06/17 EUTRx	2011/06/24 EUTRx	2011/07/01 EUTRx	2011/07/08 EUTRx	2011/07/15 EUTRx	2011/07/22 EUTRx
8,581,589	8,758,691	9,331,763	8,126,682	8,625,729	8,619,338
1,389,967	1,391,937	1,474,790	1,283,213	1,387,431	1,367,678
177,671	180,557	189,408	170,738	183,608	182,874
2,157,000	2,161,652	2,351,092	2,026,960	2,159,950	2,143,410
673,071	680,089	726,907	641,157	682,731	672,123
1,882,461	1,953,240	2,021,413	1,795,202	1,887,344	1,921,136
618,362	650,976	683,878	604,158	645,302	634,734
1,683,057	1,740,240	1,884,275	1,605,254	1,679,363	1,697,383
8,581,589	**8,758,691**	**9,331,763**	**8,126,682**	**8,625,729**	**8,619,338**

13.9	13.9	14.7	12.8	13.9	13.7
2.7	2.7	2.8	2.6	2.8	2.7
43.1	43.2	47.0	40.5	43.2	42.9
20.2	20.4	21.8	19.2	20.5	20.2
75.3	78.1	80.9	71.8	75.5	76.8
37.1	39.1	41.0	36.2	38.7	38.1
134.6	139.2	150.7	128.4	134.3	135.8
326.9	**336.7**	**359.0**	**311.6**	**328.9**	**330.2**

15-Mar-13	22-Mar-13	29-Mar-13	5-Apr-13	12-Apr-13	19-Apr-13
13	12	12	14	13	13
3	3	3	4	4	4
37	36	37	41	39	39
24	23	24	25	24	25
65	62	63	72	67	67
42	41	43	47	44	44
115	111	114	130	119	120
299	**289**	**297**	**333**	**311**	**311**

2011/07/29 EUTRx	2011/08/05 EUTRx	2011/08/12 EUTRx	2011/08/19 EUTRx	2011/08/26 EUTRx	2011/09/02 EUTRx
8,639,239	8,539,432	8,432,171	8,561,895	8,586,953	8,700,800
1,389,900	1,351,652	1,352,449	1,347,382	1,361,439	1,415,584
176,085	182,481	181,231	186,212	186,411	178,550
2,123,617	2,112,497	2,094,035	2,110,746	2,107,274	2,147,515
667,672	674,468	661,561	678,745	683,683	676,670
1,936,667	1,936,788	1,887,976	1,937,511	1,935,523	1,953,056
645,107	634,667	627,548	634,527	640,278	646,482
1,700,191	1,646,879	1,627,371	1,666,772	1,672,345	1,682,943
8,639,239	**8,539,432**	**8,432,171**	**8,561,895**	**8,586,953**	**8,700,800**

13.9	13.5	13.5	13.5	13.6	14.2
2.6	2.7	2.7	2.8	2.8	2.7
42.5	42.2	41.9	42.2	42.1	43.0
20.0	20.2	19.8	20.4	20.5	20.3
77.5	77.5	75.5	77.5	77.4	78.1
38.7	38.1	37.7	38.1	38.4	38.8
136.0	131.8	130.2	133.3	133.8	134.6
331.2	**326.0**	**321.3**	**327.8**	**328.7**	**331.6**

26-Apr-13	3-May-13	10-May-13	17-May-13	24-May-13	31-May-13
13	14	13	13	13	12
3	4	3	3	3	3
40	40	38	38	39	35
25	25	24	24	25	22
67	72	65	65	67	62
46	46	42	43	45	41
121	129	118	115	122	114
316	**330**	**303**	**301**	**314**	**289**

2011/09/09 EUTRx	2011/09/16 EUTRx	2011/09/23 EUTRx	2011/09/30 EUTRx	2011/10/07 EUTRx	2011/10/14 EUTRx
7,939,083	8,695,016	8,573,455	8,609,904	8,575,899	8,500,737
1,229,109	1,381,856	1,381,121	1,373,109	1,368,633	1,352,102
175,024	189,614	186,948	190,182	190,450	185,702
1,967,166	2,144,689	2,112,236	2,135,620	2,105,859	2,086,422
636,604	677,628	673,665	691,553	689,623	676,394
1,785,643	1,965,443	1,913,663	1,915,038	1,921,786	1,904,402
590,123	642,338	635,168	644,614	645,360	634,044
1,555,414	1,693,448	1,670,654	1,659,788	1,654,188	1,661,671
7,939,083	**8,695,016**	**8,573,455**	**8,609,904**	**8,575,899**	**8,500,737**

12.3	13.8	13.8	13.7	13.7	13.5
2.6	2.8	2.8	2.9	2.9	2.8
39.3	42.9	42.2	42.7	42.1	41.7
19.1	20.3	20.2	20.7	20.7	20.3
71.4	78.6	76.5	76.6	76.9	76.2
35.4	38.5	38.1	38.7	38.7	38.0
124.4	135.5	133.7	132.8	132.3	132.9
304.6	**332.5**	**327.4**	**328.1**	**327.3**	**325.5**

7-Jun-13	14-Jun-13	21-Jun-13	28-Jun-13	5-Jul-13	12-Jul-13
13	13	13	13	13	13
3	3	3	3	3	4
38	37	37	38	38	40
24	23	24	24	24	24
66	63	64	64	68	67
43	42	43	43	44	44
120	113	117	117	122	121
307	**294**	**300**	**301**	**312**	**313**

2011/10/21 EUTRx	2011/10/28 EUTRx	2011/11/04 EUTRx	2011/11/11 EUTRx	2011/11/18 EUTRx	2011/11/25 EUTRx
8,433,590	8,378,797	8,364,566	8,419,830	8,534,146	7,488,971
1,374,237	1,356,864	1,366,208	1,351,490	1,383,921	1,208,518
188,811	185,808	181,204	187,251	191,323	170,857
2,056,120	2,058,621	2,052,221	2,068,524	2,087,144	1,824,031
676,712	681,559	688,050	676,655	699,901	607,197
1,867,511	1,875,802	1,843,814	1,868,754	1,888,589	1,654,741
638,311	644,857	630,014	630,742	663,539	578,161
1,631,888	1,575,286	1,603,055	1,636,414	1,619,729	1,445,466
8,433,590	**8,378,797**	**8,364,566**	**8,419,830**	**8,534,146**	**7,488,971**

13.7	13.6	13.7	13.5	13.8	12.1
2.8	2.8	2.7	2.8	2.9	2.6
41.1	41.2	41.0	41.4	41.7	36.5
20.3	20.4	20.6	20.3	21.0	18.2
74.7	75.0	73.8	74.8	75.5	66.2
38.3	38.7	37.8	37.8	39.8	34.7
130.6	126.0	128.2	130.9	129.6	115.6
321.5	**317.7**	**317.9**	**321.5**	**324.4**	**285.9**

19-Jul-13	26-Jul-13	2-Aug-13	9-Aug-13	16-Aug-13	23-Aug-13
13	13	13	13	14	14
4	3	3	3	3	3
39	38	40	39	40	40
25	24	23	23	24	23
67	65	71	70	70	69
44	44	42	41	42	43
121	118	114	115	117	115
313	**306**	**307**	**305**	**310**	**306**

2011/12/02 EUTRx	2011/12/09 EUTRx	2011/12/16 EUTRx	2011/12/23 EUTRx	2011/12/30 EUTRx	2012/01/06 EUTRx
9,056,397	8,496,159	8,633,759	8,783,921	7,373,644	8,063,746
1,439,090	1,374,240	1,423,190	1,451,921	1,158,790	1,282,119
193,397	201,119	197,707	198,672	161,569	192,487
2,213,081	2,074,192	2,094,123	2,151,605	1,806,349	1,971,363
756,778	705,047	714,547	714,302	614,514	680,416
2,012,438	1,871,406	1,903,644	1,932,693	1,627,130	1,771,423
699,049	634,440	666,005	672,301	570,244	618,521
1,742,564	1,635,715	1,634,543	1,662,427	1,434,977	1,547,417
9,056,397	**8,496,159**	**8,633,759**	**8,783,921**	**7,373,644**	**8,063,746**

14.4	13.7	14.2	14.5	11.6	12.8
2.9	3.0	3.0	3.0	2.4	2.9
44.3	41.5	41.9	43.0	36.1	39.4
22.7	21.2	21.4	21.4	18.4	20.4
80.5	74.9	76.1	77.3	65.1	70.9
41.9	38.1	40.0	40.3	34.2	37.1
139.4	130.9	130.8	133.0	114.8	123.8
346.1	**323.2**	**327.4**	**332.6**	**282.7**	**307.3**

30-Aug-13	6-Sep-13	13-Sep-13	20-Sep-13	27-Sep-13	4-Oct-13
12	11	12	12	13	13
3	3	4	3	4	3
37	36	37	37	37	39
24	24	25	24	25	24
63	61	63	61	63	67
44	43	45	45	44	43
121	121	122	121	119	123
306	**298**	**307**	**303**	**304**	**312**

2012/01/13 EUTRx	2012/01/20 EUTRx	2012/01/27 EUTRx	2012/02/03 EUTRx	2012/02/10 EUTRx	2012/02/17 EUTRx
8,469,490	8,227,738	7,838,360	8,386,620	8,396,362	8,231,779
1,365,723	1,332,905	1,291,466	1,357,246	1,377,064	1,329,446
198,357	193,226	188,187	194,964	200,601	198,681
2,048,198	2,015,901	1,934,038	2,031,761	2,033,049	2,000,787
708,312	692,645	670,328	712,690	708,927	684,732
1,886,140	1,796,545	1,695,144	1,830,911	1,832,152	1,809,806
650,576	636,444	603,778	654,117	641,919	649,434
1,612,184	1,560,072	1,455,419	1,604,931	1,602,650	1,558,893
8,469,490	**8,227,738**	**7,838,360**	**8,386,620**	**8,396,362**	**8,231,779**

13.7	13.3	12.9	13.6	13.8	13.3
3.0	2.9	2.8	2.9	3.0	3.0
41.0	40.3	38.7	40.6	40.7	40.0
21.2	20.8	20.1	21.4	21.3	20.5
75.4	71.9	67.8	73.2	73.3	72.4
39.0	38.2	36.2	39.2	38.5	39.0
129.0	124.8	116.4	128.4	128.2	124.7
322.3	**312.2**	**295.0**	**319.4**	**318.7**	**312.9**

11-Oct-13	18-Oct-13	25-Oct-13	1-Nov-13	8-Nov-13	15-Nov-13
13	13	13	12	13	13
3	3	3	3	3	3
39	39	39	38	38	37
24	23	24	23	24	23
67	67	67	66	65	64
42	43	42	40	43	43
116	117	117	113	119	117
304	**305**	**305**	**295**	**305**	**300**

2012/02/24 EUTRx	2012/03/02 EUTRx	2012/03/09 EUTRx	2012/03/16 EUTRx	2012/03/23 EUTRx	2012/03/30 EUTRx
7,919,014	8,894,547	8,618,055	8,238,496	7,986,979	8,159,404
1,281,004	1,412,394	1,385,138	1,339,355	1,311,232	1,322,454
189,318	212,086	207,306	205,175	192,796	191,879
1,926,520	2,146,918	2,067,955	1,977,236	1,948,165	1,990,219
683,706	760,671	737,152	714,539	692,787	707,556
1,720,587	1,948,642	1,875,887	1,805,137	1,719,569	1,775,618
614,941	713,838	680,668	645,508	628,753	658,812
1,502,938	1,699,998	1,663,949	1,551,546	1,493,677	1,512,866
7,919,014	**8,894,547**	**8,618,055**	**8,238,496**	**7,986,979**	**8,159,404**

12.8	14.1	13.9	13.4	13.1	13.2
2.8	3.2	3.1	3.1	2.9	2.9
38.5	42.9	41.4	39.5	39.0	39.8
20.5	22.8	22.1	21.4	20.8	21.2
68.8	77.9	75.0	72.2	68.8	71.0
36.9	42.8	40.8	38.7	37.7	39.5
120.2	136.0	133.1	124.1	119.5	121.0
300.6	**339.8**	**329.4**	**312.5**	**301.8**	**308.7**

22-Nov-13	29-Nov-13	6-Dec-13	13-Dec-13	20-Dec-13	27-Dec-13
11	13	13	12	13	10
3	3	3	3	4	3
34	38	38	36	38	31
21	24	25	24	25	20
58	65	64	61	64	55
38	44	44	43	44	37
105	119	125	116	122	102
271	**305**	**312**	**296**	**310**	**258**

2012/04/06 EUTRx	2012/04/13 EUTRx	2012/04/20 EUTRx	2012/04/27 EUTRx	2012/05/04 EUTRx	2012/05/11 EUTRx
8,537,435	8,120,425	8,115,483	8,255,699	8,770,748	8,152,744
1,351,771	1,330,947	1,313,770	1,351,314	1,392,200	1,321,258
205,525	202,082	208,611	198,534	216,422	204,934
2,072,855	1,979,017	1,975,352	1,991,462	2,102,921	1,983,488
741,174	706,575	728,585	741,427	783,483	718,178
1,857,322	1,758,891	1,741,258	1,776,930	1,913,749	1,758,181
685,446	638,319	649,055	657,771	712,984	648,911
1,623,342	1,504,594	1,498,852	1,538,261	1,648,989	1,517,794
8,537,435	**8,120,425**	**8,115,483**	**8,255,699**	**8,770,748**	**8,152,744**

13.5	13.3	13.1	13.5	13.9	13.2
3.1	3.0	3.1	3.0	3.2	3.1
41.5	39.6	39.5	39.8	42.1	39.7
22.2	21.2	21.9	22.2	23.5	21.5
74.3	70.4	69.7	71.1	76.5	70.3
41.1	38.3	38.9	39.5	42.8	38.9
129.9	120.4	119.9	123.1	131.9	121.4
325.6	**306.1**	**306.1**	**312.2**	**334.0**	**308.2**

665
176
1,969
1,239
3,389
2,232
6,132
15,801

2012/05/18 EUTRx	2012/05/25 EUTRx	2012/06/01 EUTRx	2012/06/08 EUTRx	2012/06/15 EUTRx	2012/06/22 EUTRx
8,160,756	8,436,049	7,779,099	8,429,255	8,091,145	8,214,130
1,319,504	1,359,946	1,212,462	1,367,916	1,321,120	1,325,251
210,277	215,693	195,602	216,327	208,959	211,049
1,989,425	2,027,346	1,882,797	2,043,311	1,978,591	1,964,917
738,781	771,686	698,729	751,715	736,161	743,060
1,759,297	1,788,154	1,683,841	1,828,265	1,726,539	1,764,927
657,251	680,108	641,045	664,304	653,013	675,115
1,486,221	1,593,116	1,464,623	1,557,417	1,466,762	1,529,811
8,160,756	**8,436,049**	**7,779,099**	**8,429,255**	**8,091,145**	**8,214,130**

13.2	13.6	12.1	13.7	13.2	13.3
3.2	3.2	2.9	3.2	3.1	3.2
39.8	40.5	37.7	40.9	39.6	39.3
22.2	23.2	21.0	22.6	22.1	22.3
70.4	71.5	67.4	73.1	69.1	70.6
39.4	40.8	38.5	39.9	39.2	40.5
118.9	127.4	117.2	124.6	117.3	122.4
307.0	**320.3**	**296.7**	**317.9**	**303.6**	**311.5**

2012/06/29 EUTRx	2012/07/06 EUTRx	2012/07/13 EUTRx	2012/07/20 EUTRx	2012/07/27 EUTRx	2012/08/03 EUTRx
8,246,084	8,065,352	8,208,806	8,219,836	8,049,688	8,109,693
1,331,557	1,247,785	1,333,196	1,320,775	1,293,848	1,294,651
207,192	205,022	220,230	213,404	211,946	225,106
2,009,525	1,917,797	1,993,330	1,981,127	1,931,675	1,958,511
754,691	740,361	746,328	753,942	745,686	752,622
1,762,116	1,774,739	1,743,741	1,752,346	1,710,773	1,726,301
669,984	668,827	674,817	680,461	677,459	674,364
1,511,019	1,510,821	1,497,164	1,517,781	1,478,301	1,478,138
8,246,084	**8,065,352**	**8,208,806**	**8,219,836**	**8,049,688**	**8,109,693**

13.3	12.5	13.3	13.2	12.9	12.9
3.1	3.1	3.3	3.2	3.2	3.4
40.2	38.4	39.9	39.6	38.6	39.2
22.6	22.2	22.4	22.6	22.4	22.6
70.5	71.0	69.7	70.1	68.4	69.1
40.2	40.1	40.5	40.8	40.6	40.5
120.9	120.9	119.8	121.4	118.3	118.3
310.8	**308.1**	**308.9**	**311.0**	**304.5**	**305.8**

2012/08/10 EUTRx	2012/08/17 EUTRx	2012/08/24 EUTRx	2012/08/31 EUTRx	2012/09/07 EUTRx	2012/09/14 EUTRx
7,974,578	8,149,473	8,080,157	8,197,503	7,825,427	8,192,273
1,273,489	1,301,949	1,311,403	1,335,840	1,244,933	1,325,606
213,871	222,794	209,361	223,269	208,040	225,574
1,911,171	1,962,404	1,947,527	1,977,330	1,874,717	1,967,788
734,455	769,565	759,252	761,468	716,018	767,384
1,723,897	1,724,155	1,701,861	1,744,427	1,670,009	1,738,777
657,871	668,116	680,407	674,342	647,370	682,306
1,459,824	1,500,490	1,470,346	1,480,827	1,464,340	1,484,838
7,974,578	**8,149,473**	**8,080,157**	**8,197,503**	**7,825,427**	**8,192,273**

12.7	13.0	13.1	13.4	12.4	13.3
3.2	3.3	3.1	3.3	3.1	3.4
38.2	39.2	39.0	39.5	37.5	39.4
22.0	23.1	22.8	22.8	21.5	23.0
69.0	69.0	68.1	69.8	66.8	69.6
39.5	40.1	40.8	40.5	38.8	40.9
116.8	120.0	117.6	118.5	117.1	118.8
301.4	**307.8**	**304.5**	**307.8**	**297.3**	**308.3**

2012/09/21 EUTRx	2012/09/28 EUTRx	2012/10/05 EUTRx	2012/10/12 EUTRx	2012/10/19 EUTRx	2012/10/26 EUTRx
8,136,521	8,213,947	8,361,496	7,998,840	8,124,850	8,050,027
1,325,313	1,344,176	1,374,362	1,303,257	1,338,856	1,331,872
225,149	236,966	226,804	220,912	226,671	225,216
1,961,098	1,998,014	1,997,873	1,923,789	1,961,642	1,935,649
755,777	773,138	775,524	760,819	760,116	757,949
1,707,833	1,745,287	1,764,524	1,682,430	1,686,399	1,684,899
680,595	670,088	688,895	666,696	679,457	661,482
1,480,756	1,446,278	1,533,514	1,440,937	1,471,709	1,452,960
8,136,521	**8,213,947**	**8,361,496**	**7,998,840**	**8,124,850**	**8,050,027**

13.3	13.4	13.7	13.0	13.4	13.3
3.4	3.6	3.4	3.3	3.4	3.4
39.2	40.0	40.0	38.5	39.2	38.7
22.7	23.2	23.3	22.8	22.8	22.7
68.3	69.8	70.6	67.3	67.5	67.4
40.8	40.2	41.3	40.0	40.8	39.7
118.5	115.7	122.7	115.3	117.7	116.2
306.1	**305.9**	**315.0**	**300.2**	**304.8**	**301.5**

2012/11/02 EUTRx	2012/11/09 EUTRx	2012/11/16 EUTRx	2012/11/23 EUTRx	2012/11/30 EUTRx	2012/12/07 EUTRx
7,884,768	8,339,872	8,169,418	7,392,202	8,446,015	8,599,666
1,297,235	1,379,991	1,366,641	1,217,989	1,419,962	1,401,942
222,271	238,223	233,136	208,902	240,382	240,681
1,904,322	2,009,064	1,937,501	1,784,409	2,032,073	2,073,229
750,263	789,110	769,893	707,008	805,363	822,187
1,659,852	1,725,846	1,696,914	1,541,620	1,760,216	1,790,300
645,429	709,182	685,531	606,318	704,753	719,867
1,405,396	1,488,456	1,479,802	1,325,956	1,483,266	1,551,460
7,884,768	**8,339,872**	**8,169,418**	**7,392,202**	**8,446,015**	**8,599,666**

13.0	13.8	13.7	12.2	14.2	14.0
3.3	3.6	3.5	3.1	3.6	3.6
38.1	40.2	38.8	35.7	40.6	41.5
22.5	23.7	23.1	21.2	24.2	24.7
66.4	69.0	67.9	61.7	70.4	71.6
38.7	42.6	41.1	36.4	42.3	43.2
112.4	119.1	118.4	106.1	118.7	124.1
294.5	**311.9**	**306.4**	**276.3**	**314.0**	**322.7**

2012/12/14 EUTRx	2012/12/21 EUTRx	2012/12/28 EUTRx	2013/01/04 EUTRx	2013/01/11 EUTRx	2013/01/18 EUTRx
8,234,376	8,591,485	6,903,075	7,648,883	8,143,336	8,052,086
1,356,149	1,424,601	1,108,913	1,228,344	1,319,309	1,327,537
243,353	248,169	193,069	210,753	240,570	230,249
1,979,123	2,070,155	1,643,246	1,823,867	1,946,375	1,919,911
792,021	825,149	650,731	743,527	776,260	779,645
1,700,905	1,774,350	1,446,706	1,598,914	1,712,556	1,647,897
692,300	708,922	594,161	657,326	691,962	686,765
1,470,525	1,540,139	1,266,249	1,386,152	1,456,304	1,460,082
8,234,376	**8,591,485**	**6,903,075**	**7,648,883**	**8,143,336**	**8,052,086**

13.6	14.2	11.1	12.3	13.2	13.3
3.7	3.7	2.9	3.2	3.6	3.5
39.6	41.4	32.9	36.5	38.9	38.4
23.8	24.8	19.5	22.3	23.3	23.4
68.0	71.0	57.9	64.0	68.5	65.9
41.5	42.5	35.6	39.4	41.5	41.2
117.6	123.2	101.3	110.9	116.5	116.8
307.8	**320.8**	**261.2**	**288.5**	**305.5**	**302.4**

2013/01/25 EUTRx	2013/02/01 EUTRx	2013/02/08 EUTRx	2013/02/15 EUTRx	2013/02/22 EUTRx	2013/03/01 EUTRx
7,200,338	7,683,391	8,162,552	7,879,116	7,253,340	8,096,634
1,204,426	1,250,185	1,323,987	1,311,402	1,234,444	1,313,174
218,947	219,310	238,577	226,095	216,995	241,102
1,728,049	1,846,356	1,923,103	1,877,138	1,744,529	1,938,072
690,742	741,895	806,799	748,911	723,181	801,071
1,479,337	1,592,447	1,685,464	1,640,730	1,479,375	1,662,896
610,193	658,830	706,251	655,037	609,224	701,244
1,268,644	1,374,368	1,478,371	1,419,803	1,245,592	1,439,075
7,200,338	**7,683,391**	**8,162,552**	**7,879,116**	**7,253,340**	**8,096,634**

12.0	12.5	13.2	13.1	12.3	13.1
3.3	3.3	3.6	3.4	3.3	3.6
34.6	36.9	38.5	37.5	34.9	38.8
20.7	22.3	24.2	22.5	21.7	24.0
59.2	63.7	67.4	65.6	59.2	66.5
36.6	39.5	42.4	39.3	36.6	42.1
101.5	109.9	118.3	113.6	99.6	115.1
267.9	**288.2**	**307.5**	**295.0**	**267.6**	**303.3**

2013/03/08 EUTRx	2013/03/15 EUTRx	2013/03/22 EUTRx	2013/03/29 EUTRx	2013/04/05 EUTRx	2013/04/12 EUTRx
8,277,776	7,711,915	7,398,795	7,332,806	7,831,508	7,526,041
1,334,871	1,279,468	1,257,307	1,210,871	1,270,528	1,255,679
242,567	228,095	227,500	216,006	229,814	232,819
1,979,090	1,850,109	1,782,160	1,764,374	1,858,814	1,809,809
802,211	745,368	735,041	734,465	774,321	742,801
1,728,659	1,568,602	1,501,003	1,497,569	1,619,675	1,529,222
694,780	654,045	621,622	636,926	675,819	640,477
1,495,598	1,386,228	1,274,162	1,272,595	1,402,537	1,315,234
8,277,776	**7,711,915**	**7,398,795**	**7,332,806**	**7,831,508**	**7,526,041**

13.3	12.8	12.6	12.1	12.7	12.6
3.6	3.4	3.4	3.2	3.4	3.5
39.6	37.0	35.6	35.3	37.2	36.2
24.1	22.4	22.1	22.0	23.2	22.3
69.1	62.7	60.0	59.9	64.8	61.2
41.7	39.2	37.3	38.2	40.5	38.4
119.6	110.9	101.9	101.8	112.2	105.2
311.1	**288.5**	**273.0**	**272.6**	**294.1**	**279.3**

2013/04/19 EUTRx	2013/04/26 EUTRx	2013/05/03 EUTRx	2013/05/10 EUTRx	2013/05/17 EUTRx	2013/05/24 EUTRx
7,248,633	7,378,376	7,960,202	7,591,448	7,283,133	7,581,531
1,219,931	1,230,749	1,297,032	1,245,752	1,237,341	1,264,585
221,863	221,743	243,182	236,717	228,184	232,396
1,751,426	1,759,156	1,877,871	1,838,489	1,783,506	1,820,998
736,584	742,974	790,780	760,706	745,344	776,599
1,457,311	1,514,307	1,645,401	1,547,612	1,454,076	1,526,871
622,198	633,976	681,333	661,094	621,112	660,081
1,239,320	1,275,471	1,424,066	1,301,078	1,213,570	1,300,001
7,249,798	**7,379,028**	**7,960,361**	**7,591,535**	**7,283,970**	**7,581,999**

12.2	12.3	13.0	12.5	12.4	12.6
3.3	3.3	3.6	3.6	3.4	3.5
35.0	35.2	37.6	36.8	35.7	36.4
22.1	22.3	23.7	22.8	22.4	23.3
58.3	60.6	65.8	61.9	58.2	61.1
37.3	38.0	40.9	39.7	37.3	39.6
99.1	102.0	113.9	104.1	97.1	104.0
267.4	**273.8**	**298.5**	**281.3**	**266.3**	**280.5**

2013/05/31 EUTRx	2013/06/07 EUTRx	2013/06/14 EUTRx	2013/06/21 EUTRx
6,955,687	7,894,454	7,355,086	7,399,395
1,135,887	1,306,249	1,263,289	1,242,713
220,347	240,832	233,898	230,435
1,664,311	1,900,664	1,767,584	1,789,389
696,081	781,148	752,408	756,718
1,430,577	1,621,728	1,460,150	1,496,701
590,116	678,679	625,534	635,692
1,218,368	1,365,154	1,252,223	1,247,747
6,956,349	**7,895,170**	**7,355,525**	**7,399,769**

11.4	13.1	12.6	12.4
3.3	3.6	3.5	3.5
33.3	38.0	35.4	35.8
20.9	23.4	22.6	22.7
57.2	64.9	58.4	59.9
35.4	40.7	37.5	38.1
97.5	109.2	100.2	99.8
258.9	**292.9**	**270.2**	**272.2**

Kg Dispensed Actual V Budget

	4-Jan-13	11-Jan-13	18-Jan-13	25-Jan-13	1-Feb-13	8-Feb-13
Actual Weekly Kg Dispensed	288.5	305.5	302.4	267.9	288.2	307.5
Budget Kg Dispened	305.5	318.2	307.3	290.5	300.9	300.1
Weekly Difference	(17.02)	(12.69)	(4.87)	(22.62)	(12.77)	7.46
Weekly % variance	-5.6%	-4.0%	-1.6%	-7.8%	-4.2%	2.5%
YTD Actual Total	288.5	594.06	896.50	1,164.39	1,452.54	1,760.09
YTD Budget Total	305.5	623.76	931.08	1,221.59	1,522.51	1,822.60
YTD Total Difference	(17.02)	(29.71)	(34.58)	(57.20)	(69.97)	(62.51)
YTD % Variance	-5.6%	-4.8%	-3.7%	-4.7%	-4.6%	-3.4%
2013 Kg Disp Goal	15,801.3					
YTD Actual	7,106.6	<- change each week				
YTD Budget	7,634.1	<- change each week				
Actual YTD % of 2013 Goal	45.0%					
Budget YTD % of 2013 Goal	48.3%					



15-Feb-13	22-Feb-13	1-Mar-13	8-Mar-13	15-Mar-13	22-Mar-13	29-Mar-13	5-Apr-13	12-Apr-13
295.0	267.6	303.3	311.1	288.5	273.0	272.6	294.1	279.3
293.3	281.8	326.8	315.6	299.0	289.0	297.0	332.5	310.8
1.72	(14.21)	(23.50)	(4.48)	(10.54)	(16.04)	(24.43)	(38.44)	(31.45)
0.6%	-5.0%	-7.2%	-1.4%	-3.5%	-5.6%	-8.2%	-11.6%	-10.1%
2,055.12	2,322.68	2,625.94	2,937.06	3,225.52	3,498.47	3,771.07	4,065.17	4,344.51
2,115.91	2,397.68	2,724.44	3,040.03	3,339.04	3,628.02	3,925.05	4,257.58	4,568.38
(60.78)	(75.00)	(98.50)	(102.97)	(113.51)	(129.55)	(153.98)	(192.42)	(223.87)
-2.9%	-3.1%	-3.6%	-3.4%	-3.4%	-3.6%	-3.9%	-4.5%	-4.9%



19-Apr-13	26-Apr-13	3-May-13	10-May-13	17-May-13	24-May-13	31-May-13	7-Jun-13	14-Jun-13
267.4	273.8	298.5	281.3	266.3	280.5	258.9	292.9	270.2
311.3	315.9	329.9	302.9	301.0	314.4	288.8	307.2	294.3
(43.90)	(42.17)	(31.37)	(21.65)	(34.64)	(33.89)	(29.91)	(14.28)	(24.09)
-14.1%	-13.3%	-9.5%	-7.1%	-11.5%	-10.8%	-10.4%	-4.6%	-8.2%
4,611.94	4,885.69	5,184.21	5,465.47	5,731.81	6,012.34	6,271.27	6,564.19	6,834.38
4,879.70	5,195.63	5,525.52	5,828.43	6,129.41	6,443.83	6,732.67	7,039.87	7,334.14
(267.77)	(309.94)	(341.31)	(362.96)	(397.60)	(431.49)	(461.40)	(475.68)	(499.77)
-5.5%	-6.0%	-6.2%	-6.2%	-6.5%	-6.7%	-6.9%	-6.8%	-6.8%

Copy formulae above each week. Actual Data entered in the 'Kg Weekly OxyContin' v

21-Jun-13	28-Jun-13	5-Jul-13	12-Jul-13	19-Jul-13	26-Jul-13	2-Aug-13	9-Aug-13	16-Aug-13	23-Aug-13
272.2									
300.0									
(27.80)									
-9.3%									
7,106.58									
7,634.14									
(527.56)									
-6.9%									

vorksheet

30-Aug-13	6-Sep-13	13-Sep-13	20-Sep-13	27-Sep-13	4-Oct-13	11-Oct-13	18-Oct-13	25-Oct-13

1-Nov-13	8-Nov-13	15-Nov-13	22-Nov-13	29-Nov-13	6-Dec-13	13-Dec-13	20-Dec-13	27-Dec-13

Total Branded OxyContin

"= needs to be

Gross Up	0.55%	1.0055

notes: in Feb 2013, we changed to reporting from retail pharmacy only
the weekly budget is based on the agreed upon full year total, tl

	4-Jan-13	11-Jan-13	18-Jan-13	25-Jan-13
Actual Weekly TRx	112,524	120,276	118,988	108,221
Grossed Up Weekly TRx	113,143	120,938	119,642	108,816
YTD Grossed Up Weekly TRx	113,143	234,080	353,723	462,539
Budget TRx	113,143	120,938	119,642	108,816
YTD Budget Total	113,143	234,080	353,723	462,539
Weekly Difference	-	-	-	-
YTD Total Difference	-	-	-	-
Weekly % Difference	0.0%	0.0%	0.0%	0.0%

New Numbers	
2013 TRx Goal	5,810,954
YTD Rolling Grossed Up Weekly TRx	2,882,327
Difference	2,928,627
Remaining Weeks	27
Revised 2012 Weekly TRx Goal	108,468

Goal to date	2,877,921
Actual to date (grossed up)	2,882,327
YTD Difference	0.2%

: updated

to reporting retail pharmacies, mail order and LTC. The gross up simply reflects the recent difference
hen phased

1-Feb-13	8-Feb-13	15-Feb-13	22-Feb-13	1-Mar-13	8-Mar-13	15-Mar-13
115,072	121,640	117,664	109,872	120,657	123,202	116,106
115,705	122,309	118,311	110,476	121,321	123,880	116,745
578,244	700,553	818,864	929,340	1,050,661	1,174,541	1,291,285
115,705	122,309	118,311	110,476	121,321	123,880	116,745
578,244	700,553	818,864	929,340	1,050,661	1,174,541	1,291,285
-	-	-	-	-	-	-
-	-	-	-	-	-	-
0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

between weekly and monthly Rx's over a 12 month period

22-Mar-13	29-Mar-13	5-Apr-13	12-Apr-13	19-Apr-13	26-Apr-13	3-May-13
111,519	110,562	116,985	113,283	109,820	111,523	119,075
112,132	111,170	117,628	113,906	110,424	112,136	119,730
1,403,418	1,514,588	1,632,216	1,746,122	1,856,546	1,968,683	2,088,412
112,132	111,170	117,628	113,906	110,424	112,136	119,730
1,403,418	1,514,588	1,632,216	1,746,122	1,856,546	1,968,683	2,088,412
-	-	-	-	-	-	-
-	-	-	-	-	-	-
0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

10-May-13	17-May-13	24-May-13	31-May-13	7-Jun-13	14-Jun-13	21-Jun-13
114,849	110,628	115,142	105,510	119,269	111,927	112,247
115,481	111,236	115,775	106,090	119,925	112,543	112,864
2,203,893	2,315,130	2,430,905	2,536,995	2,656,920	2,769,463	2,882,327
115,481	111,236	115,775	106,090	113,641	113,642	113,643
2,203,893	2,315,130	2,430,905	2,536,995	2,650,636	2,764,278	2,877,921
-	-	-	-	6,284	(1,099)	(779)
-	-	-	-	6,284	5,185	4,406
0.0%	0.0%	0.0%	0.0%	5.5%	-1.0%	-0.7%

28-Jun-13	5-Jul-13	12-Jul-13	19-Jul-13	26-Jul-13	2-Aug-13	9-Aug-13
111,683	110,357	112,925	112,693	110,624	109,007	108,353

16-Aug-13	23-Aug-13	30-Aug-13	6-Sep-13	13-Sep-13	20-Sep-13	27-Sep-13
110,539	109,629	112,377	106,938	110,837	109,896	110,853

4-Oct-13	11-Oct-13	18-Oct-13	25-Oct-13	1-Nov-13	8-Nov-13	15-Nov-13
109,244	106,624	106,930	106,476	104,207	108,110	106,621

22-Nov-13	29-Nov-13	6-Dec-13	13-Dec-13	20-Dec-13	27-Dec-13
97,776	111,298	112,208	108,667	111,625	96,536


OxyContin Actual TRx
130,000
125,000
120,000
115,000
110,000
105,000
100,000
95,000
TRxs
4-Jan-13
18-Jan-13
1-Feb-13
15-Feb-13
1-Mar-13
15-Mar-13
29-Mar-13
Mid-Year Forec


vs. Mid-Year Update Forecast
12-Apr-13
26-Apr-13
10-May-13
24-May-13
7-Jun-13
21-Jun-13
5-Jul-13
19-Jul-13
ast Update
OxyContin TRx

From: Mahony, Edward
Sent: 2013年7月5日 9:12
To: Boer, Peter; Lewent, Judy; Pickett, Cecil; Costa, Paulo; Sackler, Beverly; Sackler, David; Sackler, Dr Kathe; Sackler, Dame Theresa; Sackler, Mortimer D.A.; Sackler, Dr Raymond R; Sackler, Dr Richard; Sackler, Jonathan; Sackler Lefcourt, Ilene; Snyderman, Ralph; Baker, Stuart D.; Stewart, John H. (US); [redacted] Gasdia, Russell; Landau, Dr. Craig; [redacted] Lundie, David; [redacted]
CC: Rosen, David (Sales and Marketing); [redacted]
Subject: June Flash Report
Attachments: 2013 June Sales Analysis Monthly Package v3.pdf

Colleagues,

The following is a flash financial report. This report focuses on sales, cash and material financial developments, if any. The report focuses on variances to the 2013 Mid-Year Forecast presented in June which projected a reduction in net sales from budget of $303.1 million, as a result in lower forecasted sales for OxyContin and Intermezzo.

Full financial statement for June will be published next week.

NET SALES

Net Sales for the six months ending June were $981.2 million --- $83.6 million lower than the same period last year and $52.0 million or 4.3% under the mid-year forecast. The reason for the under mid-year forecast sales performance is temporary fluctuations in trade stocking, discussed below. The underlying demand is tracking at or very close to the mid-year forecast.

OxyContin

OxyContin net sales for the six months ending June total $878.9 million --- $42.1 million below the mid-year forecast and $96.4 million lower than the same period last year. The variance vs. mid-year forecast is due to:

a. OxyContin demand – as reported by IMS -- is running in line with the mid-year forecast.
b. OxyContin trade inventory is running $40.9 million below the mid-year forecast. At the end of June, trade inventory was low – 1.6 months for wholesalers and pharmacy combined. Trade inventories should be back

closer to 1.8 months when orders in house at the end of June were shipped earlier this week (net sales value $32 million).

Other influences of future demand:

a. The 2013 budget assumed that the analgesic sales force would have OxyContin as the primary focus in 50% of all calls up from 30% at the end of 2012. That would have resulted in 181 thousand primary OxyContin sales calls in the first 6 months of 2013. Due to vacancies and a slower than expected implementation of this change, OxyContin was the primary focus in about 117 thousand sales calls through the end of June, 64% of target. Q3 target lists have been issued to the field force and OxyContin primary sales calls are increasing to 44% of all calls --- approaching the 50% target when secondary calls are added at ½ the value of a primary.
b. McKinsey has been engaged to work with Sales & Marketing to identify opportunities to improve performance of OxyContin. A preliminary report of this work will be made at the July 25th Board meeting.

Butrans

Butrans net sales for the six months ending June were $51.1million --- $8.0 million below the mid-year forecast and $10.5 million above the same period last year. The net sales miss is driven by contraction in trade inventory and prescriptions running slightly below the mid-year forecast. The mid-year forecast assumes full year Butrans net sales of $127 million, the same as budget. The analgesic sales force made 213 thousand primary Butrans sales calls through the end of June vs. budget of 182 thousand calls, or 117% of target.

Intermezzo

The mid-year forecast assumes full year Intermezzo net sales of $10.6 million versus budget of $44 million. Prescriptions as reported by IMS are in line with forecast.

Cash and Short Term Investments

At the end of June, unrestricted cash and short term investments totaled $839 million --- which is $15 million higher than forecast. This temporary higher-than-forecast cash balance is due to timing of payments. Actual cash payments during the month included Board approved payments related to Redacted Redacted the Better Medicine Awards ($9.1 million).

Material Financial Event in the Month
None noted.

Best Regards,
Ed

Purdue U.S.
Sales Flash Report
June 2013

Page Number

2	Sales Summary Gross to Net
3	Net Sales by Product
4	Sales Variance to Budget
5	Trade Inventory
6	Sales by Month

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Purdue US Sales Summary Gross to Net

Expressed in 000's

	June Year-to-Date				Variance 2013 YTD Actual Vs.			Full Year					
	2013 YTD Actual	2013 YTD Budget	2013 Mid Year Forecast	2012 YTD Actual	2013 YTD Budget	2013 Mid Year Forecast	2012 YTD Actual	2013 Budget	2013 Mid Year Forecast	2012 Actual	2011 Actual	2010 Actual	2009 Actual
10mg	$ 66,565	$ 78,175	$ 69,820	$ 72,162	$ (11,610)	$ (3,256)	$ (5,597)	$ 156,987	$ 142,460	$ 152,741	$ 146,784	$ 121,344	$ 133,629
15mg	17,356	18,834	17,030	15,330	(1,478)	326	2,027	37,814	35,840	33,992	27,136	23,620	16,548
20mg	171,467	209,131	184,463	194,365	(37,665)	(12,997)	(22,898)	419,948	377,709	402,472	404,149	361,266	369,289
30mg	98,178	118,244	101,912	94,674	(20,067)	(3,734)	3,504	237,429	214,549	205,335	171,730	161,048	114,431
40mg	254,286	309,840	272,904	298,560	(55,554)	(18,618)	(44,274)	622,343	555,777	618,704	633,738	682,972	708,279
60mg	155,406	193,633	162,487	158,670	(38,227)	(7,082)	(3,264)	388,817	338,266	340,746	300,721	315,742	226,251
80mg	427,709	524,433	450,604	496,605	(96,724)	(22,895)	(68,896)	1,053,126	888,508	1,023,075	1,096,778	1,331,784	1,320,222
160mg	-	-	-	-	-	-	-	-	-	-	(17)	-	-
OxyContin	**1,190,966**	**1,452,291**	**1,259,221**	**1,330,365**	**(261,325)**	**(68,255)**	**(139,399)**	**2,916,463**	**2,553,108**	**2,777,064**	**2,781,018**	**2,997,775**	**2,888,649**
				-			-						
Butrans	**63,949**	**72,958**	**72,958**	**48,929**	**(9,009)**	**(9,009)**	**15,020**	**160,025**	**160,025**	**112,887**	**73,531**	**-**	**-**
Intermezzo	**4,906**	**19,971**	**7,687**	**13,853**	**(15,066)**	**(2,782)**	**(8,947)**	**57,622**	**13,892**	**16,556**	-	-	-
Dilaudid Ampules	49	2,307	2,307	3,772	(2,258)	(2,258)	(3,723)	4,328	4,328	8,272	6,044	10,209	5,444
Dilaudid Vials	40	425	425	683	(385)	(385)	(643)	797	797	1,306	1,302	6,638	2,417
Dilaudid Tablets	6,727	6,006	6,006	7,268	721	721	(541)	11,856	11,856	14,191	17,495	18,234	24,977
Dilaudid	**6,816**	**8,738**	**8,738**	**11,723**	**(1,921)**	**(1,921)**	**(4,906)**	**16,981**	**16,981**	**23,769**	**24,842**	**35,081**	**32,838**
MS Contin	**5,649**	**5,937**	**5,937**	**6,394**	**(288)**	**(288)**	**(745)**	**11,642**	**11,642**	**12,974**	**13,339**	**15,101**	**16,860**
Ryzolt	**(521)**	-	-	**(6,250)**	**(521)**	**(521)**	**5,729**	-	-	**(6,924)**	**11,168**	**16,510**	**10,842**
Betadine First Aid	2,078	2,016	2,016	1,952	62	62	125	4,027	4,027	4,118	4,164	4,249	3,858
Betadine Hospital	2,314	2,193	2,193	2,290	122	122	24	4,401	4,401	4,653	4,412	4,196	3,864
Betadine Veterinary	482	409	409	450	73	73	32	830	830	850	793	765	729
Betadine	**4,874**	**4,617**	**4,617**	**4,692**	**257**	**257**	**182**	**9,258**	**9,258**	**9,621**	**9,369**	**9,210**	**8,451**
Betasept	**998**	**933**	**933**	**978**	**65**	**65**	**20**	**1,878**	**1,878**	**1,971**	**1,753**	**1,715**	**1,500**
Colace	11,847	12,835	12,835	12,398	(988)	(988)	(551)	25,669	25,669	25,891	23,729	22,250	22,889
Peri-Colace	2,106	2,354	2,354	2,260	(248)	(248)	(155)	4,708	4,708	4,403	3,968	3,637	3,058
Colace / Peri-Colace	**13,953**	**15,189**	**15,189**	**14,658**	**(1,236)**	**(1,236)**	**(706)**	**30,377**	**30,377**	**30,294**	**27,697**	**25,887**	**25,947**
Senokot	4,906	4,631	4,631	4,933	275	275	(26)	9,263	9,263	10,000	10,428	9,894	7,272
Senokot - S	6,094	4,822	4,822	5,511	1,272	1,272	583	9,648	9,648	11,220	13,010	12,360	11,357
Senokot	**11,000**	**9,453**	**9,453**	**10,443**	**1,547**	**1,547**	**557**	**18,911**	**18,911**	**21,220**	**23,437**	**22,253**	**18,629**
Slow-Mag	**2,760**	**2,720**	**2,720**	**2,272**	**40**	**40**	**488**	**5,316**	**5,316**	**5,554**	**5,352**	**4,585**	**4,703**
Discontinued Products	**(6)**	**-**	**-**	**(62)**	**(6)**	**(6)**	**56**	**-**	**-**	**(81)**	**(344)**	**(243)**	**3,725**
Gross Branded Sales	**$ 1,305,344**	**$ 1,592,806**	**$ 1,387,452**	**$ 1,437,996**	**$ (287,462)**	**$ (82,108)**	**$ (132,652)**	**$ 3,228,472**	**$ 2,821,387**	**$ 3,004,905**	**$ 2,971,161**	**$ 3,127,873**	**$ 3,012,143**
Fee-for-Service	$ (26,947)	$ (32,242)	$ (28,804)	$ (36,754)	$ 5,295	$ 1,858	$ 9,808	$ (65,338)	$ (57,957)	$ (69,313)	$ (74,507)	$ (79,237)	$ (76,215)
Fee-for-Service adj	2,405	-	2,404	9,198	2,405	1	(6,793)	-	2,539	9,458	13,693	12,035	10,570
SD&A w/out FFS adj	(23,491)	(34,138)	(27,722)	(31,733)	10,647	4,231	8,242	(88,198)	(54,066)	(76,476)	(63,021)	(73,347)	(71,491)
Disc. & Allowances	(21,086)	(34,138)	(25,319)	(22,535)	13,052	4,232	1,448	(88,198)	(51,526)	(67,018)	(49,328)	(61,312)	(60,921)
Ryzolt Returns Reserve	308	-		6,767	308	308	(6,459)	-	-	7,167	161	-	-
Intermezzo Returns Reserve	-	-	-	(9,001)	-	-	9,001	-	-	(8,981)	-	-	-
OxyContin Returns Reserve	-	-	-	-	-	-	-	-	-	(65,199)	(7,055)	12,519	5,359
Savings Card Discount	(21,633)	(16,502)	(21,641)	(11,243)	(5,132)	8	(10,390)	(34,537)	(41,334)	(25,104)	(15,572)	(15,691)	(17,131)
Rebates	(227,165)	(284,139)	(244,780)	(271,335)	56,974	17,615	44,170	(566,117)	(488,582)	(517,605)	(545,891)	(621,633)	(455,092)
Proposed regulation adj for Medicaid reba	(28,598)	(33,167)	(34,497)	(30,062)	4,569	5,899	1,464	(65,584)	(73,892)	(60,383)	(68,854)	(40,041)	-
Other	1,000	825	825	964	175	175	36	1,651	1,651	2,455	12,380	27,611	-
Less: Deductions Subtotal	**$ (324,122)**	**$ (399,362)**	**$ (354,216)**	**$ (373,200)**	**$ 75,240**	**$ 30,094**	**$ 49,079**	**$ (818,124)**	**$ (711,640)**	**$ (803,982)**	**$ (748,667)**	**$ (777,784)**	**$ (604,000)**
Net Branded Sales	**$ 981,222**	**$ 1,193,444**	**$ 1,033,236**	**$ 1,064,796**	**$ (212,222)**	**$ (52,014)**	**$ (83,574)**	**$ 2,410,348**	**$ 2,109,747**	**$ 2,200,922**	**$ 2,222,495**	**$ 2,350,089**	**$ 2,408,143**
Percent deductions gross to net	24.8%	25.1%	25.5%	26.0%	-0.24%	-0.70%	-0.42%	25.3%	25.2%	26.8%	25.2%	24.9%	20.1%

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Sales Summary by Product - Gross to Net

Expressed in 000's

	June Year-to-Date								Variance 2013 YTD Actual Vs.						Full Year					
	2013 YTD Actual	% of Gross Sales	2013 YTD Budget	% of Gross Sales	2013 Mid Year Forecast	% of Gross Sales	2012 YTD Actual	% of Gross Sales	2013 YTD Budget	% of Gross Sales	2013 Mid Year Forecast	% of Gross Sales	2012 YTD Actual	% of Gross Sales	2013 Budget	% of Gross Sales	2013 Mid Year Forecast	% of Gross Sales	2012 Actual	% of Gross Sales
OxyContin																				
Gross Sales	$ 1,190,966	100%	$ 1,452,291	100%	$ 1,259,221	100%	$ 1,334,061	100%	$ (261,325)	100%	$ (68,255)	100%	$ (143,095)	100%	$ 2,916,463	100%	$ 2,553,108	100%	$ 2,777,064	100%
Fee for Service	(25,119)	-2.1%	(29,829)	-2.1%	(26,657)	-2.1%	(34,559)	-2.6%	4,710	-1.8%	1,538	-2.3%	9,440	-6.6%	(59,887)	-2.1%	(53,399)	-2.1%	(65,877)	-2.4%
Sales Discounts and Allowances	(20,695)	-1.7%	(30,901)	-2.1%	(23,509)	-1.9%	(19,768)	-1.5%	10,205	-3.9%	2,814	-4.1%	(928)	0.6%	(72,658)	-2.5%	(43,013)	-1.7%	(116,425)	-4.2%
Savings Cards Discounts	(17,293)	-1.5%	(11,407)	-0.8%	(17,148)	-1.4%	(7,762)	-0.6%	(5,886)	2.3%	(145)	0.2%	(9,530)	6.7%	(22,813)	-0.8%	(31,522)	-1.2%	(18,330)	-0.7%
Rebates	(220,383)	-18.5%	(275,977)	-19.0%	(236,449)	-18.8%	(266,590)	-20.0%	55,594	-21%	16,066	-24%	46,207	-32.3%	(547,876)	-18.8%	(471,555)	-18.5%	(509,597)	-18.4%
Proposed Regulation Adjustment for Medicaid Rebates	(28,598)	-2.4%	(33,167)	-2.3%	(34,497)	-2.7%	(30,062)	-2.3%	4,569	-1.7%	5,899	-8.6%	1,464	-1.0%	(65,584)	-2.2%	(73,892)	-2.9%	(60,383)	-2.2%
OxyContin Net Sales	**878,878**	**74%**	**1,071,010**	**74%**	**920,961**	**73%**	**975,319**	**67%**	**(192,132)**	**74%**	**(42,083)**	**62%**	**(96,442)**	**67%**	**2,147,645**	**74%**	**1,879,727**	**74%**	**2,006,453**	**72%**
Butrans																				
Gross Sales	$ 63,949	100%	$ 72,958	100%	$ 72,958	100%	$ 48,929	100%	$ (9,009)	100%	$ (9,009)	100%	$ 15,020	100%	$ 160,025	100%	$ 160,025	100%	$ 112,887	100%
Fee for Service	(1,380)	-2.2%	(1,571)	-2.2%	(1,588)	-2.2%	(1,355)	-2.8%	191	-2.1%	208	-2.3%	(24)	-0.2%	(3,432)	-2.1%	(3,448)	-2.2%	(2,693)	-2.4%
Sales Discounts and Allowances	(1,524)	-2.4%	(1,738)	-2.4%	(1,305)	-1.8%	(821)	-1.7%	215	-2.4%	(219)	2.4%	(702)	-4.7%	(6,826)	-4.3%	(6,392)	-4.0%	(13,725)	-12.2%
Savings Cards Discounts	(3,674)	-5.7%	(4,001)	-5.5%	(3,775)	-5.2%	(3,380)	-6.9%	327	-3.6%	101	-1.1%	(293)	-2.0%	(8,573)	-5.4%	(8,392)	-5.2%	(6,198)	-5.5%
Rebates	(5,861)	-9.2%	(6,687)	-9.2%	(6,753)	-9.3%	(2,371)	-4.8%	826	-9.2%	891	-9.9%	(3,490)	-23.2%	(14,336)	-9.0%	(14,326)	-9.0%	(6,139)	-5.4%
Butrans Net Sales	**51,511**	**81%**	**58,961**	**81%**	**59,538**	**82%**	**41,000**	**84%**	**(7,450)**	**83%**	**(8,027)**	**89%**	**10,511**	**70%**	**126,858**	**79%**	**127,467**	**80%**	**84,131**	**75%**
Intermezzo																				
Gross Sales	$ 4,906	100%	$ 19,971	100%	$ 7,687	100%	$ 13,853	100%	$ (15,066)	100%	$ (2,782)	100%	$ (8,947)	100%	$ 57,622	100%	$ 13,892	100%	$ 16,556	100%
Fee for Service	(124)	-2.5%	(397)	-2.0%	(153)	-2.0%	(352)	-2.5%	273	-1.8%	29	-1.0%	228	-2.6%	(1,147)	-2.0%	(276)	-2.0%	(352)	-2.1%
Sales Discounts and Allowances	2,493	50.8%	(399)	-2.0%	335	4.4%	(9,920)	-71.6%	2,892	-19.2%	2,158	-77.6%	12,413	-138.7%	(6,915)	-12.0%	(852)	-6.1%	(9,908)	-59.8%
Savings Cards Discounts	(667)	-13.6%	(1,094)	-5.5%	(718)	-9.3%	(101)	-0.7%	427	-2.8%	51	-1.8%	(566)	6.3%	(3,150)	-5.5%	(1,421)	-10.2%	(576)	-3.5%
Rebates	(169)	-3.5%	(689)	-3.5%	(530)	-6.9%	(190)	-1.4%	520	-3.5%	361	-13.0%	21	-0.2%	(2,364)	-4.1%	(729)	-5.2%	(138)	-0.8%
Intermezzo Net Sales	**6,438**	**131%**	**17,391**	**87%**	**6,621**	**86%**	**3,290**	**24%**	**(10,953)**	**73%**	**(183)**	**7%**	**3,148**	**-35%**	**44,046**	**76%**	**10,615**	**76%**	**5,582**	**34%**
Total for All Products																				
Gross Sales	$ 1,305,344	100%	$ 1,592,806	100%	$ 1,387,452	100%	$ 1,437,996	100%	$ (287,462)	100%	$ (82,108)	100%	$ (132,652)	100%	$ 3,228,472	100%	$ 2,821,387	100%	$ 3,004,905	100%
Fee for Service	(26,947)	-2.1%	(32,242)	-2.0%	(28,804)	-2.1%	(36,754)	-2.6%	5,295	-1.8%	1,858	-2.3%	9,808	-7.4%	(65,338)	-2.0%	(57,957)	-2.1%	(69,313)	-2.3%
Sales Discounts and Allowances	(20,778)	-1.6%	(34,138)	-2.1%	(25,319)	-1.8%	(24,769)	-1.7%	13,360	-4.6%	4,540	-5.5%	3,991	-3.0%	(88,198)	-2.7%	(51,526)	-1.8%	(134,031)	-4.5%
Savings Cards Discounts	(21,633)	-1.7%	(16,502)	-1.0%	(21,641)	-1.6%	(11,243)	-0.8%	(5,132)	1.8%	8	0.0%	(10,390)	7.8%	(34,537)	-1.1%	(41,334)	-1.5%	(25,104)	-0.8%
Rebates	(227,165)	-17.4%	(284,139)	-17.8%	(244,780)	-17.6%	(271,335)	-18.9%	56,974	-19.8%	17,615	-21.5%	44,170	-33.3%	(566,117)	-17.5%	(488,582)	-17.3%	(517,606)	-17.2%
Proposed Regulation Adjustment for Medicaid Rebates	(28,598)	-2.2%	(33,167)	-2.1%	(34,497)	-2.5%	(30,062)	-2.1%	4,569	-1.6%	5,899	-7.2%	1,464	-1.1%	(65,584)	-2.0%	(73,892)	-2.6%	(60,383)	-2.0%
Other	1,000	0.1%	825	0.1%	825	0.1%	964	0.1%	175	-0.1%	175	-0.2%	36	0.0%	1,651	0.1%	1,651	0.1%	2,455	0.1%
Total Net Sales	**$ 981,222**	**75%**	**$ 1,193,444**	**75%**	**$ 1,033,236**	**74%**	**$ 1,064,796**	**74%**	**$ (212,222)**	**74%**	**$ (52,014)**	**63%**	**$ (83,574)**	**63%**	**$ 2,410,348**	**75%**	**$ 2,109,747**	**75%**	**$ 2,200,922**	**73%**

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Sales Variance to Forecast

	($ in millions)	
Gross Sales		
• Impact of trade inventories lower than Forecast. (1)	$ (66.3)	
• Lower OxyContin demand versus Forecast. (1)	(2.0)	
Lower OxyContin Sales.		(68.3)
• Butrans sales due to lower trade inventory and demand.		(9.0)
• Intermezzo due to lower trade inventory.		(2.8)
• All Other.		(2.1)
Sub-Total Gross Sales Variance		(82.1)
Deductions		
• Lower variable deductions due to lower Sales.		30.1
Net Branded Sales Variance to Forecast		**$ (52.0)**

(1) Each of these factors is based on estimates provided by IMS and customers.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Trade Inventory Summary

Highlights

OxyContin trade inventory growth is below Forecast by $66.3 million:
Butrans trade inventory growth is lower than Forecast likely driven by YTD sales performance.

	Inventory Value ($000's)				Months on Hand		
	YTD June 2013			FY 2013	Jun-13		
	Actual	Forecast	Variance	Forecast	Actual	Forecast	Variance
OxyContin							
Total Trade Inventory - January 1st, 2013	**$ 539,959**	**$ 539,959**	**$ -**	**$ 539,959**	**2.4**	**2.2**	**0.26**
Wholesaler - Ending (1)	170,429	224,457	(54,027)	250,000	0.7	1.0	(0.2)
Pharmacy - Ending (2)	217,572	230,110	(12,538)	154,000	0.8	1.0	(0.1)
Hospital/Other - Ending	4,956	4,671	286	4,396	0.0	0.0	0.0
Total Trade Inventory - June 30th, 2013	**$ 392,958**	**$ 459,238**	**$ (66,280)**	**$ 408,396**	**1.6**	**2.0**	**(0.4)**
Change in Trade Inventory	**$ (147,001)**	**$ (80,721)**	**(66,280)**	**$ (131,563)**	**0.8**	**0.2**	**0.6**
Butrans							
Total Trade Inventory - January 1st, 2013	**$ 21,102**	**$ 21,102**	**$ -**	**$ 21,102**	**2.1**	**1.9**	**0.2**
Wholesaler - Ending (1)	10,228	12,052	(1,824)	12,052	0.9	1.0	(0.1)
Pharmacy - Ending (2)	5,453	8,833	(3,380)	17,157	0.5	0.7	(0.3)
Hospital/Other - Ending	391	317	75	267	0.0	0.0	0.0
Total Trade Inventory - June 30th, 2013	**$ 16,072**	**$ 21,202**	**$ (5,129)**	**$ 29,476**	**1.8**	**2.4**	**(0.6)**
Change in Trade Inventory	**$ (5,029)**	**$ 100**	**$ (5,129)**	**$ 8,375**	**0.2**	**(0.5)**	**0.8**
Intermezzo							
Total Trade Inventory - January 1st, 2013	**$ 10,008**	**$ 10,008**	**$ -**	**$ 10,008**	N/A	N/A	N/A
Wholesaler - Ending (1)	2,122	3,194	(1,073)	3,194	N/A	N/A	N/A
Pharmacy - Ending (2)	5,560	6,452	(892)	6,452	N/A	N/A	N/A
Hospital/Other - Ending	-	-	-	-	N/A	N/A	N/A
Total Trade Inventory - June 30th, 2013	**$ 7,682**	**$ 9,646**	**$ (1,964)**	**$ 9,646**	N/A	N/A	N/A
Change in Trade Inventory	**$ (2,327)**	**$ (362)**	**$ (1,964)**	**$ (362)**	N/A	N/A	N/A

Footnotes

(1) - **Wholesaler** - Includes inventory held by the wholesaler derived from the Value Centric system.

(2) - **Pharmacy** - assumes the pharmacies maintain stocking levels.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Gross Sales by Month

($ Millions)	2013	2013	2012	2011	Monthly 2013 %	Monthly 2013 %	Monthly 2013 %
Month	**Actual**	**Budget**	**Actual**	**Actual**	**Budget**	**of 2012**	**of 2011**
January	$ 182.5	$ 255.7	$ 175.4	$ 215.8	71.4%	104.0%	84.5%
February	197.6	248.9	185.4	198.5	79.4%	106.6%	99.6%
March	239.9	268.8	313.2	310.9	89.3%	76.6%	77.2%
Q1	**620.0**	**773.4**	**674.0**	**725.2**	**80.2%**	**85.5%**	**89.4%**
April	252.9	275.8	238.2	260.8	91.7%	106.2%	97.0%
May	223.7	280.5	297.3	212.9	79.7%	75.2%	105.1%
June	208.7	263.1	228.4	288.5	79.3%	91.4%	72.4%
Q2	**685.3**	**819.4**	**764.0**	**762.2**	**83.6%**	**89.9%**	**85.5%**
July		279.3	219.7	209.5			
August		275.2	294.3	242.7			
September		261.9	235.5	274.1			
Q3	**-**	**816.4**	**749.6**	**726.3**			
October		282.0	235.2	221.8			
November		266.8	287.7	238.8			
December		270.4	294.4	296.8			
Q4	**-**	**819.3**	**817.3**	**757.4**			
Total	**$ 1,305.3**	**$ 3,228.5**	**$ 3,004.9**	**$ 2,971.2**	**40.4%**	**43.9%**	**41.7%**
YTD Cumulative	**$ 1,305.3**	**$ 1,592.8**	**$ 1,438.0**	**$ 1,487.4**	**81.9%**	**87.8%**	**87.4%**

Net Sales by Month

($ Millions)	2013	2013	2012	2011	Monthly 2013 %	Monthly 2013 %	Monthly 2013 %
Month	**Actual**	**Budget**	**Actual**	**Actual**	**Budget**	**of 2012**	**of 2011**
January	$ 136.4	$ 192.4	$ 126.2	$ 163.2	70.9%	108.1%	83.5%
February	143.6	$ 181.3	140.0	154.4	79.2%	102.6%	93.0%
March	181.5	$ 202.1	241.9	238.3	89.8%	75.0%	76.2%
Q1	**461.4**	**575.8**	**508.0**	**555.8**	**80.1%**	**83.0%**	**85.4%**
April	187.1	207.5	176.2	197.1	90.2%	106.2%	94.9%
May	171.5	211.2	218.2	172.9	81.2%	78.6%	99.2%
June	161.2	198.9	162.4	216.9	81.0%	99.3%	74.3%
Q2	**519.8**	**617.6**	**556.8**	**587.0**	**84.2%**	**88.6%**	**82.6%**
July		210.6	167.5	168.4			
August		208.2	218.8	185.1			
September		197.8	146.7	193.2			
Q3	**-**	**616.7**	**533.0**	**546.7**			
October		213.3	174.9	158.4			
November		202.0	213.8	181.3			
December		185.0	214.4	193.3			
Q4	**-**	**600.2**	**603.1**	**533.0**			
Total	**$ 981.2**	**$ 2,410.3**	**$ 2,200.9**	**$ 2,222.5**	**40.7%**	**44.1%**	**42.2%**
YTD Cumulative	**$ 981.2**	**$ 1,193.4**	**$ 1,064.8**	**$ 1,142.8**	**82.2%**	**85.9%**	**83.9%**





Note: The above net sales includes the impact of the proposed final rule for Medicaid rebates.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Message

From: Mahony, Edward [/O=PURDUE/OU=EXTERNAL

Sent: 7/5/2013 9:12:09 AM

To: Boer, Peter [/O=PURDUE/OU=EXTERNAL
Lewent, Judy
Pickett, Cecil
Costa, Paulo
Sackler, Beverly
Sackler, David
Sackler, Dr Kathe
Sackler, Dame Theresa
Sackler, Mortimer D.A.
Sackler, Dr Raymond R
Sackler, Dr Richard
Sackler, Jonathan
Sackler Lefcourt, Ilene
Snyderman, Ralph
Baker, Stuart D.
Stewart, John H. (US)
Dolan, James
Gasdia, Russell
Landau, Dr. Craig
Weinstein, Bert

CC: Rosen, David (Sales and Marketing)
Lowne, Jon

BCC: Stewart, John H. (US)

Subject: June Flash Report

Attachments: 2013 June Sales Analysis Monthly Package v3.pdf

Colleagues,

The following is a flash financial report. This report focuses on sales, cash and material financial developments, if any. The report focuses on variances to the 2013 Mid-Year Forecast presented in June which projected a reduction in net sales from budget of $303.1 million, as a result in lower forecasted sales for OxyContin and Intermezzo.

Full financial statement for June will be published next week.

NET SALES

Net Sales for the six months ending June were $981.2 million --- $83.6 million lower than the same period last year and $52.0 million or 4.3% under the mid-year forecast. The reason for the under mid-year forecast sales performance is temporary fluctuations in trade stocking, discussed below. The underlying demand is tracking at or very close to the mid-year forecast.

OxyContin

OxyContin net sales for the six months ending June total $878.9 million --- $42.1 million below the mid-year forecast and $96.4 million lower than the same period last year. The variance vs. mid-year forecast is due to:

a. OxyContin demand – as reported by IMS -- is running in line with the mid-year forecast.

b. OxyContin trade inventory is running $40.9 million below the mid-year forecast. At the end of June, trade inventory was low – 1.6 months for wholesalers and pharmacy combined. Trade inventories should be back closer to 1.8 months when orders in house at the end of June were shipped earlier this week (net sales value $32 million).

Other influences of future demand:

a. The 2013 budget assumed that the analgesic sales force would have OxyContin as the primary focus in 50% of all calls up from 30% at the end of 2012. That would have resulted in 181 thousand primary OxyContin sales calls in the first 6 months of 2013. Due to vacancies and a slower than expected implementation of this change, OxyContin was the primary focus in about 117 thousand sales calls through the end of June, 64% of target. Q3 target lists have been issued to the field force and OxyContin primary sales calls are increasing to 44% of all calls --- approaching the 50% target when secondary calls are added at ½ the value of a primary.

b. McKinsey has been engaged to work with Sales & Marketing to identify opportunities to improve performance of OxyContin. A preliminary report of this work will be made at the July 25th Board meeting.

Butrans

Butrans net sales for the six months ending June were $51.1million --- $8.0 million below the mid-year forecast and $10.5 million above the same period last year. The net sales miss is driven by contraction in trade inventory and prescriptions running slightly below the mid-year forecast. The mid-year forecast assumes full year Butrans net sales of $127 million, the same as budget. The analgesic sales force made 213 thousand primary Butrans sales calls through the end of June vs. budget of 182 thousand calls, or 117% of target.

Intermezzo

The mid-year forecast assumes full year Intermezzo net sales of $10.6 million versus budget of $44 million. Prescriptions as reported by IMS are in line with forecast.

Cash and Short Term Investments

At the end of June, unrestricted cash and short term investments totaled $839 million --- which is $15 million higher than forecast. This temporary higher-than-forecast cash balance is due to timing of payments. Actual cash payments during the month included Board approved payments related to the Pike County settlement ($4 million) and the Better Medicine Awards ($9.1 million).

Material Financial Event in the Month
None noted.

Best Regards,
Ed

Purdue U.S.
Sales Flash Report
June 2013

Page Number

2	Sales Summary Gross to Net
3	Net Sales by Product
4	Sales Variance to Budget
5	Trade Inventory
6	Sales by Month

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Purdue US Sales Summary Gross to Net

Expressed in 000's

	June Year-to-Date				Variance 2013 YTD Actual Vs.			Full Year					
	2013 YTD Actual	2013 YTD Budget	2013 Mid Year Forecast	2012 YTD Actual	2013 YTD Budget	2013 Mid Year Forecast	2012 YTD Actual	2013 Budget	2013 Mid Year Forecast	2012 Actual	2011 Actual	2010 Actual	2009 Actual
10mg	$ 66,565	$ 78,175	$ 69,820	$ 72,162	$ (11,610)	$ (3,256)	$ (5,597)	$ 156,987	$ 142,460	$ 152,741	$ 146,784	$ 121,344	$ 133,629
15mg	17,356	18,834	17,030	15,330	(1,478)	326	2,027	37,814	35,840	33,992	27,136	23,620	16,548
20mg	171,467	209,131	184,463	194,365	(37,665)	(12,997)	(22,898)	419,948	377,709	402,472	404,149	361,266	369,289
30mg	98,178	118,244	101,912	94,674	(20,067)	(3,734)	3,504	237,429	214,549	205,335	171,730	161,048	114,431
40mg	254,286	309,840	272,904	298,560	(55,554)	(18,618)	(44,274)	622,343	555,777	618,704	633,738	682,972	708,279
60mg	155,406	193,633	162,487	158,670	(38,227)	(7,082)	(3,264)	388,817	338,266	340,746	300,721	315,742	226,251
80mg	427,709	524,433	450,604	496,605	(96,724)	(22,895)	(68,896)	1,053,126	888,508	1,023,075	1,096,778	1,331,784	1,320,222
160mg	-	-	-	-	-	-	-	-	-	-	(17)	-	-
OxyContin	**1,190,966**	**1,452,291**	**1,259,221**	**1,330,365**	**(261,325)**	**(68,255)**	**(139,399)**	**2,916,463**	**2,553,108**	**2,777,064**	**2,781,018**	**2,997,775**	**2,888,649**
				-			-						
Butrans	**63,949**	**72,958**	**72,958**	**48,929**	**(9,009)**	**(9,009)**	**15,020**	**160,025**	**160,025**	**112,887**	**73,531**	**-**	**-**
Intermezzo	**4,906**	**19,971**	**7,687**	**13,853**	**(15,066)**	**(2,782)**	**(8,947)**	**57,622**	**13,892**	**16,556**	**-**	**-**	**-**
Dilaudid Ampules	49	2,307	2,307	3,772	(2,258)	(2,258)	(3,723)	4,328	4,328	8,272	6,044	10,209	5,444
Dilaudid Vials	40	425	425	683	(385)	(385)	(643)	797	797	1,306	1,302	6,638	2,417
Dilaudid Tablets	6,727	6,006	6,006	7,268	721	721	(541)	11,856	11,856	14,191	17,495	18,234	24,977
Dilaudid	**6,816**	**8,738**	**8,738**	**11,723**	**(1,921)**	**(1,921)**	**(4,906)**	**16,981**	**16,981**	**23,769**	**24,842**	**35,081**	**32,838**
MS Contin	**5,649**	**5,937**	**5,937**	**6,394**	**(288)**	**(288)**	**(745)**	**11,642**	**11,642**	**12,974**	**13,339**	**15,101**	**16,860**
Ryzolt	**(521)**	**-**	**-**	**(6,250)**	**(521)**	**(521)**	**5,729**	**-**	**-**	**(6,924)**	**11,168**	**16,510**	**10,842**
Betadine First Aid	2,078	2,016	2,016	1,952	62	62	125	4,027	4,027	4,118	4,164	4,249	3,858
Betadine Hospital	2,314	2,193	2,193	2,290	122	122	24	4,401	4,401	4,653	4,412	4,196	3,864
Betadine Veterinary	482	409	409	450	73	73	32	830	830	850	793	765	729
Betadine	**4,874**	**4,617**	**4,617**	**4,692**	**257**	**257**	**182**	**9,258**	**9,258**	**9,621**	**9,369**	**9,210**	**8,451**
Betasept	**998**	**933**	**933**	**978**	**65**	**65**	**20**	**1,878**	**1,878**	**1,971**	**1,753**	**1,715**	**1,500**
Colace	11,847	12,835	12,835	12,398	(988)	(988)	(551)	25,669	25,669	25,891	23,729	22,250	22,889
Peri-Colace	2,106	2,354	2,354	2,260	(248)	(248)	(155)	4,708	4,708	4,403	3,968	3,637	3,058
Colace / Peri-Colace	**13,953**	**15,189**	**15,189**	**14,658**	**(1,236)**	**(1,236)**	**(706)**	**30,377**	**30,377**	**30,294**	**27,697**	**25,887**	**25,947**
Senokot	4,906	4,631	4,631	4,933	275	275	(26)	9,263	9,263	10,000	10,428	9,894	7,272
Senokot - S	6,094	4,822	4,822	5,511	1,272	1,272	583	9,648	9,648	11,220	13,010	12,360	11,357
Senokot	**11,000**	**9,453**	**9,453**	**10,443**	**1,547**	**1,547**	**557**	**18,911**	**18,911**	**21,220**	**23,437**	**22,253**	**18,629**
Slow-Mag	**2,760**	**2,720**	**2,720**	**2,272**	**40**	**40**	**488**	**5,316**	**5,316**	**5,554**	**5,352**	**4,585**	**4,703**
Discontinued Products	**(6)**	**-**	**-**	**(62)**	**(6)**	**(6)**	**56**	**-**	**-**	**(81)**	**(344)**	**(243)**	**3,725**
Gross Branded Sales	**$ 1,305,344**	**$ 1,592,806**	**$ 1,387,452**	**$ 1,437,996**	**$ (287,462)**	**$ (82,108)**	**$ (132,652)**	**$ 3,228,472**	**$ 2,821,387**	**$ 3,004,905**	**$ 2,971,161**	**$ 3,127,873**	**$ 3,012,143**
Fee-for-Service	$ (26,947)	$ (32,242)	$ (28,804)	$ (36,754)	$ 5,295	$ 1,858	$ 9,808	$ (65,338)	$ (57,957)	$ (69,313)	$ (74,507)	$ (79,237)	$ (76,215)
Fee-for-Service adj	2,405	-	2,404	9,198	2,405	1	(6,793)	-	2,539	9,458	13,693	12,035	10,570
SD&A w/out FFS adj	(23,491)	(34,138)	(27,722)	(31,733)	10,647	4,231	8,242	(88,198)	(54,066)	(76,476)	(63,021)	(73,347)	(71,491)
Disc. & Allowances	(21,086)	(34,138)	(25,319)	(22,535)	13,052	4,232	1,448	(88,198)	(51,526)	(67,018)	(49,328)	(61,312)	(60,921)
Ryzolt Returns Reserve	308	-		6,767	308	308	(6,459)	-	-	7,167	161	-	-
Intermezzo Returns Reserve	-	-	-	(9,001)	-	-	9,001	-	-	(8,981)	-	-	-
OxyContin Returns Reserve	-	-	-	-	-	-	-	-	-	(65,199)	(7,055)	12,519	5,359
Savings Card Discount	(21,633)	(16,502)	(21,641)	(11,243)	(5,132)	8	(10,390)	(34,537)	(41,334)	(25,104)	(15,572)	(15,691)	(17,131)
Rebates	(227,165)	(284,139)	(244,780)	(271,335)	56,974	17,615	44,170	(566,117)	(488,582)	(517,605)	(545,891)	(621,633)	(455,092)
Proposed regulation adj for Medicaid reba	(28,598)	(33,167)	(34,497)	(30,062)	4,569	5,899	1,464	(65,584)	(73,892)	(60,383)	(68,854)	(40,041)	-
Other	1,000	825	825	964	175	175	36	1,651	1,651	2,455	12,380	27,611	-
Less: Deductions Subtotal	**$ (324,122)**	**$ (399,362)**	**$ (354,216)**	**$ (373,200)**	**$ 75,240**	**$ 30,094**	**$ 49,079**	**$ (818,124)**	**$ (711,640)**	**$ (803,982)**	**$ (748,667)**	**$ (777,784)**	**$ (604,000)**
Net Branded Sales	**$ 981,222**	**$ 1,193,444**	**$ 1,033,236**	**$ 1,064,796**	**$ (212,222)**	**$ (52,014)**	**$ (83,574)**	**$ 2,410,348**	**$ 2,109,747**	**$ 2,200,922**	**$ 2,222,495**	**$ 2,350,089**	**$ 2,408,143**
Percent deductions gross to net	24.8%	25.1%	25.5%	26.0%	-0.24%	-0.70%	-0.42%	25.3%	25.2%	26.8%	25.2%	24.9%	20.1%

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Sales Summary by Product - Gross to Net

Expressed in 000's

	June Year-to-Date								Variance 2013 YTD Actual Vs.						Full Year					
	2013 YTD Actual	% of Gross Sales	2013 YTD Budget	% of Gross Sales	2013 Mid Year Forecast	% of Gross Sales	2012 YTD Actual	% of Gross Sales	2013 YTD Budget	% of Gross Sales	2013 Mid Year Forecast	% of Gross Sales	2012 YTD Actual	% of Gross Sales	2013 Budget	% of Gross Sales	2013 Mid Year Forecast	% of Gross Sales	2012 Actual	% of Gross Sales
OxyContin																				
Gross Sales	$ 1,190,966	100%	$ 1,452,291	100%	$ 1,259,221	100%	$ 1,334,061	100%	$ (261,325)	100%	$ (68,255)	100%	$ (143,095)	100%	$ 2,916,463	100%	$ 2,553,108	100%	$ 2,777,064	100%
Fee for Service	(25,119)	-2.1%	(29,829)	-2.1%	(26,657)	-2.1%	(34,559)	-2.6%	4,710	-1.8%	1,538	-2.3%	9,440	-6.6%	(59,887)	-2.1%	(53,399)	-2.1%	(65,877)	-2.4%
Sales Discounts and Allowances	(20,695)	-1.7%	(30,901)	-2.1%	(23,509)	-1.9%	(19,768)	-1.5%	10,205	-3.9%	2,814	-4.1%	(928)	0.6%	(72,658)	-2.5%	(43,013)	-1.7%	(116,425)	-4.2%
Savings Cards Discounts	(17,293)	-1.5%	(11,407)	-0.8%	(17,148)	-1.4%	(7,762)	-0.6%	(5,886)	2.3%	(145)	0.2%	(9,530)	6.7%	(22,813)	-0.8%	(31,522)	-1.2%	(18,330)	-0.7%
Rebates	(220,383)	-18.5%	(275,977)	-19.0%	(236,449)	-18.8%	(266,590)	-20.0%	55,594	-21%	16,066	-24%	46,207	-32.3%	(547,876)	-18.8%	(471,555)	-18.5%	(509,597)	-18.4%
Proposed Regulation Adjustment for Medicaid Rebates	(28,598)	-2.4%	(33,167)	-2.3%	(34,497)	-2.7%	(30,062)	-2.3%	4,569	-1.7%	5,899	-8.6%	1,464	-1.0%	(65,584)	-2.2%	(73,892)	-2.9%	(60,383)	-2.2%
OxyContin Net Sales	**878,878**	**74%**	**1,071,010**	**74%**	**920,961**	**73%**	**975,319**	**67%**	**(192,132)**	**74%**	**(42,083)**	**62%**	**(96,442)**	**67%**	**2,147,645**	**74%**	**1,879,727**	**74%**	**2,006,453**	**72%**
Butrans																				
Gross Sales	$ 63,949	100%	$ 72,958	100%	$ 72,958	100%	$ 48,929	100%	$ (9,009)	100%	$ (9,009)	100%	$ 15,020	100%	$ 160,025	100%	$ 160,025	100%	$ 112,887	100%
Fee for Service	(1,380)	-2.2%	(1,571)	-2.2%	(1,588)	-2.2%	(1,355)	-2.8%	191	-2.1%	208	-2.3%	(24)	-0.2%	(3,432)	-2.1%	(3,448)	-2.2%	(2,693)	-2.4%
Sales Discounts and Allowances	(1,524)	-2.4%	(1,738)	-2.4%	(1,305)	-1.8%	(821)	-1.7%	215	-2.4%	(219)	2.4%	(702)	-4.7%	(6,826)	-4.3%	(6,392)	-4.0%	(13,725)	-12.2%
Savings Cards Discounts	(3,674)	-5.7%	(4,001)	-5.5%	(3,775)	-5.2%	(3,380)	-6.9%	327	-3.6%	101	-1.1%	(293)	-2.0%	(8,573)	-5.4%	(8,392)	-5.2%	(6,198)	-5.5%
Rebates	(5,861)	-9.2%	(6,687)	-9.2%	(6,753)	-9.3%	(2,371)	-4.8%	826	-9.2%	891	-9.9%	(3,490)	-23.2%	(14,336)	-9.0%	(14,326)	-9.0%	(6,139)	-5.4%
Butrans Net Sales	**51,511**	**81%**	**58,961**	**81%**	**59,538**	**82%**	**41,000**	**84%**	**(7,450)**	**83%**	**(8,027)**	**89%**	**10,511**	**70%**	**126,858**	**79%**	**127,467**	**80%**	**84,131**	**75%**
Intermezzo																				
Gross Sales	$ 4,906	100%	$ 19,971	100%	$ 7,687	100%	$ 13,853	100%	$ (15,066)	100%	$ (2,782)	100%	$ (8,947)	100%	$ 57,622	100%	$ 13,892	100%	$ 16,556	100%
Fee for Service	(124)	-2.5%	(397)	-2.0%	(153)	-2.0%	(352)	-2.5%	273	-1.8%	29	-1.0%	228	-2.6%	(1,147)	-2.0%	(276)	-2.0%	(352)	-2.1%
Sales Discounts and Allowances	2,493	50.8%	(399)	-2.0%	335	4.4%	(9,920)	-71.6%	2,892	-19.2%	2,158	-77.6%	12,413	-138.7%	(6,915)	-12.0%	(852)	-6.1%	(9,908)	-59.8%
Savings Cards Discounts	(667)	-13.6%	(1,094)	-5.5%	(718)	-9.3%	(101)	-0.7%	427	-2.8%	51	-1.8%	(566)	6.3%	(3,150)	-5.5%	(1,421)	-10.2%	(576)	-3.5%
Rebates	(169)	-3.5%	(689)	-3.5%	(530)	-6.9%	(190)	-1.4%	520	-3.5%	361	-13.0%	21	-0.2%	(2,364)	-4.1%	(729)	-5.2%	(138)	-0.8%
Intermezzo Net Sales	**6,438**	**131%**	**17,391**	**87%**	**6,621**	**86%**	**3,290**	**24%**	**(10,953)**	**73%**	**(183)**	**7%**	**3,148**	**-35%**	**44,046**	**76%**	**10,615**	**76%**	**5,582**	**34%**
Total for All Products																				
Gross Sales	$ 1,305,344	100%	$ 1,592,806	100%	$ 1,387,452	100%	$ 1,437,996	100%	$ (287,462)	100%	$ (82,108)	100%	$ (132,652)	100%	$ 3,228,472	100%	$ 2,821,387	100%	$ 3,004,905	100%
Fee for Service	(26,947)	-2.1%	(32,242)	-2.0%	(28,804)	-2.1%	(36,754)	-2.6%	5,295	-1.8%	1,858	-2.3%	9,808	-7.4%	(65,338)	-2.0%	(57,957)	-2.1%	(69,313)	-2.3%
Sales Discounts and Allowances	(20,778)	-1.6%	(34,138)	-2.1%	(25,319)	-1.8%	(24,769)	-1.7%	13,360	-4.6%	4,540	-5.5%	3,991	-3.0%	(88,198)	-2.7%	(51,526)	-1.8%	(134,031)	-4.5%
Savings Cards Discounts	(21,633)	-1.7%	(16,502)	-1.0%	(21,641)	-1.6%	(11,243)	-0.8%	(5,132)	1.8%	8	0.0%	(10,390)	7.8%	(34,537)	-1.1%	(41,334)	-1.5%	(25,104)	-0.8%
Rebates	(227,165)	-17.4%	(284,139)	-17.8%	(244,780)	-17.6%	(271,335)	-18.9%	56,974	-19.8%	17,615	-21.5%	44,170	-33.3%	(566,117)	-17.5%	(488,582)	-17.3%	(517,606)	-17.2%
Proposed Regulation Adjustment for Medicaid Rebates	(28,598)	-2.2%	(33,167)	-2.1%	(34,497)	-2.5%	(30,062)	-2.1%	4,569	-1.6%	5,899	-7.2%	1,464	-1.1%	(65,584)	-2.0%	(73,892)	-2.6%	(60,383)	-2.0%
Other	1,000	0.1%	825	0.1%	825	0.1%	964	0.1%	175	-0.1%	175	-0.2%	36	0.0%	1,651	0.1%	1,651	0.1%	2,455	0.1%
Total Net Sales	**$ 981,222**	**75%**	**$ 1,193,444**	**75%**	**$ 1,033,236**	**74%**	**$ 1,064,796**	**74%**	**$ (212,222)**	**74%**	**$ (52,014)**	**63%**	**$ (83,574)**	**63%**	**$ 2,410,348**	**75%**	**$ 2,109,747**	**75%**	**$ 2,200,922**	**73%**

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Sales Variance to Forecast

	($ in millions)	
Gross Sales		
• Impact of trade inventories lower than Forecast. (1)	$ (66.3)	
• Lower OxyContin demand versus Forecast. (1)	(2.0)	
Lower OxyContin Sales.		(68.3)
• Butrans sales due to lower trade inventory and demand.		(9.0)
• Intermezzo due to lower trade inventory.		(2.8)
• All Other.		(2.1)
Sub-Total Gross Sales Variance		(82.1)
Deductions		
• Lower variable deductions due to lower Sales.		30.1
Net Branded Sales Variance to Forecast		**$ (52.0)**

(1) Each of these factors is based on estimates provided by IMS and customers.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Trade Inventory Summary

Highlights

OxyContin trade inventory growth is below Forecast by $66.3 million:
Butrans trade inventory growth is lower than Forecast likely driven by YTD sales performance.

	Inventory Value ($000's)				Months on Hand		
	YTD June 2013			FY 2013	Jun-13		
	Actual	Forecast	Variance	Forecast	Actual	Forecast	Variance
OxyContin							
Total Trade Inventory - January 1st, 2013	**$ 539,959**	**$ 539,959**	**$ -**	**$ 539,959**	**2.4**	**2.2**	**0.26**
Wholesaler - Ending (1)	170,429	224,457	(54,027)	250,000	0.7	1.0	(0.2)
Pharmacy - Ending (2)	217,572	230,110	(12,538)	154,000	0.8	1.0	(0.1)
Hospital/Other - Ending	4,956	4,671	286	4,396	0.0	0.0	0.0
Total Trade Inventory - June 30th, 2013	**$ 392,958**	**$ 459,238**	**$ (66,280)**	**$ 408,396**	**1.6**	**2.0**	**(0.4)**
Change in Trade Inventory	**$ (147,001)**	**$ (80,721)**	**(66,280)**	**$ (131,563)**	**0.8**	**0.2**	**0.6**
Butrans							
Total Trade Inventory - January 1st, 2013	**$ 21,102**	**$ 21,102**	**$ -**	**$ 21,102**	**2.1**	**1.9**	**0.2**
Wholesaler - Ending (1)	10,228	12,052	(1,824)	12,052	0.9	1.0	(0.1)
Pharmacy - Ending (2)	5,453	8,833	(3,380)	17,157	0.5	0.7	(0.3)
Hospital/Other - Ending	391	317	75	267	0.0	0.0	0.0
Total Trade Inventory - June 30th, 2013	**$ 16,072**	**$ 21,202**	**$ (5,129)**	**$ 29,476**	**1.8**	**2.4**	**(0.6)**
Change in Trade Inventory	**$ (5,029)**	**$ 100**	**$ (5,129)**	**$ 8,375**	**0.2**	**(0.5)**	**0.8**
Intermezzo							
Total Trade Inventory - January 1st, 2013	**$ 10,008**	**$ 10,008**	**$ -**	**$ 10,008**	N/A	N/A	N/A
Wholesaler - Ending (1)	2,122	3,194	(1,073)	3,194	N/A	N/A	N/A
Pharmacy - Ending (2)	5,560	6,452	(892)	6,452	N/A	N/A	N/A
Hospital/Other - Ending	-	-	-	-	N/A	N/A	N/A
Total Trade Inventory - June 30th, 2013	**$ 7,682**	**$ 9,646**	**$ (1,964)**	**$ 9,646**	N/A	N/A	N/A
Change in Trade Inventory	**$ (2,327)**	**$ (362)**	**$ (1,964)**	**$ (362)**	N/A	N/A	N/A

Footnotes

(1) - **Wholesaler** - Includes inventory held by the wholesaler derived from the Value Centric system.

(2) - **Pharmacy** - assumes the pharmacies maintain stocking levels.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Gross Sales by Month

($ Millions)	2013	2013	2012	2011	Monthly 2013 %	Monthly 2013 %	Monthly 2013 %
Month	**Actual**	**Budget**	**Actual**	**Actual**	**Budget**	**of 2012**	**of 2011**
January	$ 182.5	$ 255.7	$ 175.4	$ 215.8	71.4%	104.0%	84.5%
February	197.6	248.9	185.4	198.5	79.4%	106.6%	99.6%
March	239.9	268.8	313.2	310.9	89.3%	76.6%	77.2%
Q1	**620.0**	**773.4**	**674.0**	**725.2**	**80.2%**	**85.5%**	**89.4%**
April	252.9	275.8	238.2	260.8	91.7%	106.2%	97.0%
May	223.7	280.5	297.3	212.9	79.7%	75.2%	105.1%
June	208.7	263.1	228.4	288.5	79.3%	91.4%	72.4%
Q2	**685.3**	**819.4**	**764.0**	**762.2**	**83.6%**	**89.9%**	**85.5%**
July		279.3	219.7	209.5			
August		275.2	294.3	242.7			
September		261.9	235.5	274.1			
Q3	**-**	**816.4**	**749.6**	**726.3**			
October		282.0	235.2	221.8			
November		266.8	287.7	238.8			
December		270.4	294.4	296.8			
Q4	**-**	**819.3**	**817.3**	**757.4**			
Total	**$ 1,305.3**	**$ 3,228.5**	**$ 3,004.9**	**$ 2,971.2**	**40.4%**	**43.9%**	**41.7%**
YTD Cumulative	**$ 1,305.3**	**$ 1,592.8**	**$ 1,438.0**	**$ 1,487.4**	**81.9%**	**87.8%**	**87.4%**

Net Sales by Month

($ Millions)	2013	2013	2012	2011	Monthly 2013 %	Monthly 2013 %	Monthly 2013 %
Month	**Actual**	**Budget**	**Actual**	**Actual**	**Budget**	**of 2012**	**of 2011**
January	$ 136.4	$ 192.4	$ 126.2	$ 163.2	70.9%	108.1%	83.5%
February	143.6	$ 181.3	140.0	154.4	79.2%	102.6%	93.0%
March	181.5	$ 202.1	241.9	238.3	89.8%	75.0%	76.2%
Q1	**461.4**	**575.8**	**508.0**	**555.8**	**80.1%**	**83.0%**	**85.4%**
April	187.1	207.5	176.2	197.1	90.2%	106.2%	94.9%
May	171.5	211.2	218.2	172.9	81.2%	78.6%	99.2%
June	161.2	198.9	162.4	216.9	81.0%	99.3%	74.3%
Q2	**519.8**	**617.6**	**556.8**	**587.0**	**84.2%**	**88.6%**	**82.6%**
July		210.6	167.5	168.4			
August		208.2	218.8	185.1			
September		197.8	146.7	193.2			
Q3	**-**	**616.7**	**533.0**	**546.7**			
October		213.3	174.9	158.4			
November		202.0	213.8	181.3			
December		185.0	214.4	193.3			
Q4	**-**	**600.2**	**603.1**	**533.0**			
Total	**$ 981.2**	**$ 2,410.3**	**$ 2,200.9**	**$ 2,222.5**	**40.7%**	**44.1%**	**42.2%**
YTD Cumulative	**$ 981.2**	**$ 1,193.4**	**$ 1,064.8**	**$ 1,142.8**	**82.2%**	**85.9%**	**83.9%**





Note: The above net sales includes the impact of the proposed final rule for Medicaid rebates.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Message

From: Stewart, John H. (US)

Sent: 7/7/2013 11:06:43 AM

To: Sackler, Mortimer D.A.

CC: Boer, Peter
Lewent, Judy
Pickett, Cecil
Costa, Paulo
Sackler, Beverly
Sackler, David
Sackler, Dr Kathe
Sackler, Dame Theresa
Sackler, Dr Raymond R
Sackler, Dr Richard
Sackler, Jonathan
Sackler Lefcourt, Ilene
Snyderman, Ralph
Baker, Stuart D.
Gasdia, Russell
Mahony, Edward
Rosen, David (Sales and Marketing)

BCC: Stewart, John H. (US)

Subject: June Flash Report - McKinsey OxyContin Project

Attachments: 20130707104023657.pdf

Mortimer

McKinsey is performing an independent, detailed analysis of the of the factors that are affecting/driving OxyContin's current sales/prescription performance – including such factors as the performance of the overall market, OxyContin positioning and messaging, prescriber segmentation and targeting, salesforce execution, MCO coverage of Oxy and its impacts, medical/scientific support, S&P spend levels and characteristics of new to brand patients. I have attached a copy of a document that describes the workplan in greater detail.

McKinsey was selected on the basis of the quality of the work they have already do for us with respect to OxyContin, and also because of their great familiarity with us, the product and the issues it is facing – as well as the positive factors such as the abuse-deterrent properties and findings of the epidemiologic studies. As a result, they were able to begin the analytics substantially earlier – and we are very interested in receiving a report in time to take action to positively influence 2013 performance of the product.

The cost for the project is $850,000.00, and there is a potential to add a second phase in which McKinsey would work with us to develop and oversee the execution of a plan to pursue the greatest opportunities for boosting growth – that arise out of the current project. The cost of Phase 2, should we proceed, would be approximately $1 million .

John

From: Sackler, Mortimer D.A.
Sent: Saturday, July 06, 2013 11:14 PM
To: Mahony, Edward
Cc: Boer, Peter; Lewent, Judy; Pickett, Cecil; Costa, Paulo; Sackler, Beverly; Sackler, David; Sackler, Dr Kathe; Sackler, Dame Theresa; Sackler, Dr Raymond R; Sackler, Dr Richard; Sackler, Jonathan; Sackler Lefcourt, Ilene; Snyderman, Ralph; Baker, Stuart D.; Stewart, John H. (US)
Subject: Re: June Flash Report

Ed,

How much is the McKinsey work costing and how were they selected vs say Bain? What are they specifically doing for us?

Regards,

Mortimer

On Jul 5, 2013, at 3:12 PM, "Mahony, Edward" [redacted]@pharma.com> wrote:

Colleagues,

The following is a flash financial report. This report focuses on sales, cash and material financial developments, if any. The report focuses on variances to the 2013 Mid-Year Forecast presented in June which projected a reduction in net sales from budget of $303.1 million, as a result in lower forecasted sales for OxyContin and Intermezzo.

Full financial statement for June will be published next week.

NET SALES

Net Sales for the six months ending June were $981.2 million --- $83.6 million lower than the same period last year and $52.0 million or 4.3% under the mid-year forecast. The reason for the under mid-year forecast sales performance is temporary fluctuations in trade stocking, discussed below. The underlying demand is tracking at or very close to the mid-year forecast.

OxyContin

OxyContin net sales for the six months ending June total $878.9 million --- $42.1 million below the mid-year forecast and $96.4 million lower than the same period last year. The variance vs. mid-year forecast is due to:

a. OxyContin demand – as reported by IMS -- is running in line with the mid-year forecast.

b. OxyContin trade inventory is running $40.9 million below the mid-year forecast. At the end of June, trade inventory was low – 1.6 months for wholesalers and pharmacy combined. Trade inventories should be back closer to 1.8 months when orders in house at the end of June were shipped earlier this week (net sales value $32 million).

Other influences of future demand:

a. The 2013 budget assumed that the analgesic sales force would have OxyContin as the primary focus in 50% of all calls up from 30% at the end of 2012. That would have resulted in 181 thousand primary OxyContin sales calls in the first 6 months of 2013. Due to vacancies and a slower than expected implementation of this change, OxyContin was the primary focus in about 117 thousand sales calls through the end of June, 64% of target. Q3 target lists have been issued to the field force and OxyContin primary sales calls are increasing to 44% of all calls --- approaching the 50% target when secondary calls are added at ½ the value of a primary.

b. McKinsey has been engaged to work with Sales & Marketing to identify opportunities to improve performance of OxyContin. A preliminary report of this work will be made at the July 25th Board meeting.

Butrans

Butrans net sales for the six months ending June were $51.1million --- $8.0 million below the mid-year forecast and $10.5 million above the same period last year. The net sales miss is driven by contraction in trade inventory and prescriptions running slightly below the mid-year forecast. The mid-year forecast assumes full year Butrans net sales of $127 million, the same as budget. The analgesic sales force made 213 thousand primary Butrans sales calls through the end of June vs. budget of 182 thousand calls, or 117% of target.

Intermezzo

The mid-year forecast assumes full year Intermezzo net sales of $10.6 million versus budget of $44 million. Prescriptions as reported by IMS are in line with forecast.

Cash and Short Term Investments

At the end of June, unrestricted cash and short term investments totaled $839 million --- which is $15 million higher than forecast. This temporary higher-than-forecast cash balance is due to timing of payments. Actual cash payments during the month included Board approved payments related to Redacted the Better Medicine Awards ($9.1 million).

Material Financial Event in the Month

None noted.

Best Regards,
Ed

<2013 June Sales Analysis Monthly Package v3.pdf>

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

DRAFT

OxyContin Growth Opportunities

Week 0 discussion

May 24, 2013

CONFIDENTIAL AND PROPRIETARY
Any use of this material without specific permission of McKinsey & Company is strictly prohibited

McKinsey&Company

PURDUE-COR-00015178

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Proposed objectives for today

1. Review/refine workplan	~ 10 minutes
2. Get your input on initial market research plan	~ 20 minutes
3. Discuss getting started on affiliation analysis	~ 20 minutes
4. Next steps	~ 10 minutes

PURDUE-COR-00015179

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

GRANULAR GROWTH OPPORTUNITIES FOR OXYCONTIN

Phase 1 workplan (1/4)

DEVELOPED WITH DAVID ROSEN & MIKE RONNING

Kicking off immediately

Area	Critical questions to address	Supporting analyses
1 **Market landscape & demand forecast**	▪ **Does Oxy performance reflect broader opioid market performance?** – *What are the major sources of growth and decline for overall pain market and for Oxy?* – Are MDs increasingly reluctant to prescribe opiates due to negative perceptions? – Are MD behaviors shifting toward low dose opiates and smaller Rx sizes? – Are recently trained MDs less likely to Rx EROs, especially Oxy? – What policies do pharmacists follow?	▪ Analyze detailed sales data and identify trends: – MDs: Biggest losers and biggest gainers – Sources of growth by specialty; book of business and level of access; account type[1] – Geographies: Lowest and highest growth ▪ Quantify impact of coverage shifts (e.g., share in plans where Oxy has moved from "advantaged" to "parity" vs. competitor) ▪ Understand underlying demand for opioids and identify prescribing trends across branded and gx: by MD age cohort; by dose, by Rx size,
	▪ **What are the drivers of the OxyContin financial forecast and are they aligned with market dynamics?**	▪ Pressure test key model assumptions – Overall patient volumes and shifts over time – Mix of prescribers over time (e.g. PCP vs. spec – MD behavior change (e.g., cyclers) – Total Rx; NBRx / Dose / Pills /
	▪ **What other additional trends exists that would dampen opioid prescribing, e.g.,** new products aimed at limiting opioid use	▪ Quantify impact and spillover effects of relevant trends and technologies

1Account as defined in part (3) segmentation and targeting

PURDUE-COR-00015180

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

GRANULAR GROWTH OPPORTUNITIES FOR OXYCONTIN

Phase 1 workplan (2/4)

DEVELOPED WITH DAVID ROSEN & MIKE RONNING

Kicking off immediately

Area	Critical questions to address	Supporting analyses
2 **Messaging & positioning**	▪ **Are MDs (esp. low or non-prescribers) aware of Oxy label change and current value proposition?** – How would awareness change behavior? – To what extent does 'Oxy' brand equity deter or encourage prescribing?	▪ Understand beliefs held among high writers, non-writers, and historically high writers; test Oxy value proposition ▪ Analysis of message delivery and understanding of abuse deterrence (among targets and non-targets)
3 **Segmentation & targeting**	▪ **How does Oxy prescribing behavior vary by account type?** – How does centralized decision-making and control impact use of branded opiates (e.g., IDNs; aligned group practices)? – How does Oxy performance differ in B2B vs. B2C environments? What are the resourcing implications?	▪ Affiliate MDs with groups and assess performance among subset of group practices ▪ Determine prescribing homogeneity for sample of 'loser' and 'gainer' entities[2]
	▪ **Is sales force targeting the highest potential prescribers? At the appropriate resource levels?**	▪ Analysis of sales coverage universe vs. patient volumes and growth rates – Reach : ▫ PCPs vs. specialists ▫ Pain market universe vs. ERO – Frequency and type of coverage: ▫ Promo response curves by decile; by spec ▫ Maintenance vs. prospecting accounts
	▪ **How does Oxy performance and potential, vary at a 'micro-market' level (district/zip)?**	▪ Gx and branded opioid growth rates by zip/district ▪ Analysis of differential performance by district / zip (e.g., based on gx penetration, quality of payer access, rep access); predictive modeling [2]

1Account as defined in part (3) segmentation and targeting
[2] Optional further analyses pending initial results

PURDUE-COR-00015181

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

GRANULAR GROWTH OPPORTUNITIES FOR OXYCONTIN

Phase 1 workplan (3/4)

DEVELOPED WITH DAVID ROSEN & MIKE RONNING

Area	Critical questions to address	Supporting analyses
4 **Field execution & focus**	▪ **Are there areas of performance gaps** (e.g., many low performing rep)? – Is there opportunity from…Improving target lists? Closing actual reach / frequency gaps? Message delivery and understanding? ▪ **Has the field lost focus on Oxy due to Butrans launch?** – What is the right balance?	▪ Assess highest vs. lowest performing territories oxy vs. other branded opioid share ▪ Quantify potential upside if performance gaps can be closed ▪ Analyze portfolio incentive comp relative to revenue and profit opportunity for Purdue
5 **Access & availability**	▪ **What is the impact of payer trends on current prescribing (e.g., restrictions, controls)?** – How do payors view the opportunity to manage this class more aggressively? ▪ How has stocking affected demand (one-time or broader issue)? ▪ How, if at all, have pharmacists played a more active role in controlling access?	▪ Analyze plan-level share performance for top plans across advantaged, parity and disadvantaged accounts ▪ Qualitatively understand historic and planned management of class across key payers (e.g., impact of Medicaid and spillover; UHC; Medco/ESI) ▪ Compare access perception vs. reality ▪ Quantify potential upside if performance gaps can be closed ▪ Understand source and impact of pharmacist (e.g., corporate-driven; regionally-driven)
6 **Scientific support**	▪ **Is there opportunity to leverage MSLs for strategic accounts** (e.g., key accounts; large group practices) **or key geographies** (e.g., Boston; NW)?	▪ Benchmark MSL force size, activities, accounts ▪ Understand gaps in education and market understanding of Oxy

[1] Optional further analyses pending initial results

PURDUE-COR-00015182

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

GRANULAR GROWTH OPPORTUNITIES FOR OXYCONTIN

Phase 1 workplan (4/4)

DEVELOPED WITH DAVID ROSEN & MIKE RONNING

Area	Critical questions to address	Supporting analyses
7 Commercial spend levels	▪ **Is there opportunity to re-allocate sales efforts away from low to high potential accounts and geographies?** ▪ **Is Purdue under-resourcing the large number of un-covered MDs?** – What is the untapped potential?	▪ Compare Oxy spend allocation relative to other comparably differentiated, mature brands in competitive classes ▪ Analyze specific levers and 'impact' (e.g., speaker programs) ▪ Analyze spend on unbranded, disease state education relative to other highly ▪ Quantify potential from long tail of uncovered docs
8 Patient funnel	▪ **How important are patients in the treatment decision?** – What is the impact of patient pushback on MD reluctance to prescribe? ▪ **How is increasing patient cost burden shaping usage?** – Is there opportunity to improve efficiency and effectiveness of copay mitigation?	▪ Interview physicians and pharmacists / review existing patient research ▪ Analyze activities and impact of patient advocacy groups ▪ Correlate zip level with copay programs / redemptions with average incomes / Mcaid pop'n ▪ Analyze Purdue patient research and sources of growth and decline by patient segment[1]

Our full assessment and analysis would help us in address your primary questions:

1. **What are the drivers of performance and the shortfall? How do these drivers differ by customer and market segment?**
2. **What is the true potential of the brand?**

[1] Optional further analyses pending initial results

PURDUE-COR-00015183

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Comments on workplan– for discussion

1 **Market landscape**	▪ What appropriate strategies from a marketing, PR, and advocacy point of view can we undertake to combat this? ▪ Might want to look at rate of new prescribers and repeat prescribers over time; how many new rx'ers do we need to achieve forecast? At what rate do we need current prescribers to Rx OxyContin vs. other EROs? ▪ Also look at prescribing patterns analysis
2 **Messaging & positioning**	▪ Make sure you factor for reach of sales and marketing messages in this analysis.
3 **Segmentation & targeting**	▪ Assume analysis is by territory and district? ▪ We need to understand whether we are making the correct number of calls to physicians with whom we are attempting to maintain business versus those we believe we can grow business. Also, we need to consider targeting on NBRx volume. Do we need to make a lot of calls on physicians with a high number of continuing patients ▪ By prescribing behavior segment too?
5 **Access & availability**	▪ Are recent changes (the FDA decisions on OXY and on Opana ER) affecting how payers view the market?
6 **Scientific support**	▪ How about leveraging HECON data as well?
7 **Commercial spend levels**	▪ Should also compare ability to move brand volume/share as well for a mature brand.

PURDUE-COR-00015184

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Proposed objectives for today

1. Review/refine workplan	~ 10 minutes
2. Get your input on initial market research plan	~ 20 minutes
3. Discuss getting started on affiliation analysis	~ 20 minutes
4. Next steps	~ 10 minutes

PURDUE-COR-00015185

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Proposed initial wage of primary research (1/2)

FOR DISCUSSION

Interviewees	High level interview topics
Prescribers – Pain specialists – PCPs – Mix of other prescriber groups (orthopedic surgeons, oncologists, neurologists, rehabilitation)	▪ Evolution of thinking around treatment of chronic pain ▪ Changes in treatment behaviors by specialty ▪ Brand perceptions across opioids including abuse deterrence ▪ Differential behaviors by geography ▪ Etc
Payers	▪ Degree of focus on analgesics, opioid and non, – Anticipated management of classes – Aspired gx utilization levels
Pharmacists	▪ Perspective on patient population with moderate/severe pain (trends and current) ▪ Changes in prescription patterns on pain medications
Other – Patient advocacy – Pain clinic managers	▪ Activity levels, initiatives, geographic focus perceived impact

PURDUE-COR-00015186

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

FOR DISCUSSION

Proposed initial wave of primary research (2/2)

Purdue analytics required

Interviewees	Number	Target audience
Prescribers		▪ Mix of
– Pain specialists	~10-15	– Loyalists/high OxyContin prescribers (>10 per week)
– PCPs	~15-20	– OxyContin non-prescribers, but high pain prescribers
– Mix of other prescriber groups (e.g.. orthopods, oncologists, neurologists, rehab)	~ 5-7	– OxyContin prescribers and non-prescribers affiliated with ~100 largest corporate providers (pending affiliation analysis[1])
		– Pain fellows/specialists in 1st 1-3 years in practice
		– Pain thought leaders
Payers	~5-7	▪ Mix of degree of control, regional and national payers (e.g., BCBS Michigan, UHC, Florida Blue, Medicaid, PBMs)
Pharmacists	~5-7	▪ Focus on areas/zip codes with largest prescription decline
Other		
– Patient advocacy, Pain clinic	~3-5	▪ Managers of pain clinics ▪ Leaders of patient advocacy groups

Estimated cost: ~35-45k

1 Plan to build prescribing behavior with qualitative perspectives

PURDUE-COR-00015187

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

High level topics to address in prescriber interviews

	Key topics to address in interviews
Pain market perspectives	▪ Overall approach to prescribing pain therapies ▪ Perspective on patient population of patients with moderate/severe pain (trends and current) ▪ Broad patient segments and approach to each ▪ Evolution of thinking and approach over time ▪ Perspective on branded vs. generic pain medications/opioids ▪ Perspective on pipeline, potential game changers ▪ Perspective on abuse deterrents and new formulations
Prescriber behavior	▪ Overall perceptions of individual drugs: Non-opioids (Lyrica, Neurontin, Celebrex) and opioids (OxyContin, Opana, etc.) ▪ Key factors driving decision-making (e.g., payer reimbursement, clinical evidence, protocols) ▪ Key considerations/concerns when prescribing opioids and impact on decision making ▪ Referral patterns-Determinants of referrals vs. prescribing, follow ship and change over time
Messaging and positioning	▪ Messaging associated with each drug ▪ Perceived clinical differentiation for each drug ▪ Perspectives on companies and reps/medical field force ▪ Frequency of sales rep contact by brand
Perspective on future market	▪ Perceived market changes and likely evolution of prescribing patterns ▪ Key drivers of demand for opioids vs. other pain medications ▪ Expected changes in patient volume for moderate/severe pain

SOURCE: McKinsey team analysis

PURDUE-COR-00015188

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

High level topics to address in payer interviews

	Key topics to address in interviews
Historical perspective on pain market	▪ Prescription/demand patterns for opioids vs. non-opioids ▪ Changes in drug class management over time (e.g., preference for opioids/non-opioids, reimburse for certain disease types only) ▪ Perspective on patient population of patients with moderate/severe pain (trends and current)
Perspective on current pain market and brands	▪ Perspective on the pain market today (opioids vs. non-opioids) ▪ Overall perceptions of individual drugs: Non-opioids (Lyrica, Neurontin, Celebrex) and opioids (OxyContin, Opana, etc.) ▪ Expected changes in patient volume for moderate/severe pain ▪ Potential regulatory changes (e.g., FDA, Healthcare reform) that could impact pain medication/opioid market
Re-imbursement perspective	▪ Current reimbursement structure for opioids (e.g., what patient populations/treatment areas) vs. non-opioid pain medications ▪ Thinking around branded vs. generic opioids (e.g., limit reimbursement to generics where available) ▪ Issues/concerns in the pain/opioid market today

SOURCE: McKinsey team analysis

PURDUE-COR-00015189

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

High level topics to address in pharmacist interviews

	Key topics to address in interviews
Pain market perspectives	▪ Perspective on overall market trends in pain medication market (e.g., changes in total number of prescriptions, drug types, brands) ▪ Perspective on patient population of patients with moderate/severe pain (trends and current)
Opioid brand perception	▪ Perspective on opioid drugs vs. non-opioid pain medication ▪ Overall perceptions of individual drugs: Non-opioids (Lyrica, Neurontin, Celebrex) and opioids (OxyContin, Opana, etc.) ▪ Interaction with opioid sales reps (e.g., frequency, specific brands)
Degree of pharmacist involvement	▪ Pharmacists ability to change prescription specifications (e.g., change to generic, change # of pills), drivers of decision making

SOURCE: McKinsey team analysis

PURDUE-COR-00015190

Message

From: Sackler, Mortimer D.A [redacted]

Sent: 7/7/2013 11:21:51 AM

To: Stewart, John H. (US) [redacted]

CC: Boer, Peter [redacted] Lewent, Judy [redacted]; Pickett, Cecil [redacted] Costa, Paulo [redacted] Sackler, Beverly [redacted] Sackler, David [redacted] Sackler, Dr Kathe [redacted] Sackler, Dame Theresa [redacted] Sackler, Dr Raymond R [redacted] Sackler, Dr Richard [redacted] Sackler, Jonathan [redacted] Sackler Lefcourt, Ilene [redacted] Snyderman, Ralph [redacted] Baker, Stuart D. [redacted] Gasdia, Russell [redacted] Mahony, Edward [redacted] Rosen, David (Sales and Marketing) [redacted]

BCC: Stewart, John H. (US) [redacted]

Subject: Re: June Flash Report - McKinsey OxyContin Project

Thank you for the information. I look forward to hearing about the results at the next Board meeting. Sounds like it will be very informative.

Regards,

Mortimer

On Jul 7, 2013, at 5:06 PM, "Stewart, John H. (US)" <[redacted]@pharma.com> wrote:

Mortimer

McKinsey is performing an independent, detailed analysis of the of the factors that are affecting/driving OxyContin's current sales/prescription performance – including such factors as the performance of the overall market, OxyContin positioning and messaging, prescriber segmentation and targeting, salesforce execution, MCO coverage of Oxy and its impacts, medical/scientific support, S&P spend levels and characteristics of new to brand patients. I have attached a copy of a document that describes the workplan in greater detail.

McKinsey was selected on the basis of the quality of the work they have already do for us with respect to OxyContin, and also because of their great familiarity with us, the product and the issues it is facing – as well as the positive factors such as the abuse-deterrent properties and findings of the epidemiologic studies. As a result, they were able to begin

the analytics substantially earlier -- and we are very interested in receiving a report in time to take action to positively influence 2013 performance of the product.

The cost for the project is $850,000.00, and there is a potential to add a second phase in which McKinsey would work with us to develop and oversee the execution of a plan to pursue the greatest opportunities for boosting growth – that arise out of the current project. The cost of Phase 2, should we proceed, would be approximately $1 million .

John

From: Sackler, Mortimer D.A.
Sent: Saturday, July 06, 2013 11:14 PM
To: Mahony, Edward
Cc: Boer, Peter; Lewent, Judy; Pickett, Cecil; Costa, Paulo; Sackler, Beverly; Sackler, David; Sackler, Dr Kathe; Sackler, Dame Theresa; Sackler, Dr Raymond R; Sackler, Dr Richard; Sackler, Jonathan; Sackler Lefcourt, Ilene; Snyderman, Ralph; Baker, Stuart D.; Stewart, John H. (US)
Subject: Re: June Flash Report

Ed,

How much is the McKinsey work costing and how were they selected vs say Bain? What are they specifically doing for us?

Regards,

Mortimer

On Jul 5, 2013, at 3:12 PM, "Mahony, Edward" <[redacted]@pharma.com> wrote:

Colleagues,

The following is a flash financial report. This report focuses on sales, cash and material financial developments, if any. The report focuses on variances to the 2013 Mid-Year Forecast presented in June which projected a reduction in net sales from budget of $303.1 million, as a result in lower forecasted sales for OxyContin and Intermezzo.

Full financial statement for June will be published next week.

NET SALES

Net Sales for the six months ending June were $981.2 million --- $83.6 million lower than the same period last year and $52.0 million or 4.3% under the mid-year forecast. The reason for the under mid-year forecast sales performance is temporary fluctuations in trade stocking, discussed below. The underlying demand is tracking at or very close to the mid-year forecast.

OxyContin

OxyContin net sales for the six months ending June total $878.9 million --- $42.1 million below the mid-year forecast and $96.4 million lower than the same period last year. The variance vs. mid-year forecast is due to:

a. OxyContin demand – as reported by IMS -- is running in line with the mid-year forecast.

b. OxyContin trade inventory is running $40.9 million below the mid-year forecast. At the end of June, trade inventory was low – 1.6 months for wholesalers and pharmacy combined. Trade inventories should be back closer to 1.8 months when orders in house at the end of June were shipped earlier this week (net sales value $32 million).

Other influences of future demand:

a. The 2013 budget assumed that the analgesic sales force would have OxyContin as the primary focus in 50% of all calls up from 30% at the end of 2012. That would have resulted in 181 thousand primary OxyContin sales calls in the first 6 months of 2013. Due to vacancies and a slower than expected implementation of this change, OxyContin was the primary focus in about 117 thousand sales calls through the end of June, 64% of target. Q3 target lists have been issued to the field force and OxyContin primary sales calls are increasing to 44% of all calls --- approaching the 50% target when secondary calls are added at ½ the value of a primary.

b. McKinsey has been engaged to work with Sales & Marketing to identify opportunities to improve performance of OxyContin. A preliminary report of this work will be made at the July 25th Board meeting.

Butrans

Butrans net sales for the six months ending June were $51.1million --- $8.0 million below the mid-year forecast and $10.5 million above the same period last year. The net sales miss is driven by contraction in trade inventory and prescriptions running slightly below the mid-year forecast. The mid-year forecast assumes full year Butrans net sales of $127 million, the same as budget. The analgesic sales force made 213 thousand primary Butrans sales calls through the end of June vs. budget of 182 thousand calls, or 117% of target.

Intermezzo

The mid-year forecast assumes full year Intermezzo net sales of $10.6 million versus budget of $44 million. Prescriptions as reported by IMS are in line with forecast.

Cash and Short Term Investments

At the end of June, unrestricted cash and short term investments totaled $839 million --- which is $15 million higher than forecast. This temporary higher-than-forecast cash balance is due to timing of payments. Actual cash payments during the month included Board approved

payments related to Redacted the Better Medicine Awards ($9.1 million).

Material Financial Event in the Month
None noted.

Best Regards,
Ed

<2013 June Sales Analysis Monthly Package v3.pdf>
<20130707104023657.pdf>

Message

From: Sackler, Dr Richard [redacted]
Sent: 7/7/2013 12:41:42 PM
To: mdas[redacted]
Subject: FW: June Flash Report - McKinsey OxyContin Project

Do you want to attend the interim presentation Jul 17? We should talk about the benefit of doing this.

From: <Rosen>, "David (Sales and Marketing)" <[redacted]@pharma.com>
Date: Sunday, July 7, 2013 12:33 PM
To: John Stewart <[redacted]@pharma.com>
Cc: "Richard S. Sackler" <[redacted]@pharma.com>, Mortimer Sackler <[redacted]@pharma.com>, "Gasdia, Russell" <[redacted]@pharma.com>
Subject: Re: June Flash Report - McKinsey OxyContin Project

Hi, all. The last timeline agreed to has an interim presentation on July 17 with final results at the end of August. The project is progressing well on this schedule.

Thanks,
David

On Jul 7, 2013, at 12:14 PM, "Stewart, John H. (US)" <[redacted]@pharma.com> wrote:

Richard

David Rosen is the internal lead on this project, and the original schedule calls for the findings to be presented the week of July 22 – with a final report likely due a couple of weeks later. By copy of this email, I'll ask David to advise if the project remains on this schedule.

John

From: Sackler, Dr Richard
Sent: Sunday, July 07, 2013 11:09 AM
To: Stewart, John H. (US); Sackler, Mortimer D.A.
Cc: Boer, Peter; Lewent, Judy; Pickett, Cecil; Costa, Paulo; Sackler, Beverly; Sackler, David; Sackler, Dr Kathe; Sackler, Dame Theresa; Sackler, Dr Raymond R; Sackler, Jonathan; Sackler Lefcourt, Ilene; Snyderman, Ralph; Baker, Stuart D.; Gasdia, Russell; Mahony, Edward; [redacted] Rosen, David (Sales and Marketing); JHS (US)
Subject: Re: June Flash Report - McKinsey OxyContin Project

Thanks.
Who is the point person in Purdue on this project? Can s/he give a time line for the project?

From: <Stewart>, John Stewart <[redacted]@pharma.com>
Date: Sunday, July 7, 2013 11:06 AM
To: Mortimer Sackler <[redacted]@pharma.com>
Cc: Peter Boer <[redacted]@boer.org>, Judy Matk Lewent <[redacted]@pharma.com>, Cecil internet [redacted]@pharma.com>, Paulo Ferraz Costa <[redacted]@pharma.com>, "Sackler, Beverly" [redacted]@pharma.com>, "Sackler, David" <[redacted]@pharma.com>, "Sackler, Dr Kathe" <[redacted]@pharma.com>, "Sackler, Dame Theresa" <[redacted]@mdsackler.co.uk>, Raymond Sackler <[redacted]@pharma.com>, "Richard S. Sackler" <[redacted]@pharma.com>, "Sackler, Jonathan" <[redacted]@pharma.com>, "Sackler Lefcourt, Ilene" <[redacted]@pharma.com>, "Snyderman, Ralph" <[redacted]@pharma.com>, Chadbourne SDB <[redacted]@chadbourne.com>, "Gasdia, Russell"

[redacted]@pharma.com>, Ed Mahony <edward.mahony@pharma.com> [redacted]
[redacted]@pharma.com>, "Rosen, David (Sales and Marketing)" [redacted]@pharma.com> [redacted]
<[redacted]@pharma.com>
Subject: June Flash Report - McKinsey OxyContin Project

Mortimer

McKinsey is performing an independent, detailed analysis of the of the factors that are affecting/driving OxyContin's current sales/prescription performance – including such factors as the performance of the overall market, OxyContin positioning and messaging, prescriber segmentation and targeting, salesforce execution, MCO coverage of Oxy and its impacts, medical/scientific support, S&P spend levels and characteristics of new to brand patients. I have attached a copy of a document that describes the workplan in greater detail.

McKinsey was selected on the basis of the quality of the work they have already do for us with respect to OxyContin, and also because of their great familiarity with us, the product and the issues it is facing – as well as the positive factors such as the abuse-deterrent properties and findings of the epidemiologic studies. As a result, they were able to begin the analytics substantially earlier – and we are very interested in receiving a report in time to take action to positively influence 2013 performance of the product.

The cost for the project is $850,000.00, and there is a potential to add a second phase in which McKinsey would work with us to develop and oversee the execution of a plan to pursue the greatest opportunities for boosting growth – that arise out of the current project. The cost of Phase 2, should we proceed, would be approximately $1 million .

John

From: Sackler, Mortimer D.A.
Sent: Saturday, July 06, 2013 11:14 PM
To: Mahony, Edward
Cc: Boer, Peter; Lewent, Judy; Pickett, Cecil; Costa, Paulo; Sackler, Beverly; Sackler, David; Sackler, Dr Kathe; Sackler, Dame Theresa; Sackler, Dr Raymond R; Sackler, Dr Richard; Sackler, Jonathan; Sackler Lefcourt, Ilene; Snyderman, Ralph; Baker, Stuart D.; Stewart, John H. (US)
Subject: Re: June Flash Report

Ed,

How much is the McKinsey work costing and how were they selected vs say Bain? What are they specifically doing for us?

Regards,

Mortimer

On Jul 5, 2013, at 3:12 PM, "Mahony, Edward" <[redacted]@pharma.com> wrote:

Colleagues,

The following is a flash financial report. This report focuses on sales, cash and material financial developments, if any. The report focuses on variances to the 2013 Mid-Year Forecast presented in June which projected a reduction in net sales from budget of $303.1 million, as a result in lower forecasted sales for OxyContin and Intermezzo.

Full financial statement for June will be published next week.

NET SALES

Net Sales for the six months ending June were $981.2 million --- $83.6 million lower than the same period last year and $52.0 million or 4.3% under the mid-year forecast. The reason for the under mid-year forecast sales performance is temporary fluctuations in trade stocking, discussed below. The underlying demand is tracking at or very close to the mid-year forecast.

OxyContin

OxyContin net sales for the six months ending June total $878.9 million --- $42.1 million below the mid-year forecast and $96.4 million lower than the same period last year. The variance vs. mid-year forecast is due to:

a. OxyContin demand – as reported by IMS -- is running in line with the mid-year forecast.

b. OxyContin trade inventory is running $40.9 million below the mid-year forecast. At the end of June, trade inventory was low – 1.6 months for wholesalers and pharmacy combined. Trade inventories should be back closer to 1.8 months when orders in house at the end of June were shipped earlier this week (net sales value $32 million).

Other influences of future demand:

a. The 2013 budget assumed that the analgesic sales force would have OxyContin as the primary focus in 50% of all calls up from 30% at the end of 2012. That would have resulted in 181 thousand primary OxyContin sales calls in the first 6 months of 2013. Due to vacancies and a slower than expected implementation of this change, OxyContin was the primary focus in about 117 thousand sales calls through the end of June, 64% of target. Q3 target lists have been issued to the field force and OxyContin primary sales calls are increasing to 44% of all calls --- approaching the 50% target when secondary calls are added at 1Ž2 the value of a primary.

b. McKinsey has been engaged to work with Sales & Marketing to identify opportunities to improve performance of OxyContin. A preliminary report of this work will be made at the July 25th Board meeting.

Butrans

Butrans net sales for the six months ending June were $51.1million --- $8.0 million below the mid-year forecast and $10.5 million above the same period last year. The net sales miss is driven by contraction in trade inventory and prescriptions running slightly below the mid-year forecast. The mid-year forecast assumes full year Butrans net sales of $127 million, the same as budget. The analgesic sales force made 213 thousand primary Butrans sales calls through the end of June vs. budget of 182 thousand calls, or 117% of target.